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General Introduction
1.1 STEM CELLS
Stem cells are generally described as unspecialized cells with unlimited 
proliferation capacity that can differentiate into various cell types with specific 
functions. Two types of stem cells have been identified based on their origin, 
namely embryonic stem cells and adult stem cells. Embryonic stem (ES) cells 
are defined as cells that can commit to all the different cell types of the adult 
body (43, 168), while differentiation of adult stem cells is constrained to a 
limited number of cell types. 
ES cells are present during the early stages of embryonic development 
in the inner cell mass of the blastocyst. When isolated ES cells are reintroduced 
in early embryos, they form functional cells of all lineages in the developing 
mouse (167, 168). ES cells are therefore called pluripotent. Adult stem cells 
are referred to as multipotent, indicating that they have a less wide-ranging 
potential than ES cells, and that their differentiation capacity is restricted 
to particular cell types in the body. Adult stem cells have been found in 
various tissues throughout the body where they reside in a specific micro-
environment, also referred to as the stem cell niche, which is formed by 
differentiated somatic cells and extracellular matrix. For proper development 
and tissue homeostasis, stem cells receive multiple signals from their niche, 
including secreted cytokines and growth factors, as well as signals mediated 
by cell-cell interactions and interactions with extracellular matrix which 
control the processes of stem cell quiescence, self-renewal and differentiation 
(85, 231). 
Stem cells are not only required for development and organogenesis, 
but also for tissue maintenance (117) and tissue repair (134). For these 
processes, the stem cell compartment is essential to give the full range of 
differentiated cells while also maintaining a pool of undifferentiated cells. 
This is accomplished by a characteristic property of stem cells, namely 
their ability to self-renew. This implies that stem cells can proliferate while 
maintaining their pluripotent or multipotent character. Self-renewal can also 
occur by so-called asymmetrical cell division, which implies that upon division 
one daughter cell becomes a committed progenitor cell that subsequently 
undergoes further differentiation, while the other daughter cell remains a 
stem cell with identical characteristics as the mother cell, thereby keeping 
the size of the stem cell pool  intact (231). 
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Stem cell biology is of great clinical and scientific interest. 
Understanding stem cell development will provide molecular insight in such 
processes as early embryogenesis, but also in  tumour formation and e.g. 
autoimmune diseases (108). Both embryonic and adult stem cells have been 
shown to be able to differentiate into specialized cell types and contribute to 
the restoration of damaged tissue after transplantation into rodents (reviewed 
by Passier & Mummery (181)). Stem cell biology is therefore of particular 
interest for its possible applications in regenerative medicine whereby 
damaged or dysfunctional cells are replenished in such cases as Parkinson’s 
disease, heart failure, diabetes mellitus or skin burns.
Several types of adult stem cells have been characterized and can 
be cultured in vitro, including neural stem cells, hematopoietic stem cells, 
mesenchymal stem cells and epithelial stem cells (for overview see ref. 190). 
As our research focuses on bone biology, we have a particular interest in 
mesenchymal stem cells since these cells provide the bone forming cells 
in our body. Mesenchymal stem cells have already been applied in bone 
tissue engineering, by growing them on three-dimensional scaffolds that 
are subsequently implanted in vivo to produce new bone (34, 68, 179). In 
addition to optimization of their use in bone tissue engineering, understanding 
mesenchymal stem cell behaviour can be of great relevance in order to 
understand and intervene with bone diseases such as osteoporosis. 
 Of essential importance in understanding the mechanisms controlling 
stem cell differentiation, is to find answers to the following questions: 1) 
what are the extrinsic and intrinsic triggers that prevent or induce stem cells 
to differentiate into a specialized cell lineage, 2) what are the differentiation 
pathways induced and by which markers can such differentiated cells be 
characterized, 3) what mechanisms control the process of self-renewal? 
Solving these issues is also of clinical importance since development of stem 
cell culture techniques will eventually provide opportunities for controlling 
stem cell behaviourior ex vivo. The challenge will be to employ their self-
renewal capacity to expand stem cells in culture in order to generate sufficient 
amounts of cells, and subsequently to trigger the cells to differentiate into 
a specific cell type. Transplantation into the body of such in vitro expanded 
and differentiated cells has promising potentials for replacing cells and tissue 
affected by degenerative disorders. 
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1.2 STEM CELL DIFFERENTIATION
1.2.1 The hierarchical model of stem cell differentiation
The pluripotentiality of embryonic stem cells and the multipotentiality 
of adult stem cells implies that intricate stimulatory and regulatory 
mechanisms determine the irreversible commitment of such cells to acquire 
a particular specialized function. Although the lineage commitment and 
further differentiation of embryonic and adult stem cells may be diverse and 
cell type specific at the molecular level, some general concepts apply in the 
development of stem cells. Stem cells produce intermediate cell types with 
restricted differentiation capacity, called progenitors, which can be formed 
during asymmetric self renewal. Subsequently, progenitor cells can give rise 
to mature cell types. In comparison with their parent stem cells, progenitor 
cells are committed to a limited number of cell types generally within a single 
lineage. Furthermore, progenitor cells still have the ability to proliferate, but 
unlike stem cells they cannot self-renew. 
Stem cell differentiation has been considered to be hierarchical in 
nature, such that the generation of specialized cell types occurs stepwise 
through defined intermediate stages. To date, the best-described model of 
adult stem cell differentiation is that of the hematopoietic stem cell, from which 
all cells of the blood and immune system are formed. The model presented 
in Fig. 1 is illustrative for lineage commitment and further differentiation 
of adult stem cells. As a first event, hematopoietic stem cells can form 
two distinct progenitors, namely a myeloid and a lymphoid progenitor. The 
latter progenitor generates mature immune cells such as B lymphocytes, T 
lymphocytes and natural killer cells, while the myeloid progenitor differentiates 
into erythrocytes, platelets, neutrophils, macrophages and monocytes. 
According to this model, stem cells generate restricted progenitor cells that 
become gradually more specialized by losing their ability to differentiate along 
alternative pathways. Similar hierarchical models have been described for 
differentiation of other adult stem cells, including intestinal stem cells (189), 
epidermal stem cells (139), neural stem cells (237) and, as will be discussed 
below,  for mesenchymal stem cells.        
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1.2.2 Is stem cell differentiation really hierarchical?
The hierarchical differentiation model suggests that stem cell 
commitment and lineage progression is uni-directional. This implies that, 
once committed, cells would only be able to differentiate into a particular 
cell type. However, evidence is accumulating that the process is more 
flexible. For instance, the hierarchical model of hematopoietic lineage 
commitment has been challenged, based on studies on hematopoietic stem 
cells in culture (58, 188). When synchronized hematopoietic stem cells are 
Figure 1. 
The hierarchical model of hematopoietic stem cell differentiation.
Hematopoietic stem cells (HSC) differentiate into specialized mature cells via 
progenitor cells. HSC can form two types of progenitor cells, namely a common 
myeloid progenitor (CMP) and a common lymphoid progenitor (CLP), which are 
restricted in their differentiation capacity relative to the parent HSC. The CLP can 
differentiate into cells of the immune system, while in its turn the CMP gives rise to 
progenitors that are committed to a limited number of cell types. According to this 
hierarchical model, progenitor cells gradually lose their ability to differentiate along 
alternative pathways. 
Abbreviations: MEP, megakaryocyte/erythrocyte progenitor; GMP, granulocyte/
monocyte progenitor; EoP, eosinophyl progenitor; BMCP, basophil/mast cell 
progenitor; MCP, mast cell progenitor; BaP, basophil progenitor. 
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treated with granulocyte-macrophage differentiation medium, the outcome 
of differentiation appears to depend on the position of the cells in the cell 
cycle at the moment that the differentiation medium is added. This has led to 
the introduction of the term “differentiation hotspots”, which are defined as 
phases during the cell cycle during which differentiation is directed towards a 
specific lineage, such as myeloblasts or megakaryocytes. These observations 
are supported by studies on cell cycle dependent expression of adhesion 
proteins (21, 30) and cytokine receptors (192). Based on these findings, it 
has been speculated that a reversible continuum of a hematopoietic cell exists 
that behaves like a stem cell as well as a progenitor, dependent on the cell 
cycle stage, thus arguing against a stem cell/progenitor hierarchy. This would 
imply that the early steps of stem cell commitment are reversible, as has 
indeed also been shown for epithelial stem cells in vitro (37).
Another argument against the hierarchical model is the observation 
that flexibility in differentiation potential of cells does not appear to be 
limited to the earliest steps of stem cell commitment. Cells can undergo 
transdifferentiation, which implies that differentiated cells can change their 
phenotype. In the literature, this term is also often used for the flexible 
behaviour of stem cells, but here the term will be used restrictively for the 
flexibility of differentiated cells. For instance, a subset of human peripheral 
blood monocytes can give rise to both macrophages and T cells in vitro 
(246). Since macrophages develop from a myeloid progenitor, while T cells 
develop from a lymphoid progenitor, this suggests that a supposedly mature 
monocyte can exhibit properties of a hematopoietic stem cell. Similarly, 
preadipocytes can be converted into fully differentiated osteoblasts (206), 
while osteoblasts can be converted into adipocytes (171), all cells of the 
mesenchymal lineage. A possible mechanism to explain transdifferentiation is 
that committed cells first dedifferentiate and subsequently redifferentiate into 
another cell type. It is known that during regeneration of amputated tissues 
in amphibians, terminally differentiated cells lose their characteristics and 
dedifferentiate into immature cells, which then redifferentiate to generate 
new tissue (42). In mammals, no examples of dedifferentiation are known in 
vivo, but such phenomena have been observed e.g. in cultured murine C2C12 
myoblasts. Such myoblast progenitor cells fuse into multinucleated myotubes 
when grown under low serum conditions. However, upon ectopic expression 
of the homeobox transcription factor gene Msx1 from a tetracycline-inducible 
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vector in multinucleated myotubes, the myotubes are cleaved and the 
resulting mononucleated cells can subsequently differentiate into adipocytes, 
osteoblasts or chondrocytes when cultured in appropriate differentiation 
supportive media (172). 
It is important to note that these observations have been obtained 
from in vitro culture experiments. It is well possible that cell culture 
conditions change the fate of cells, since it has frequently been observed that 
the developmental potential of progenitors is different under in vitro and in 
vivo conditions (117). Nevertheless, the in vitro data provide a basis for the 
concept that supposedly committed and differentiated cells are not entirely 
constrained to differentiate along predetermined specific lineages, but that 
they can be manipulated to change their differentiation fate. 
1.2.3 Adult stem cell plasticity 
While transdifferentiation is related to differentiated cells, the term 
stem cell plasticity refers to the concept that adult stem cells may differentiate 
into specialized cell types of other lineages than where they are derived from. 
There are indications that stem cells can cross tissue boundaries and can 
differentiate into cells of tissues that are either derived from the same or from 
another embryonic germ layer. Stem cell plasticity has been suggested from 
numerous published studies in which isolated adult stem cells were transplanted 
into mice and found to be engrafted in regenerating damaged tissues other 
than their tissue of origin. For instance, bone marrow-derived mesenchymal 
stem cells migrate to the brain after injection in mice and differentiate into 
neural cell types, while hematopoietic stem cells differentiate into various 
tissues including skin, liver and lung (reviewed in reference 181). However, 
these data are still controversial, since other mechanisms than plasticity might 
account for the results obtained, including impurity of the test population, cell 
fusion, or the co-purification of rare pluripotent stem cells (228). Care must 
therefore be taken to interpret results that suggest lineage conversion. Cell 
fusion, for example, has been shown to occur spontaneously in co-cultures of 
embryonic stem cells and bone marrow cells (216) or neural progenitor cells 
of the brain  (243). Moreover, transplanted hematopoietic bone marrow cells 
may contribute to regeneration of non-hematopoietic tissues, but it has also 
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been shown that these results may arise from the fusion of bone marrow cells 
with for example Purkinje neurons, liver hepatocytes, or cardiac muscle cells 
(7, 224, 230, 232). 
The plasticity of hematopoietic stem cells  has been debated by Wagers 
and coworkers, since they were  unable to detect GFP-labelled hematopoietic 
stem cells in non-hematopoietic tissues of recipient mice, while reconstitution 
of blood cells was observed (227). On the other hand, two recent independent 
studies showed that purified bone marrow-derived hematopoietic stem cells 
are able to produce osteoblasts in bone (70, 175), ruling out the possibilities 
of contamination or cell fusion (70). From these studies it was concluded that 
in the bone marrow a common progenitor exists that can either give rise to 
hematopoietic or osteogenic differentiation. 
 Plasticity of mesenchymal stem cells has been claimed from studies in 
which bone marrow-derived mesenchymal stem cells (MSC) were injected into 
brains, and shown to engraft and differentiate into cells that express neuronal 
markers (13, 40, 132). This observation suggests that these cells have the 
capability to form cell types from different embryonic germ layers. This is 
supported by in vitro data showing that MSC cannot only be stimulated to 
differentiate into osteoblasts, chondrocytes, adipocytes (184) and endothelial 
cells (176), which are all of mesodermal origin, but also into neurons and glia 
which originate from the neuroectoderm during development (75, 118, 200, 
235), or into hepatocytes which are of the endodermal lineage (137, 140). 
These results suggest that adult stem cells can be reprogrammed and, at least 
to some extent, possess pluripotent characteristics. It has been hypothesized 
that adult stem cells express genes of many lineages at low levels which 
are specifically repressed during differentiation along a particular lineage 
(247). Undifferentiated MSC express low levels of neurogenic as well as 
osteogenic markers, and during osteogenic differentiation neural markers are 
repressed, while vice versa osteoblast markers are repressed during neuronal 
differentiation (75). Similarly, hematopoietic stem cells express many different 
hematopoietic lineage-specific genes at a low level, but also genes of non-
hematopoietic tissues including liver, brain, muscle, kidney and heart, which 
are down-regulated upon differentiation (4, 103, 217). Stem cells generally 
express genes from multiple lineages when compared  to progenitor cells 
which are more restricted in their expression pattern (4). It therefore seems 
that stem cell differentiation proceeds by lineage repression, since not only 
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differentiation-specific genes are upregulated, but at the same time genes 
characteristic for other differentiation directions are downregulated. It can 
thus be proposed that broad expression profiles observed in undifferentiated 
stem cells is part of  an intrinsic program that allows for lineage conversion 
and plasticity. 
 It is not known whether plasticity normally occurs in the body, and 
to what extent it is a characteristic of all adult stem cells. In fact, if adult 
stem cells indeed exhibit plasticity in vivo, they may not have completely 
lost their pluripotent character which is thought to be unique for embryonic 
stem cells. Interestingly, adult stem cells have been isolated with apparent 
unrestricted differentiation capacity. Kogler and colleagues (130) reported the 
isolation of stem cells from human umbilical cord blood, referred to as USSC 
(unrestricted somatic stem cells), which can differentiate into mesenchymal, 
hematopoietic and neural cell lineages in vitro, and are able to form hepatic 
cells, hematopoietic cells and cardiomyocytes after transplantation into 
animals. Since USSC were shown to contribute to bone reconstitution 
and chondrogenesis after transplantation into rodents, but also show 
hematopoietic engraftment in sheep, they are obviously able to differentiate 
into various functional cells in vivo. Another somatic stem cell with the 
capacity to differentiate in vitro into cells of all three germ layers has been 
found to co-purify with adult bone marrow-derived mesenchymal stem cells 
(115). These so-called MAPC (multipotent adult progenitor cells) contribute 
to the formation of most somatic tissues when injected into early blastocysts. 
MAPC and USSC are thus believed to exhibit intrinsic pluripotency. 
Altogether, it is becoming more clear that adult stem cells and possibly 
also committed progenitor cells express a repertoire of genes that makes the 
cells flexible in their behaviour. It can be questioned whether adult stem cells 
are indeed limited in their differentiation capacity, or that they are in fact 
pluripotent-like embryonic stem cells, as long as the appropriate conditions 
are applied. The origin of adult stem cells in the body is still not known, and 
one possibility is that they are in fact remnants of ES cells. It is also possible 
that in addition to lineage specific adult stem cells, ES-like stem cells are still 
present in the body (135).
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1.2.4 Growth factor control of stem cell behaviour: The Wnt pathway
The generation of different cell types from specific stem cells 
requires the balanced activity of a variety of signalling pathways that direct 
differentiation towards a specific lineage. Signalling induced by members 
of the Wnt, TGFβ, FGF, Notch and Hedgehog families of growth factors, as 
well as by nuclear hormones such as retinoic acid, is responsible for the 
specification and differentiation of germ layers during development (for 
overview see Loebel et al. (150)). In analogy, these growth factors have the 
capability to promote differentiation of embryonic stem cells in culture along 
mesoderm, endoderm and ectoderm lineages (for reviews see e.g. references 
125 and 150). The above signalling pathways appear also important for 
regulating maintenance and differentiation of both embryonic and adult stem 
cells. On the one hand, the growth factors are important for self-renewal of 
stem cells, while on the other hand they are determinants for lineage-specific 
differentiation. Recently, Wnt signalling has drawn the particular attention of 
bone researchers, since Wnt activity appears to be positively correlated with 
bone mass (95, 122). 
Wnts are small, lipid-containing polypeptides that act on target cells 
by binding to seven-transmembrane receptors of the Frizzled (Fzd) family 
and their co-receptors LRP5/6 (low-density lipoprotein receptor-related 
proteins) to transduce a signal to the cytosolic protein Dishevelled (Dsh). 
From this point, the signal can diverge into three possible pathways: the so-
called canonical pathway, the Wnt/Ca2+ pathway or the planar cell polarity 
(PCP) pathway (23, 180, 225). Activation of the Wnt/Ca2+ pathway results 
in elevated Ca2+ levels that activate calcineurin which dephosphorylates the 
transcription factor NFAT. As a result, NFAT accumulates in the nucleus and 
mediates gene expression. The PCP pathway mediates signalling by activation 
of the c-Jun amino-terminal kinase. However, by far the best characterized of 
the three cascades is the canonical signalling pathway (Figure 2). 
The central player in the canonical Wnt pathway is CTNNB1, better 
known as β-catenin. In the absence of Wnt signals, cytoplasmic β-catenin 
is associated with a multiprotein complex consisting of APC (adenematous 
polyposis coli), axin and GSK3B (glycogen synthase kinase 3 beta). In this 
complex, β-catenin is constitutively phosphorylated by GSK3B which leads to 
its ubiquitination and subsequent proteasomal degradation. When Wnt binds 
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Figure 2.
The canonical Wnt / β-catenin pathway.
The central player in the canonical Wnt pathway is β-catenin. In the absence of 
activating Wnt signals, cytoplasmic β-catenin is phosphorylated by a multiprotein 
complex containing Apc (Adenomatous Polyposis Coli), Axin and Gsk-3B 
(glycogen synthase kinase-3β), resulting in the degradation of β-catenin. The 
pathway is activated when Wnt interacts with a receptor complex formed by the 
transmembrane proteins Frizzled and Lrp5/6, thereby transmitting the signal to Dsh 
(disheveled) which eventually leads to inhibition of β-catenin phosphorylation. As a 
result, β-catenin is stabilized, and translocates into the nucleus where it turns TCF/
LEF (T-cell transcription factor / lymphocyte enhancer factor) into a transcriptional 
activator. 
At the extracellular level, Wnt signals can be modulated by various molecules that 
can inhibit Wnt signalling either by preventing interaction between Wnt and Fzd, or 
by depleting Lrp5/6 receptors from the membrane. See text for details.
to its cognate receptors, Dsh inactivates GSK3B with the result that β-catenin 
remains unphosphorylated, accumulates and translocates to the nucleus. 
There, stabilized β-catenin interacts with the transcription factors of the TCF/
LEF (T-cell transcription factor / lymphocyte enhancer factor) family which 
results in the transcriptional activation of Wnt target genes. 
Specificity of Wnt signalling is achieved by the expression of specific 
Wnts, Fzd receptors, Lrp co-receptors and extracellular Wnt modulating 
proteins. Currently, 19 different Wnt genes have been identified in human 
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and mice, in combination with more than 10 different Fzd receptors (for 
up-to-date overview see ref. 1). At the extracellular level, Wnt signalling 
activity is modulated by various classes of secreted proteins, including Dkk 
(Dickkopfs), Sfrp (Secreted Frizzled-related proteins), Cerberus, Wif1 (Wnt 
inhibitory factor 1) and Wise (124). Of these molecules, Sfrp, Wif1 and 
Cerberus can modulate Wnt activity by binding to either Wnt itself or to Fzd, 
thereby preventing functional interaction between Wnt and its receptor (14, 
102, 183). Alternatively, Dkk and Wise modulate Wnt activity by forming a 
complex with the Wnt coreceptor Lrp. Dkks interact with Lrp and Kremen, 
which results in the subsequent internalization of this complex  by endocytosis 
(15, 156, 157). Due to this removal of Lrp from the plasma membrane, Wnt 
is unable to induce its signalling activity.
The many players in the Wnt cascade hamper the precise elucidation 
of the mechanisms by which Wnt signalling specificity is achieved (47). Gain- 
or loss-of-function studies in mice have revealed the function of various 
components of the pathway, including Wnts, Fzd receptors and intracellular 
mediators (For overview see ref. 151). These studies have shown that Wnt 
signalling is involved in numerous developmental processes such as pattern 
formation and tissue specification, but also in maintaining tissue homeostasis. 
As shown by mutational analysis of several Wnt signalling components, 
the maintenance of pluripotency, self-renewal and lineage specification of 
embryonic and adult stem cells is controlled by the Wnt pathway (193). For 
instance, Wnts have been shown to promote the self-renewal of different 
types of adult stem cells in vivo, including hematopoietic stem cells (194, 
233), intestinal epithelial cells (20, 222), stem cells of the skin (104) and 
neural stem cells (55). Recently, it has been shown that canonical Wnt 
signalling promotes osteoblast differentiation in vivo by controlling the cell 
fate choice of progenitor cells in the mesenchymal condensations that give 
rise to the skeleton, as will be discussed below (chapter 1.3.3).
1.2.5 Mesenchymal stem cell differentiation
Mesenchymal stem cells (MSC) are multipotent adult stem cells of 
mesodermal origin with the ability to differentiate into cells of multiple tissues 
including muscle, bone, cartilage, fat, tendon and marrow stroma (179). 
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Multipotent MSC have been isolated from various adult tissues including 
bone marrow (59), skeletal muscle (10) , adipose tissue (248), umbilical 
cord blood (198) and fetal lung (109). MSC can most easily be harvested 
from bone marrow. When placed in culture, bone marrow-derived MSC retain 
their multipotential capacity and can differentiate into at least osteoblasts, 
chondrocytes and adipocytes (184). 
The origin and development of MSCs in the body is poorly understood, 
since it is not exactly known how adult stem cells arise from embryonic stem 
cells. Pretreatment of embryonic stem cells with retinoic acid induces a MSC-
like intermediate cell that can subsequently be triggered to differentiate 
into osteoblasts, chondrocytes or adipocytes (62, 123), but the underlying 
mechanisms remain to be solved. Moreover, the exact nature of progenitor 
cells that are responsible for the lineage commitment of mesenchymal stem 
cells is less well understood than in the case of hematopoietic stem cells due 
to a lack of specific markers to characterize intermediate stages. In particular, 
the early commitment steps of mesenchymal stem cells and the identity of 
the progenitor cells involved need further elucidation. 
The commitment of MSC and progression along specific lineages 
requires the transcriptional control of specific sets of genes. Genes encoding 
transcription factors that have been identified as driving forces in mesenchymal 
lineages, are PPARg2 (peroxisome proliferator-activated receptor gamma 2) 
and C/EBP (CCAAT-enhancer binding protein alpha) for adipocyte; SOX9 
for chondrocyte; and RUNX2 (Runt-related transcription factor 2) and OSX 
(Osterix) for osteoblast differentiation. Expression of these transcription 
factors in progenitor cells marks early differentiation and determines their 
lineage commitment. The precise identity, hierarchy, and differentiation 
capacity of intermediate progenitors during mesenchymal stem cell 
differentiation is not fully understood, but it has been postulated that it occurs 
either via tripotential or bipotential progenitors (145). Tripotential progenitors 
would have the capacity to differentiate into osteoblasts, chondrocytes and 
adipocytes, while the bipotential progenitors can differentiate either into 
osteoblasts and chondrocytes (osteo-chondroprogenitor) or into osteoblasts 
and adipocytes (osteo-adipoprogenitor) (Figure 3). Recent literature has 
provided genetic evidence for the in vivo existence of distinct osteo-chondro 
and osteo-adipoprogenitors, in which Runx2, Osterix, Sox9, and Pparg2 
function in cell fate determination, as will be discussed later on. Interestingly, 
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each of these genes induces a particular phenotype, by actively suppressing 
other lineage directions. The focus of this introduction will be particularly on 
the differentiation of osteoblasts, because of its direct relevance for frequently 
occurring bone disorders such as osteoporosis. 
1.3 MESENCHYMAL STEM CELLS, OSTEOBLAST DIFFERENTIATION AND 
BONE DEVELOPMENT
1.3.1 The role of the transcription factor Runx2 in skeletal development
Osteoblasts, chondrocytes and adipocytes originate from a common 
mesenchymal stem cell during development. Intrinsic regulators that direct 
the progenitors towards one of these three cell types are the transcription 
factors Runx2, Osx, Sox9 and Pparg2. Genetic inactivation of individual factors 
in mice does not only result in impaired differentiation into one pathway, but 
also in ectopic gene expression characteristic for the other differentiation 
pathways. Mesenchymal stem cell differentiation is thus characterized by 
promoting one lineage at the expense of others, and the cell fate of choice is, 
at least in part, controlled by Runx2, Osx, Sox9 and Pparg2. 
During embryonic development skeletal elements are formed 
from condensations of mesenchymal stem cells (18) (Figure 4). The best-
characterized transcription factor that determines lineage commitment and 
further differentiation of mesenchymal cells towards osteoblasts is the Runt-
related transcription factor Runx2 (formerly known as Cbfa1/Osf2/Pepb2αA). 
Runx2 has been identified as a transcriptional activator of the osteoblast-
specific gene Bglap1 (bone gamma-carboxyglutamate protein 1 or osteocalcin) 
(73). The role of Runx2 as an osteoblast inducing transcription factor is 
further underlined by the observation that forced expression of Runx2 in 
non-osteoblastic cells induces expression of osteoblast marker genes such as 
Bglap1, Col1a1 (collagen type I, alpha 1), Ibsp (integrin binding sialoprotein 
or bone sialoprotein) and Spp1 (secreted phosphoprotein 1 or osteopontin) 
(16, 73, 99, 127). Genetic evidence that Runx2 plays an important role in 
skeletal development is provided by the lack of bone formation in Runx2 
homozygous mutant mice. Osteoblast differentiation in these Runx2 (-/-) 
mice is completely arrested with the result that their skeleton remains entirely 
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cartilaginous (131, 178). Furthermore, heterozygous loss of Runx2 in mice 
causes hypoplastic clavicles and delayed bone formation in the suture (178), 
thereby mimicking the human disorder cleidocranial dysplasia which is caused 
by inactivating mutations in the RUNX2 gene (128, 163). The importance 
of Runx2 in skeletal biology is underscored by the observation that Runx2 
Figure 3.
Model of mesenchymal stem cell commitment via bipotential progenitors. 
Osteoblasts, chondrocytes and adipocytes originate from bipotential precursor cells 
in vivo, in which the transcription factors Runx2, Osterix (Osx), Pparg and Sox9 are 
key regulators of lineage specification. Osteo-chondroprogenitor cells express both 
Runx2 and Sox9. The canonical Wnt signalling pathway regulates differentiation 
of osteo-chondroprogenitor cells in such a way that high β-catenin levels promote 
Runx2 (▲) and inhibit Sox9 (▼) expression, resulting in osteoblast differentiation. 
Low β-catenin levels in osteo-chondroprogenitor cells result in increased Sox9 and 
decreased Runx2 expression, resulting in chondrocyte differentiation. Expression 
of Runx2 and Osx establishes the osteoblast phenotype by inducing osteoblast 
differentiation while simultaneously inhibiting chondrocyte differentiation (┤). 
Conversely Sox9 inhibits osteoblast differentiation. 
Osteo-adipoprogenitor cells have the capacity to differentiate into osteoblasts or 
adipocytes, a choice that can be regulated by Wnt signalling. Wnt activity promotes 
osteoblast differentiation by inducing Runx2 and Osx expression, thereby inhibiting 
adipocyte differentiation. Runx2 and Pparg inhibit each others activities. The 
existence of tripotential precursors of bipotential cells in vivo has not been shown 
to date. See text for further details. 
24
Chapter 1
25
General Introduction
has a broader function than just controlling osteoblast differentiation during 
development. Runx2 also exerts a positive control on bone matrix deposition 
by differentiated osteoblasts during postnatal life (72), while Runx2 has also 
been shown to negatively regulate cell growth of (pre)osteoblasts in culture 
(86, 187). Besides expression and function in osteoblasts, Runx2 is also 
expressed in chondrocytes during cartilage development where it promotes 
their maturation into hypertrophic chondrocytes, as evidenced by the induction 
of markers for chondrocyte hypertrophy such as Col10a1 (procollagen, type 
X, alpha 1) (77, 110, 213, 221). 
1.3.2 Runx2 is a determinant of mesenchymal lineage commitment: 
Evidence for bipotential progenitors
Cells in the mesenchymal condensations at the onset of murine 
skeletal development co-express Runx2 and Sox9 at low levels (241). 
Expression of Sox9 precedes that of Runx2 and occurs before mesenchymal 
condensations takes place. In this way progenitors with chondrogenic as 
well as osteogenic potential are formed and these cells are thus defined as 
osteo-chondroprogenitors (5). Promoting Runx2 expression and inhibiting 
Sox9 expression in these cells will induce osteoblast differentiation, while 
an increase of Sox9 expression and a decrease in Runx2 expression results 
in chondrocyte differentiation (64). In mouse embryos, expression of Runx2 
in mesenchymal condensations has been detected from 10.5 dpc (days post 
coitum) (71, 178). However, expression of osteoblast marker genes, such as 
Ibsp, is only detectable after 13 dpc, which has been explained by transient 
inhibition of Runx2 function as a result of a physical interaction of the DNA 
binding domain of Runx2 with Twist proteins (33). Upon release of Runx2 
from Twist inhibition, expression of osteoblast marker genes is induced. The 
absence of Twist expression in chondrocytes during embryonic development 
(33) suggests that its role to inhibit Runx2 is specific for osteoblasts. The reason 
for this delay between Runx2 expression in embryonic mesenchymal cells and 
its function in inducing the osteoblast phenotype still has to be established. 
The observation that the periosteum in Runx2 (-/-) mice is thinner than in 
wild-type embryos (169, 178) indicates that Runx2 is required for formation 
of the mesenchymal condensation, prior to differentiation. It is also likely that 
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Runx2 expression during this period is necessary for predetermination of the 
lineage commitment of MSC, conceivably by suppression of chondrogenic and 
adipogenic differentiation. This hypothesis is supported by the observation 
that Runx2 (-/-) calvaria-derived cells in culture spontaneously differentiate 
into adipocytes in the absence, or into chondrocytes in the presence of BMP2, 
but not into osteoblasts (129). Furthermore, chondrocytes isolated from 
Runx2 (-/-) mice undergo spontaneous adipocyte differentiation in vitro and 
express the marker gene Pparg (78). Expression of Runx2 is not sufficient, 
however, for full commitment of a mesenchymal cell towards the osteoblast 
Figure 4.
Bone development.  
During development, bone is formed via two processes, endochondral ossification 
(A) and intramembranous ossification (B). During both process, mesenchymal stem 
cells aggregate to form a so-called mesenchymal condensation that forms the shape 
of the skeletal elements. Long bones in the skeleton develop via endochondral 
ossification, a two-step process in which the mesenchymal cells in the centre of the 
condensation first differentiate into chondrocytes to form a cartilage template which 
is subsequently gradually replaced by bone. In the central region of the cartilage, 
chondrocytes become hypertrophic and secrete cartilage matrix. Subsequently, the 
hypertrophic chondrocytes undergo apoptosis and the cartilage template is invaded 
by blood vessels accompanied by osteoblasts from the periostal mesenchyme layer 
and osteoclasts. The cartilage matrix is then degraded by osteoclasts and replaced 
by bone matrix deposited by osteoblasts. In contrast, flat bones are formed by 
intramembranous ossification, in which the mesenchymal stem cells differentiate 
directly into osteoblasts. (Figure adapted from Baron, 2003, see ref 18). 
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lineage, which requires at least expression of Osx (osterix). This osteoblast 
specific transcription factor promotes osteoblast differentiation downstream 
of Runx2, which is evidenced by the observation that Osx (-/-) mutants 
express Runx2 but no late osteoblast markers (169). Interestingly, skeletal 
cells from Osx (-/-) mice show ectopic expression of the chondrocyte marker 
genes Sox9, Sox5, Col2a1 (procollagen, type II, alpha 1) and Ihh (Indian 
hedgehog). Both Runx2 and Osx thus induce osteoblast differentiation, and at 
the same time suppress chondrogenic differentiation of mesenchymal cells. 
Conversely, Sox9 acts as a negative regulator of osteoblast 
differentiation in skeletal progenitor cells by inhibiting Runx2 and Osx 
expression. In the head, skeletal elements are derived from two different 
origins, namely mesodermal cells and neural crest cells (114). Conditional 
inactivation of Sox9 in cranial neural crest cells results in a block of 
chondrocyte differentiation and instead expression of the osteoblast marker 
genes Runx2, Osx and Col1a1 (collagen type I alpha 1) is induced in cartilage 
of these Sox9 mutant mice (162). 
A similar repressive effect on osteoblast differentiation is exerted 
by Pparg. Heterozygous Pparg deficient mice show enhanced bone mass as 
a result of an increase in osteogenesis from bone marrow precursor cells, 
while adipocyte numbers are decreased (6). When cultured ex vivo, Pparg 
(+/-)-derived bone marrow cells show increased expression levels of Runx2, 
Osx, Col1a1 and Bglap1. On the other hand, calvaria-derived osteoblasts 
from Pparg (+/-) mice in culture behave similar to wild-type cells, indicating 
that Pparg haploinsufficiency affects bone marrow progenitors, but not cells 
that are already committed to osteoblasts. Taken together, these results are 
indicative for the existence of an osteo-adipo progenitor cell in the bone 
marrow. 
Unlike wild-type blastocyst-derived embryonic stem cells, Pparg (-
/-)-derived ES cells express the osteoblast markers Runx2 and Bglap1 also 
under regular culture conditions, so in the absence of osteo-inducing factors 
(6). From this observation it has been concluded that also osteoblasts and 
adipocytes are derived from a common progenitor cell in vivo. This is further 
supported by the observation that adipose-derived stromal cells seeded on 
a polymer are able to heal cranial defects by bone formation (61) while in 
patients with osteoporosis a disturbance of the balance between adipogenesis 
and osteogenesis has been observed (see section 1.4.2).
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 Taken together, these data provide evidence for the existence of at 
least two distinct bipotential progenitors in vivo in which Runx2, Sox9 and 
Pparg appear to regulate their cell fate determination. Runx2 promotes 
osteoblast differentiation, while repressing adipocyte and chondrocyte 
differentiation in both osteo-chondro and osteo-adipo progenitors. Sox9 
induces chondrocyte differentiation, thereby exerting a negative effect on 
osteoblast differentiation. Pparg regulates adipocyte differentiation and 
suppresses osteoblast differentiation (Figure 3). Although these data show 
that these distinct progenitors are bipotential, it can not be excluded that they 
are still able to differentiate into other cell types. For instance, expression 
of adipoctye markers has not been examined in Runx2 (-/-) and Sox9 (-/-) 
mice, while expression of chondrocyte markers has  not been studied in 
Pparg (+/-) mice. The existence of distinguishable bipotential progenitors 
has also been shown in vitro by Okamoto et al. (173). Clonal analysis of 
human immortalized MSC showed the presence of osteo-chondro-adipo 
tripotential progenitors, as well as osteo-chondro and osteo-adipo bipotential 
progenitors, and monopotential progenitors, but no chondro-adipo bipotential 
progenitors were identified. As shown in the next section, canonical Wnt 
signalling has been shown to modulate the expression levels of Runx2, Sox9 
and Pparg in MSC in vivo and consequently their lineage commitment during 
development. 
1.3.3 Extrinsic control of mesenchymal lineage determination by Wnt 
signalling
The existence of distinct Wnts, Wnt (co)receptors and extracellular 
modulators of Wnt activity complicates the studies on the role of Wnt 
signalling in osteogenesis, since specificity of interactions between the 
players involved is largely unknown, while in addition components of the 
Wnt signalling pathway have been shown to be redundant. The effect of the 
canonical pathway on developmental processes can best be investigated by 
using mice with a Ctnnb1 deletion, or by overexpressing a stabilized form of 
β-catenin. Such studies have provided in vivo evidence that canonical Wnt 
signalling is involved in the determination of mesenchymal cell fate during 
development. Apparently, the differentiation route of the bipotential osteo-
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chondroprogenitor cells, that express both Sox9 and Runx2 in the skeletal 
condensations, is determined by β-catenin levels. Recently, it has been shown 
by two groups that β-catenin controls MSC commitment at an early stage 
of differentiation (64, 101), such that high Wnt signalling activity induces 
osteoblast differentiation and suppresses chondrocyte differentiation, while 
low Wnt activity represses osteoblast differentiation and induces chondrocyte 
formation. 
Conditional inactivation of the β-catenin gene in early mesenchymal 
condensations before the onset of chondrocyte and osteoblast differentiation 
resulted in ectopic chondrocyte differentiation at the expense of osteoblast 
formation during ossification (64, 101). In comparison with control embryos, 
Sox9 expression was ectopically induced in β-catenin deletion mutants, 
while Runx2 and Osx expression was reduced. Furthermore, inactivation of 
β-catenin led to reduced bone mineral formation, but enhanced chondrocyte 
differentiation of calvaria-derived mesenchymal progenitors cells (64). 
Conversely, high β-catenin levels downregulated Sox9 expression in 
developing limb buds, but did not result in an increased differentiation 
of osteoblasts (101). Canonical Wnt signalling is thus a pathway that 
controls both osteoblast and chondrocyte differentiation. Day et al. (64) 
further showed that β-catenin is present in the nucleus of differentiating 
osteoblasts in developing bone. High levels of Wnt signalling are therefore 
believed to be critical for the induction of osteoblast differentiation and 
suppression of chondrocyte differentiation by inducing Runx2 and at the 
same time decreasing Sox9 expression. Lower Wnt signalling decreases 
Runx2 and increases Sox9 expression resulting in induction of chondrocyte 
differentiation and suppression of osteoblast differentiation. This concept is 
further supported by studies on ectopic expression of Wnt14 in chondrocytes, 
a gene that is endogenously expressed in differentiating osteoblasts (122) 
and signals via the β-catenin mediated canonical pathway (98). Wnt14 was 
found to block chondrocyte differentiation and the subsequent endochondral 
bone formation upon overexpression in chondrocytes (64). 
 A role for Wnt signalling has also been observed in determining 
mesenchymal cell fate in the bone marrow. Here, canonical Wnt signalling 
determines the cell fate of osteo-adipoprogenitor cells in their choice to 
become adipocytes or osteoblasts. Transgenic expression of Wnt10b from 
the FABP4 promoter drives expression of this gene specifically in adipose 
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tissue and bone marrow of mice (152). Wnt10b is an inhibitor of adipocyte 
differentiation in vitro (27) and FABP4-Wnt10b mice show indeed reduced 
adipose tissue (152). In contrast, transgenic Wnt10b expression caused 
increased bone mass as measured by trabecular number and trabecular 
thickness. Retroviral expression of Wnt10b in the mesenchymal progenitor 
cell line ST2 promotes expression of osteogenic markers, including Runx2 
and Osx, while inhibiting expression of the adipogenic genes C/EBP, Pparg 
and Fabp4 (26). Furthermore, Wnt10b (-/-) mice show a reduced bone 
mass when compared to wild-type mice as a result of decreased functional 
osteoblasts (26). These data show that Wnt10b is an endogenous regulator 
of the differentiation of osteoblast and adipocyte progenitors. To summarize, 
accurately balanced Wnt signals are crucial in the control of lineage decisions 
during the early stages of MSC differentiation (Figure 3). Activation of Wnt 
signalling drives bipotential progenitor cells (osteo/chondro progenitors and 
osteo/adipo progenitors) towards the osteoblast lineages by increasing Runx2 
expression, thereby reducing expression of Sox9 or Pparg. In contrast, low 
Wnt activity allows the progenitors to differentiate along the chondrocyte or 
adipocyte lineage, respectively. 
1.3.4 How is the identity of osteoblasts established?
Although the function of osteoblasts as bone depositing cells is 
unambiguous, it is much less clear how this specificity is achieved at the 
genetic level. The regulatory genes Runx2 and Osx, as well as genes encoding 
matrix proteins such as Col1a1, Ibsp and Bglap1, are generally considered as 
markers of the osteoblast phenotype according to their high expression levels 
in osteoblasts, in comparison with other cell types. However, osteoblasts 
strongly resemble fibroblasts in terms of their overall gene expression 
profile (71), and currently only one osteoblast-specific transcript, namely 
Bglap1 (osteocalcin), is known. Therefore, the question remains what gene 
expression repertoire determines that a mesenchymal stem cell becomes a 
functional osteoblast? 
The full process of osteoblast differentiation from a stem cell to a 
terminally differentiated osteoblast can be viewed as occurring in different 
phases, each of which is characterized by specific gene expression patterns 
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(211) (Figure 5). At the level of functional processes, the osteoblast growth 
and differentiation program proceeds through five phases, namely a 
commitment, a proliferation, a matrix deposition, and a matrix mineralization 
phase, eventually followed by apoptosis. At the cellular level, a more 
detailed description of the hierarchy of osteoblast lineage commitment 
and differentiation has been made. On the basis of expression patterns of 
marker genes, distinct cellular stages have been distinguished ranging from 
multipotential stem cell via immature and mature osteoprogenitor cells, 
preosteoblast and mature osteoblast to osteocyte (11, 12). 
Recognition of these stages resulted from gene expression studies 
on populations of differentiating cells. At the single cell level, however, 
morphologically indistinguishable mature osteoblasts undergoing matrix 
mineralization have been shown to exhibit different molecular phenotypes, 
indicating that gene expression in osteoblasts might be heterogeneous (148). 
Individual mature osteoblasts appear to differ in their profile of osteoblast 
markers, since strong differences in both mRNA and protein expression levels 
have been observed for Spp1, Ibsp and Bglap1 in distinct clonally derived 
osteoblast colonies. Remarkably, immunocytochemical analyses revealed that 
functionally identical, adjacent osteoblasts express osteocalcin at different 
levels (148). Similar heterogeneity has been observed in osteoblasts of 
calvaria in vivo, and of the various lineage markers tested only Akp2 (alkaline 
phosphatase 2, liver) and Pthr1 (pth/pthrp receptor) showed expression in 
all osteoblasts (49). Gene expression analysis of 9 osteoblast genes in 99 
individual differentiating clones of calvaria-derived osteoprogenitor cells 
did confirm this heterogeneity, but interestingly did not support the linear 
and deterministic sequence in gene expression pattern that is observed in a 
population of differentiating osteoblasts (154). Instead, it was concluded that 
not the sequential order of gene expression, but the combined expression of 
particular genes is required to drive a cell to develop into a mature osteoblast. 
This conclusion argues against a hierarchical order of gene expression during 
differentiation, and implies that different pathways of gene expression can 
lead to the same functional end point. 
Moreover, differentiation flexibility of mature osteoblasts has been 
described. Human bone marrow-derived MSC transfected with the gene 
encoding green fluorescent protein from the osteocalcin promoter could be 
differentiated into osteoblasts and subsequently sorted from other cells based 
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on their fluorescence. Still, these isolated cells were subsequently  able to 
differentiate into chondrocytes or adipocytes, indicating that homogeneous 
mature osteoblasts can undergo transdifferentiation (207). This conversion of 
osteocalcin-expressing osteoblasts into adipocytes has also been observed in 
other studies (171). These results imply that putative mature osteoblasts still 
exhibit flexibility in their differentiation potential. 
Taken together, the results described in this section indicate that 
the identity of an osteoblast is not well-established at the molecular level. 
A thorough description of osteoblast differentiation and lineage commitment 
would require the identification of additional markers that correspond to the 
distinct stages of differentiation. When such osteoblast markers are identified 
on a genome-wide basis, they can provide information about regulatory 
pathways that play a role in osteoblast differentiation and reveal general 
processes that can take place during differentiation into other cell types 
as well. In addition, analysis of genome-wide osteoblast gene expression 
patterns would be relevant to understand the basis and possible treatment of 
bone-related disorders. 
Figure 5.
Stages during osteoblast differentiation. 
Growth and differentiation of mesenchymal stem cells into mature osteoblasts 
can be described by five distinct stages: commitment, proliferation, matrix 
deposition, matrix mineralization and apoptosis. At the cellular level, six different 
cell populations have been distinguished in cell culture, based on the expression of 
marker genes. Mesenchymal stem cells commit to form Runx2- and Osx-expressing 
osteoprogenitors, which further differentiate into Akp2-expressing preosteoblasts. 
Subsequently, Bglap1-expressing osteoblasts are formed that eventually mature 
into lining cells or osteocytes. (Figure adapted from Lian et al. 2003, see ref 145). 
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1.4 BONE REMODELLING AND OSTEOPOROSIS
1.4.1 Consider the osteoblast!
Osteoporosis is a frequently occurring age-related bone disorder that 
is associated with quantitative bone loss. The fragile bones of these patients 
make them susceptible to fractures which in the case of hip fractures appears 
lethal in 20% of the cases (60). In our Western society, approximately 25% 
of ageing (postmenopausal) females and 10% of the males are affected 
by osteoporosis (164). Patient prospects have been improved by current 
treatments including hormone replacement therapies, which include 
estrogens or selective estrogen receptor modulators and bisphosphonates 
to further prevent loss of bone mass. Still the number of patients will rise 
with the increased ageing of the human population, indicating the clinical 
relevance of developing effective treatments. A prerequisite for developing 
successful approaches is a thorough knowledge of specific cellular and 
molecular processes that underlie bone biology. 
At the first sight bone appears to be a static organ. In fact, however, it 
is highly dynamic since it is continuously being broken down (bone resorption) 
and rebuilt (bone deposition) (165). At the microscopic level, bone consists 
of a collagenous matrix that is mineralized by crystallization of calcium and 
phosphate. Deposition and mineralization of the bone matrix is controlled by 
the osteoblasts. During bone remodelling, the bone matrix is degraded by 
activation of multinucleated osteoclasts. Subsequently, osteoblasts enter the 
site where bone has been resorbed and start to produce new bone matrix. 
In the first three decades of our life, the rate of bone deposition exceeds 
that of bone resorption and consequently the total bone mass is increasing. 
As humans age, however, this balance is shifting. Bone resorption begins 
to prevail new bone formation, resulting in a gradually decreasing bone 
mass. Progressive loss of bone mass, however, can occur e.g. as a result of 
decreased estrogen levels, as observed in menopausal women.
To maintain bone homeostasis at an appropriate level, an accurate 
balance is required between the number and activity of osteoblasts on 
the one, and the number and activity of osteoclasts on the other hand. 
Disturbance of this equilibrium is the cause of several diseases characterized 
by either increased bone mass (e.g. osteopetrosis) or progressive bone 
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loss (e.g. osteoporosis). Most of the current strategies to prevent and treat 
osteoporosis are based on reducing osteoclast activity and thereby the 
process of bone resorption (93, 196). Despite successful application of this 
strategy, it only prevents further degradation of bone but does not restore the 
bone that has already been lost. For this reason, it is important to understand 
mechanisms that stimulate the formation of functional osteoblasts, in order 
to develop anabolic agents. 
1.4.2 Stem cells and osteoporosis
Identifying the mechanisms involved in mesenchymal stem cell 
commitment can be of significance for the treatment of (age-related) 
osteoporosis. In the ageing bone marrow, a decrease in the number of 
osteoblasts is observed in parallel with an  increase in the number of adipocytes 
(90, 199). Also during osteoporosis, the balance between osteoblastogenesis 
and adipogenesis in bone marrow shifts appears to be shifted in favour of 
adipogenesis (170). The common progenitor cell in the bone marrow from 
which both osteoblasts and adipocytes are derived may be at the basis of 
this inverse correlation between fat and bone tissue. The differentiation of 
adipocytes and osteoblasts from mesenchymal stem cells in vitro has been 
shown to be reciprocal (29), a result supported by the observation that Pparg 
(+/-) mice show increased osteoblastogenesis, but decreased adipogenesis 
(6). Furthermore, trabecular bone-derived cells can express both osteoblastic 
and adipocytic phenotypes, dependent upon their culture conditions (171). The 
observed shift in commitment during osteoporosis can therefore be ascribed 
to a disturbed differentiation potential of MSC. This can result from increased 
production of an as yet uncharacterized endogenous PPARg activator(s) in the 
ageing bone marrow (161), or from age-related alteration in the activities of 
TGFβ (89) and BMP (161), as well as from other mechanisms that remain to 
be determined. It is interesting to note that expression level of the BMPR1B 
receptor (161) which has been shown to mediate osteoblast differentiation 
(52) decreases in mesenchymal stem cells upon ageing. The reciprocal 
relationship between osteogenesis and adipogenesis, in combination with the 
increased adipogenesis during ageing and osteoporosis, opens opportunities 
to influence bone mass by manipulating the balance between osteoblast and 
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adipocyte differentiation from mesenchymal stem cells. A possible approach 
could be to decrease adipocyte differentiation, accompanied by an increase of 
osteoblast formation.
It has been hypothesized that osteoporosis might be a stem cell 
disease. Mice deficient for the surface protein Sca1/Ly6a (stem cell antigen 1 
/ lymphocyte antigen 6) acquire an age-related osteoporosis phenotype (39). 
In Sca1 (-/-) mice, osteoblastogenesis and adipogenesis appear to be normal 
but the number of osteoprogenitors is limited due to reduced self-renewal 
capacity of the mesenchymal stem cells. A tight correlation thus exists 
between age-related bone loss and aberrant stem cell development. Together, 
these observations demonstrate the importance of stem cell research in order 
to treat or prevent osteopenic disorders. 
1.5 GENOME-WIDE EXPRESSION ANALYSIS
1.5.1 The transcriptome
The transcriptome has been defined as the whole population of 
mRNA transcripts in a cell, weighted by their expression levels see: http:
//bioinfo.mbb.yale.edu/what-is-it/omes/). Much research has focused on the 
identification of expressed genes that determine cell type specificity. Decades 
of research efforts have already resulted in the identification and functional 
analysis of many of such genes. Despite the importance and enormous success 
of the approaches used, they provide only a glimpse of the complexity of the 
transcriptome, since the entire collection of genes in the genome that can be 
expressed has not been known until a few years ago. 
In the year 2001, a milestone in biological sciences was reached when 
a draft sequence of the complete human genome was presented (136, 226). 
This achievement resulted in a progressive improvement in the understanding 
of the structural and functional features of our chromosomes and genes. 
One important insight obtained was the number of protein-encoding genes 
present in the genome. Until the completion of the human genome sequence, 
it was assumed that the number of genes in the human genome would 
range between 30,000 and 140,000. Based on the full DNA sequence a 
computer-based estimation resulted in a total number of only 31,000 (136) 
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or 26,000 (226) protein encoding genes. However, further complexity of 
the final expression and functional appearance of proteins is determined by 
many additional factors, including mRNA stability, alternative gene splicing 
events and post-translational modifications such as phosphorylation and 
glycosylation. Especially alternative gene splicing provides a mechanism by 
which diversity of gene expression can be achieved, since different mRNA 
molecules and their corresponding proteins can be formed from a single 
gene. It seems likely that cell type specificity is largely determined by the 
exact combination of expressed genes that provide a specific function within 
a cell. So, as a first step in fully understanding cell type determination, it is 
of interest to ascertain which particular genes out of the whole genome are 
activated in a cell type of interest, either temporarily or continuously. 
1.5.2 Microarray-based transcriptome analysis
Microarrays, also referred to as DNA chips, have become the standard 
tool for simultaneously monitoring multiple gene transcripts. A microarray is 
a solid support on which large numbers of biomolecules are immobilized that 
represent sequences from different genes (for reviews see references 54, 74, 
147, 191). Hybridization of such microarrays with fluorescently labelled cDNA 
results in their specific binding to complementary probes on the array. When 
test samples versus reference samples are compared, the ratio in fluorescence 
intensity is a measure of the relative mRNA levels. Microarrays can therefore 
be used as a tool for quantitative expression analysis of many gene transcripts 
in parallel. Two different types of such gene expression arrays are commonly 
used, namely cDNA arrays and oligonucleotide arrays. 
1.5.2.1 cDNA microarrays
 cDNA microarrays are manufactured by robot-based spotting of cDNA 
probes on a membrane. The probes are obtained as PCR products from 
existing data bases such as GenBank, Unigene and dbEST, or other cDNA 
libraries of interest. The first use of these microarrays as a tool for analyzing 
gene expression profiles was carried out in 1995 by Schena and co-workers 
who used an array containing 48 different cDNAs to monitor differential gene 
expression between leaf and root tissue of the plant Arabidopsis thaliana 
(201). Importantly, they showed that the array proved to be sensitive enough 
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to identify a single overexpressed gene within a pool of total Arabidopsis 
mRNA, thereby establishing the usefulness of microarrays to screen for 
specific gene expression patterns. The promising potential of microarray-
based expression analysis was further illustrated by employing cDNA arrays 
containing over 1000 human sequences, resulting in the identification of novel 
heat-shock responsive genes (202), inflammatory disease-related genes 
(100) or genes specifically expressed in tumorigenic cells (67). Progress in 
spotting technology led to the generation of chips which contain thousands of 
different cDNA probes. 
1.5.2.2 Oligonucleotide arrays
A disadvantage of cDNA arrays is that target cDNA can hybridize in 
a non-specific manner with other applied clones that share high sequence 
homology. The sequence specificity of microarrays can be increased when 
probes are used that exist of oligonucleotides (20-25 nt) which are unique 
for the gene of interest, a method first described by Lockhart and co-
workers (149). These arrays can be made by ‘on chip’ chemical synthesis of 
oligonucleotides (82). On such oligonucleotide arrays genes are represented 
by pairs of probes, each containing a full complementary probe (perfect 
match) and a mismatch probe that contains a single base mismatch at a 
central position of the probe. By calculating the signal intensities for perfect 
match and mismatch probes, a discrimination can be made between specific 
binding and non-specific cross-hybridization. This method requires sequence 
knowledge of all relevant genes to generate gene-specific probes, but once 
known the specificity can be largely improved, for example by creating exon-
specific probes to detect splice variants (57, 81, 116).
These pioneering studies demonstrated that oligonucleotide arrays, 
similar to cDNA arrays, are sensitive enough to detect a single mRNA transcript 
per cell (149, 202), therefore allowing detection of low abundance messengers. 
The simultaneous development of microarray manufacturing technology and 
the availability of whole genome sequence information for yeast (92, 159) led 
to the generation of arrays containing probes for all estimated 6,200 yeast 
genes, thereby establishing whole-genome transcription profiling (234). 
Since then, the field progressed rapidly and microarrays found wide-spread 
applications in life sciences and diagnostics, and nowadays the whole human 
genome is covered on both oligonucleotide and cDNA microarrays. 
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1.5.3 Applications of array technology
The very fast increase in the number of publications on microarray 
studies (65) reflects the successful application of this technology in 
identification of gene expression patterns during a variety of biological 
processes. The power of microarray technology is based on the acquisition 
of gene expression data on a large scale in order to find consistencies in the 
expression modulation of groups of genes, a possibility that did previously 
not exist. Indeed, microarrays have proven their importance for instance in 
cancer diagnosis. Expression profiling of tumour samples of a large number of 
patients showed that expression patterns of groups of genes were indicative 
for previously unrecognized subtypes of various tumours including breast 
cancer (182, 208), lung cancer (22, 32, 87), leukemia (94, 242), prostate 
cancer (138) and gliomas (186, 203). Importantly, microarray-based 
expression analysis of patient tumour samples provided molecular prognosis 
signatures and can therefore be used to predict responses to therapy (143, 
204, 208, 223). 
Microarray-based genome-wide expression analysis is not only 
valuable for the identification of gene expression in various biological 
samples, but it has also dramatically improved our fundamental knowledge 
about the genetic information that is encoded in the chromosomes. The 
completion and availability of human chromosome sequences has formed 
the basis for mapping transcriptional activity on chromosomes (31, 50, 53, 
120, 174, 195). Interestingly, from these studies it emerged that many genes 
without prior annotation are expressed and that antisense and non-coding 
RNAs form a large part of the mammalian transcriptome (51, 119, 174). Rinn 
(195) observed that 9.8% of the expressed, but previously un-annotated 
fragments of human chromosome 22 were located entirely within introns, 
often in antisense orientation with respect to the encoding gene. It further 
appeared that the number of independent transcripts obtained is an order of 
magnitude higher than the amount of estimated genes in the human genome 
(120), in agreement with a similar observation that has been made for the 
mouse genome (50). Microarray technology has further been applied for 
many other purposes than mRNA profiling. Customized arrays have been used 
successfully to study expression of small non-coding microRNAs (28, 48, 79, 
111, 146) that repress mRNA translation and thereby regulate differentiation 
38
Chapter 1
39
General Introduction
and development (8, 19). Combining microarray analysis and bioinformatics 
predictions has resulted in the identification of at least 800 of such microRNAs 
in the human genome (28), a number far exceeding the microRNAs that had 
previously been identified experimentally. Furthermore, single nucleotide 
polymorphisms (97), DNA copy number (185), chromosomal deletions (45, 
155), chromosomal rearrangements (244) and changes in DNA methylation 
(2, 91) can be analyzed by application of microarray technology. Microarrays 
thus give a genome-wide insight in both the genetic and epigenetic processes 
that control developmental processes. 
1.5.4 Microarray data analysis
Microarray experiments yield large amounts of data that can be 
difficult to interpret. Eisen and colleagues (76) introduced the method of 
hierarchical clustering to arrange genes into distinct groups or clusters, 
according to their expression profiles.  Clustering is achieved by calculating 
the similarities between expression profiles of all selected genes by means of 
mathematical analysis (e.g. the standard correlation or Euclidian distance). 
Other clustering algorithms that are commonly being used to analyze 
microarray data, include k-means clustering (215) and self-organizing maps 
(214). Choosing a particular method can be dependent on the type of data, or 
the goal and preferences of the researcher. These methods have in common 
that they simplify the results obtained, such that distinct patterns of gene 
expression can be distinguished. 
Genes can also functionally be classified according to Gene Ontology 
(GO). Each gene belongs to one or more specific GO categories, depending 
on the function of its protein. A subset of genes identified by microarray 
analysis can subsequently be tested for significant enrichment of genes that 
belong to a specific GO category. Eisen and co-workers showed that clustering 
of data obtained from time-dependent serum stimulation of primary human 
fibroblasts  led to the observation that functionally related genes are co-
regulated, and thus cluster together (76). This relationship between co-
regulation and functional similarity appears not to be restricted to clusters 
obtained from time course experiments, but was also observed in combined 
yeast data-sets. Moreover, expression profiling of 55 murine tissues revealed 
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that more than 50% of all regulated genes are co-expressed with a set of 
genes that is significantly enriched in at least one functional GO category 
(245). Based on similarity in expression patterns, these authors predicted 
the function of a novel gene (Pwp1) to be involved in RNA processing and 
ribosome biogenesis, and were able to confirm this function in yeast (245). 
Taken together, microarray data can reveal functional information for sets of 
uncharacterized genes (106, 107, 236). 
The notion that expression patterns are enriched for genes with similar 
function, supports the concept that co-regulated genes have common cis-
regulatory elements. Indeed, computer-based searches for shared motives 
has led to the identification of common transcriptional regulatory motifs in 
the promoters of co-regulated (113, 210, 215) or functionally related genes 
(105), and has in addition resulted in the identification of novel transcription 
factor target genes (153). Integration of gene expression data analysis with 
in silico computational methods thus provides a basis to unravel underlying 
mechanisms controlling gene transcription. A challenging method to describe 
microarray data from a regulatory point of view is in terms of a genetic network 
(36, 41, 160, 238). These are mathematical models that analyse a functional 
or regulatory  relationship between a set of genes, by analysing how at the 
mRNA level the expression of one gene affects the expression level of all 
others. Theoretically, it is possible to set up regulatory transcription networks 
from mRNA expression data based on a reverse engineering approach. Gene 
networks have for instance been inferred from yeast expression data, in 
order to discover transcriptional regulatory networks of the yeast cell cycle, 
resulting in the discovery of distinct modules of co-regulated genes that 
control the cell cycle (107, 142, 205). 
Microarrays provide information about the expression of all genes in 
the genome (the transcriptome) as far as they are represented on the array 
used. To understand regulatory mechanisms during biological processes, 
it is of particular interest to analyze the differential transcriptome, which 
may be defined as the set of genes that is differentially expressed during 
cellular transitions (65). Dependent on the experimental setup, the data 
contain a wealth of useful information about specificity of gene expression, 
gene function, regulatory events, genetic pathways and interactions. Such 
transcriptome information is not only a good starting point for detailed 
insight into the functioning of cells, but also holds promise for the subsequent 
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identification of candidate genes and their corresponding proteins as novel 
drug targets. 
1.6 MODEL SYSTEMS TO STUDY OSTEOBLAST DIFFERENTIATION
Various model systems have been employed to study osteoblast 
differentiation in vitro, including cultured stem cells, primary cells and cell 
lines. The ideal model system to study (stem) cell commitment and further 
progression along the osteoblast lineage would have to represent all stages 
of osteoblastogenesis from multipotency to lineage commitment and matrix 
mineralization. In addition, the model system must preferably undergo 
homogeneous differentiation with respect to time and induced cell type, in 
order to achieve the highest specificity of gene expression in a microarray-
based screening. 
1.6.1 Stem cell models of osteoblast differentiation
1.6.1.1 Embryonic stem cells
Cultured stem cells provide model systems by which the mechanisms 
that recapitulate lineage commitment and cellular differentiation during 
development can be studied. Differentiation of embryonic and adult stem cells 
into mature cell types has been accomplished successfully upon in vitro culture 
(for review on ES cell differentiation in culture see Keller (125)) and both ES 
cells and MSC can undergo osteoblast differentiation in vitro. Mammalian ES 
can be maintained as long-term self-renewing cell lines in culture and have 
been isolated from blastocyst stage embryos of several species, including 
mouse (80, 158), human (218), monkey (219) and pig (144). When grown 
in suspension culture, ES form small aggregates of cells surrounded by 
an outer layer of visceral endoderm (126). Such aggregates have been 
termed embryoid bodies and are often used as model systems for studying 
differentiation and gene expression control during early development.
Human ES can be induced to differentiate into osteoblasts in vitro 
(35, 209), but most studies have been carried out using murine ES cells. 
Dependent on culture conditions, such ES can give rise to cell populations 
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from the mesenchymal lineage including skeletal muscle (197), adipocytes 
(62, 250), chondrocytes (123, 133, 250) and osteoblasts (46, 123, 249). 
Differentiation of the established murine ES cell line D3 into osteoblasts 
can be induced by a combination of dexamethasone, ascorbic acid and 
β-glycerophosphate (dex/aa/β-glyc) (46), and is enhanced by vitamin D3 
(249). Kawaguchi et al. showed that BMP4 induces osteoblast marker gene 
expression in another murine ES cell line, but additional dex/aa/β-glyc was 
necessary to induce calcium deposition (123). BMP4 and BMP2 have also 
been shown to induce modest induction of Alcian blue-stained areas in ES cell 
cultures, which is indicative for chondrocyte differentiation (133). Induction 
of chondrogenesis by BMP was not observed in the experiment described 
by Kawaguchi et al., but could instead be induced by treatment with TGFB3 
(123). A combination of BMP2 and TGFB1 has been shown to drive mouse 
ES towards both chondrogenesis and adipogenesis (250). As these examples 
illustrate, the outcome of ES differentiation in vitro appears highly dependent 
on the cell lines and/or culture conditions used. However, the distinct effects 
of various stimuli on these stem cells may also be indicative for the existence 
of different kinds of progenitors in culture. 
1.6.1.2 Adult stem cells 
The differentiation capacity of adult stem cells is limited in comparison 
with embryonic stem cells. Adult stem cells thus provide a less complicated 
model system to study differentiation pathways. However, the multipotential 
capacity of adult stem cells still allows for studies on lineage specification 
and stem cell self-renewal. MSC derived from bone marrow form the model 
system that is generally being used for studying the process of osteoblast 
differentiation. They form an adherent cell layer in tissue culture and have 
retained their multipotent capacity to form adipocytes, chondrocytes and 
osteoblasts (184) (for reviews on MSC differentiation see references 66, 
96, 179). Osteoblast differentiation of MSC can be  induced in culture media 
containing dexamethasone, ascorbic acid and β-glycerophosphate (112). 
Since MSC mineralize their extracellular matrix, as measured by von Kossa 
staining, it appears that all stages of osteoblast differentiation are represented 
in this model system. 
Studies with clonal cultures of MSC have shown that single cells 
have the intrinsic ability to differentiate into osteoblasts, chondrocytes and 
42
Chapter 1
43
General Introduction
adipocytes. This tripotentiality of MSC  implies that these cells can well 
be used to investigate how differentiation along a particular pathway is 
accomplished. On the other hand, in some studies the majority of cells had lost 
this capacity and were only bi- or monopotential under the assay conditions 
used (166, 173), possibly as a result of progression of the cells towards a 
specific differentiation pathway. On the other hand, optimal culture conditions 
still have to be established which drive a tripotential MSC exclusively into a 
single differentiation direction. As a consequence of such variation in lineage 
potential and inhomogeneous differentiation, differentiating MSC often reflect 
a mixture of phenotypes, which may be a drawback for their use in microarray 
experiments. 
A further disadvantage of the use of such cells is that the amount of 
MSC that can be obtained from human bone marrow aspirates is limited while 
in addition MSC have a limited proliferative capacity which is (17, 44, 112) 
accompanied with progressive shortening of telomeres in comparison with 
ES cells (17). Although their bone forming capacity does not appear to be 
affected during this process of replicative senescence (44, 112), MSC lose their 
multilineage differentiation capacity upon prolonged ex vivo expansion (166). 
Therefore, new batches of MSC need to be isolated frequently from donors. It 
is therefore a challenge to identify factors that promote self-renewal in order 
to to prolong culture periods without losing differentiation capacity. 
1.6.2 Primary osteoblasts
When research interest is focused on the differentiation and maturation 
of osteoblasts rather than on lineage commitment, primary cultures of 
preosteoblastic cells can be used as a model system. Primary osteoblasts are 
usually obtained by means of proteolytical release from neonatal rat or mouse 
calvaria, since this tissue can easily be dissected. Calvaria-derived cells provide 
a physiologically relevant model system for studying osteoblast differentiation 
since these cells are able to form bone-like nodules in vitro upon treatment with 
ascorbic acid and dexamethasone. These nodules are formed by proliferation 
and differentiation of osteoprogenitor cells that constitute less than 1% of the 
total number of cells in the isolated population (24). Two distinct populations 
of such osteoprogenitors are present in the primary culture; one population 
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is formed by immature Akp2-negative cells which require dexamethasone 
for differentiation, and the other by more mature Akp2-positive cells that 
differentiate in the absence of dexamethasone (220). These cultures thus 
represent a heterogeneous mixture of osteoblast progenitors at different 
developmental stages. The majority of these progenitors is restricted to 
the osteoblast lineage and thus unable to differentiate into adipocytes (25). 
However, as a population, calvaria-derived primary cultures do express 
adipogenic markers under osteogenic differentiation conditions (88), likely 
due to the presence of osteo-adipoprogenitors and committed adipocyte 
progenitors in the cell culture. Calvaria-derived osteoblasts are thus a valid 
model system to study bone formation, but the heterogeneity of the culture 
and the restricted differentiation capacity of the cells is a limitation for the 
investigation of mechanisms that underlie osteoblast commitment in relation 
to other mesenchymal lineages. 
1.6.3 Clonal cell lines
Due to their limited proliferation capacity, MSC and primary cultures 
need to be isolated freshly, thereby introducing possible variations between 
experiments as a result of cell isolations from different donors. Clonal cell 
lines have the advantage that they provide homogenous populations that 
can often be maintained in culture for many passages. A well-established 
model system to study osteoblast differentiation and maturation in culture is 
formed by the murine cell line MC3T3, a spontaneously immortalized alkaline 
phosphatase-rich clone from a population of calvaria-derived cells (212). The 
cells behave as immature, committed osteoblasts that further upregulate 
alkaline phosphatase and osteocalcin protein levels by stimulation with BMP2 
(56) and are able to form a mineralized matrix when cultured in the additional 
presence of ascorbic acid and β-glycerophosphate (83, 84, 212). MC3T3 
cells provide a mono-potential model system for osteoblast maturation 
and mineralization, but since these cells are already committed toward the 
osteoblast lineage, they give no information about the early events involved 
in cell type determination. 
In order to study mechanisms of lineage specification, it is necessary 
to use cells with the flexibility to differentiate along multiple mesenchymal 
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lineages. Examples of cell lines with this property are the adult mouse bone 
marrow-derived cell line ST2, and the fibroblastic cell line C3H10T1/2 which 
has been derived from early mouse embryos. ST2 cells differentiate into 
osteoblasts by treatment with BMPs (240) or ascorbic acid (177) and into 
adipocytes by treatment with insulin (69). C3H10T1/2 cells can be stimulated 
by various BMPs to differentiate into the three cell types osteoblasts, 
chondroblasts, and adipocytes, dependent on the applied BMP concentration 
(3, 9, 229). This tripotentiality makes the C3H10T1/2 in principle suitable for 
investigating the early commitment of multipotent stem cells. However, for 
reasons that are not well understood, C3H10T1/2 cells show a heterogeneous 
response to BMPs, resulting in a mixture of osteoblasts, chondrocytes and 
adipocytes (9, 63). Using such a mixed population, it would be impossible to 
address changes in gene expression to a particular cell type. 
For the purpose of a microarray analysis on all stages of osteoblast 
differentiation it is preferable to have a homogeneously differentiating cell 
culture model system that recapitulates the earliest events of (stem) cell 
commitment, but also fully differentiates into mature osteoblasts. As a model 
system for our microarray studies, we preferred to use the myogenic cell 
line C2C12, which is a subclone isolated from C2 myoblasts established from 
adult mouse muscle (38, 239). When cultured in low serum containing media, 
C2C12 cells fuse into multinucleated myoblasts. However, BMPs prevent this 
process and induce these cells to differentiate into osteoblasts. This results 
in expression of the late phase bone marker osteocalcin at both the mRNA 
and the protein level (121, 141) while at the same time expression of muscle 
specific genes such as MyoD and myogenin is repressed (121). This latter 
observation is of particular interest, since it is still poorly understood how 
mesenchymal cells that have initiated differentiation along one defined 
lineage can be reprogrammed and transdifferentiate into another lineage. 
Our motivation to use these cells is based upon three arguments: 1) 
BMP is able to induce homogeneous differentiation of C2C12 cells, which is a 
requirement for obtaining clean microarray data, 2) induction of osteoblast 
differentiation from progenitor cells may accompany key regulatory pathways 
involved in bone formation, 3) TGFβ antagonizes the effect of BMP on C2C12 
cells (121) and therefore a screen for genes differentially regulated by BMP 
and TGFβ allows for identification of specific BMP-induced signalling pathways 
that lead to osteoblast differentiation (thesis Diana S. de Jong, 2005).
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1.7 THESIS OUTLINE 
The main objective of the studies presented in this thesis was to 
identify genes of which expression and function are specifically associated 
with osteoblast differentiation and bone formation. Osteoblasts originate 
from mesenchymal stem cells, which undergo differentiation from cells with 
multipotential lineage potency to the highly specialized cells that exert the task 
of bone formation. The physiological function of osteoblasts is well understood, 
but the genetic programs that determine development of mesenchymal 
stem cells into the osteoblast phenotype and control the function of mature 
osteoblasts are still to be discovered. Such knowledge is indispensable in the 
search of focus points for therapeutic strategies in order to prevent and treat 
bone homeostasis anomalies. Microarray-based gene expression profiling was 
employed to analyze the transcriptome of differentiating osteoblasts during in 
vitro cell culture as well as during skeletogenesis.  
In Chapter 2, novel stage-specific markers for osteoblast 
differentiation were identified by means of time-dependent gene expression 
profiling in C2C12 cells which were induced by bone morphogenetic protein 
2 (BMP2) to undergo osteoblast differentiation. For at least three of these 
novel marker genes, namely the Wnt antagonist Wif1 and 2 ESTs, expression 
in developing bone of mouse embryos confirmed that these genes are indeed 
novel markers for in vivo bone development. 
 The identification of Wif1 expression as a marker for osteoblasts 
suggests a functional involvement of the Wnt signalling pathway in osteoblast 
differentiation. In Chapter 3 we showed that of all Wnt signalling components 
present on microarray, predominantly the Wnt antagonists are induced 
during late stages of osteoblast differentiation. We have further shown that 
continuous activation of the Wnt pathway inhibits BMP-induced osteoblast 
differentiation. Together, these results led to the hypothesis that endogenous 
inhibition of Wnt signalling is essential for controlling osteoblast maturation 
by providing a negative Wnt feedback loop.
The canonical Wnt pathway-related transcription factor Tcf7 was 
identified as an early mediator of osteoblast differentiation by expression 
profiling during the osteoblast commitment phase (Chapter 4). Tcf7 was 
found to modulate BMP-induced osteoblast marker genes when stably 
expressed in C2C12 cells. These data imply that the BMP and Wnt signalling 
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pathways interact during early stages of osteoblast differentiation and that 
Wnt signalling is able to modulate osteoblast-specific gene expression.
In Chapter 5, a genetic network is presented, which describes 
interactions between genes in differentiating C2C12 cells towards the 
osteoblastic or the myogenic lineage. The network suggests that expression 
of the extracellular matrix encoding genes Dcn (decorin) and Postn (periostin) 
is the trigger to initiate the process of matrix maturation and mineralization.  
In Chapter 6, we extended our microarray-analyses on osteoblasts 
in their physiological context by using an in vivo model system of bone 
development. Expression profiling of intramemembranous and endochondral 
skeletal tissue of both wild-type and Runx2-deficient murine embryos led to 
the identification of 22 in vivo Runx2 target genes. Furthermore, bioinformatics 
analysis revealed that in addition to the known functions of Runx2 in osteoblast 
and chondrocyte differentiation, Runx2 may also participate in the regulation 
of other processes including cell migration, axon guidance and hematopoietic 
stem cell commitment during skeletal development. 
In Chapter 7, we show that Runx2 expression is required for skin 
development. Microarray analysis of murine calvaria including the adjacent 
skin layer revealed strongly downregulated expression of marker genes for 
terminally differentiating keratinocytes in Runx2 (-/-) tissue. The results 
underscore the use of microarray technology in studying phenotypes of 
mutant animals.  
The implications of these results for our understanding of stem cell 
and osteoblast differentiation, with emphasis on the role of Wnt signalling 
in this process, as well as the identification of potential therapeutic targets 
against bone–related diseases, are discussed in Chapter 8.
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ABSTRACT
 Osteoblasts are cells responsible for matrix deposition during bone 
development and although temporal expression of many genes has been related 
to osteoblast differentiation, a complete description of osteoblast specific gene 
regulation will lead to a better understanding of osteoblast function. In this 
study, microarray technology was employed to analyse gene expression on 
a broad scale during osteoblast differentiation. Expression analysis of 9,596 
sequences revealed 342 genes and ESTs to be differentially modulated during 
a time course experiment in which murine C2C12 mesenchymal progenitor 
cells were induced to differentiate into mature osteoblasts by treatment with 
bone morphogenetic protein 2 (BMP2). By means of hierarchical clustering, 
these genes were grouped by similarities in their expression profiles, 
resulting in subsets of early, intermediate and late response genes, which are 
representative of the distinct stages of osteoblast differentiation. In order to 
identify new bone markers, the bone specificity of the late response genes 
was determined by comparing BMP-induced expression in C2C12 and MC3T3 
osteoblasts with that in NIH3T3 fibroblasts. This resulted in the identification 
of 9 novel genes and ESTs that were specifically induced in osteoblasts, in 
addition to the well-known markers alkaline phosphatase and osteocalcin. For 
at least one of these novel genes, Wnt inhibitory factor 1, and two of the ESTs, 
expression in developing bone was verified in vivo by in situ hybridization of 
E16.5 mouse embryos. In conclusion, by a combination of in vitro and in vivo 
screening approaches, a set of new genes related to osteoblast differentiation 
and skeletal development has been identified.
INTRODUCTION
 Bone is mineralized tissue of the vertebrate skeleton that arises from 
condensation of undifferentiated mesenchymal stem cells during embryonic 
development. These mesenchymal cells can subsequently differentiate into 
osteoblasts. Bone formation occurs during growth and fracture repair, whereby 
osteoblasts function in the deposition and mineralization of the bone matrix. 
During adult life, bone is constantly being remodelled and a delicate balance 
between mineralized matrix deposition by osteoblasts and matrix resorption 
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by osteoclasts is crucial for the maintenance of a steady bone mass.
During in vitro differentiation from osteoprogenitor to mature 
osteoblast, three distinct phases can be distinguished that reflect the 
maturation stages of osteoblasts in vivo (1). A proliferation phase is followed 
by a matrix maturation phase, after which the extracellular matrix becomes 
mineralized. Different markers have been associated with each of these 
phases, such as alkaline phosphatase for the matrix maturation phase and 
osteocalcin for the matrix mineralization phase. However, expression of these 
genes is not restricted to osteoblasts (2, 3), suggesting that the combination 
of genes expressed might determine the specificity of osteoblast function. It is 
believed that osteoblast differentiation and osteoblast function are controlled 
by the key regulator Cbfa1 and promoter binding elements for Cbfa1 have 
been found in several genes expressed in osteoblasts, including osteocalcin 
(4, 5).
The mesenchymal stem cells from which osteoblasts are derived 
have the additional potential to differentiate into myoblasts, adipocytes and 
chondrocytes. Among agents that induce differentiation into osteoblasts, are 
the bone morphogenetic proteins (BMPs) which belong to the TGF-β family 
of cytokines. BMPs have been shown to induce osteoblast differentiation of 
in vitro cultured stem cells, while recently also effects of BMPs on osteoblast 
formation in vivo have been demonstrated (6). Mice carrying a homozygous 
mutation in Cbfa1 fail to calcify bone and die shortly after birth. However, 
in cells isolated from Cbfa1-/- mice, BMP is still able to induce expression 
of the osteoblast markers alkaline phosphatase and osteocalcin, suggesting 
that there are additional regulators of osteoblast differentiation (7). Recently, 
the novel gene Osterix, has been identified as a transcription factor acting 
downstream of Cbfa1 in controlling osteoblast differentiation (8).
A better understanding of the regulatory events involved in osteoblastic 
differentiation would require a detailed analysis of the genes expressed 
during the various phases of this process. Moreover, a full description of 
genes involved in osteoblast differentiation could lead to the identification of 
so far unidentified osteoblast specific genes and novel key regulators of this 
process. The recent development of the microarray technology has facilitated 
the simultaneous expression analysis of large sets of genes (9, 10). In this 
study, we have applied this technique to study gene expression profiles over 
a 6 days time course in which murine C2C12 cells were treated with BMP. 
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In the presence of BMP, these multipotent mesenchymal cells develop into 
mature osteoblasts within a period of 6 days, resulting in the consequent 
expression of alkaline phosphatase and osteocalcin as markers for the mature 
osteoblast phenotype. Data analysis revealed groups of genes with different 
kinetics of induction which are representative for the distinct differentiation 
phases. Co-regulation of functionally related genes was observed, as well as a 
time dependent shift in regulation of genes that encode proteins from distinct 
functional classes.
The number of marker genes for bone differentiation is still limited. 
In this study we have focussed on late BMP-responsive genes and identified 
9 novel genes and ESTs that were regulated in an osteoblast specific manner. 
Expression of some of these new bone markers was verified in vivo during 
bone development in the mouse embryo, as studied by in situ hybridization. 
Interestingly, distinct expression patterns in developing bone and other BMP 
target tissues were observed for each of these new marker genes. These 
studies on genes regulated during the late phase of osteoblast differentiation 
provide not only important information about the function and activity of 
mature osteoblasts, but could also facilitate the identification of key upstream 
regulators in this process, which are potential targets for drugs aimed at 
treatment of bone-related diseases.
MATERIALS AND METHODS
Cell culture
 C2C12 murine mesenchymal progenitor cells and NIH3T3 murine 
fibroblasts (both obtained from the American Type Culture Collection) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% newborn calf serum (HyClone®), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) at 37°C in a humidified atmosphere containing 
7.5% CO2. Murine MC3T3 osteoblast precursor cells were maintained in α-
MEM supplemented with 10% NCS. For differentiation experiments, cells were 
seeded at a density of 2.0x104 cells/cm2 and grown for 24 hrs. Subsequently, 
medium was replaced by DMEM or α-MEM containing 5% NCS in the presence 
or absence of 300 ng/ml recombinant human bone morphogenetic protein 2 
(BMP2). During time course experiments medium and BMP2 were changed on 
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alternate days. Recombinant human BMP2 was kindly provided by Genetics 
Institute (Cambridge, MA).
RNA isolation
 Total RNA was extracted according to an acid guanidium thiocyanate-
phenol-chloroform method (TriPure® Isolation Reagent, Boehringer Mannheim) 
and RNA concentrations were determined by measuring the absorbance at 
260 nm. Poly(A)+ RNA was prepared from total RNA using the OligotexTM 
Method (Qiagen). Quantification of poly(A)+ RNA was carried out according to 
the RibogreenTM RNA quantitation assay (Molecular Probes).
Northern Blot analysis
 Samples of 20 μg of total RNA were separated electrophoretically on 
1% sodium phosphate-glyoxal-agarose gels and subsequently transferred to 
Hybond+ membranes (Amersham Pharmacia) using 25 mM sodium phosphate 
buffer, pH 6.5. RNA was crosslinked to the membrane by baking for two hours 
at 80°C. Prehybridization and hybridization were performed in Church buffer 
(0.5 M sodium phosphate buffer, pH 7.2, 7% SDS, 1 mM EDTA) at 65°C. The 
following rat probes were used: osteocalcin (11), alkaline phosphatase (12) 
and GAPDH (PCR product). Probes were labelled with [α-32P]-dCTP using 
random priming labelling (Ready-To-GoTM DNA labelling beads, Amersham 
Pharmacia). For visualization, membranes were exposed to Kodak X-AR films 
at -80°C using intensifying screens. To test equal loading of RNA, 2 µg of each 
sample were separated on a 1% agarose gel.
Microarray analysis
 After RNA isolation, the poly(A)+ RNA was labelled by reverse 
transcriptase with nucleotides containing either a Cy3 or a Cy5 fluorophore. 
The following hybridization experiments were performed in duplicate with a 
fluor reversal to minimize possible bias caused by the molecular structure 
of the Cy3 and Cy5 dyes: 1, 2, 3 and 6 days after BMP stimulation versus 
nonstimulated cells at day 0. For the hybridization experiments, the mouse 
Unigene 1 array from Incyte Genomics (Palo Alto, USA) was used. Incyte 
Genomics performed both the labelling and the microarray hybridizations 
according to described protocols (9). Signals from individual elements on the 
array were used to calculate Cy3:Cy5 ratios. Genes were selected for further 
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analysis, if the signal to background ratio of a particular gene exceeded 2.5 
and in addition at least 40% of the spotted area could be used for signal 
computation in at least one of the two channels. To account for systematic 
errors caused by non-linear differences in signal intensities of the Cy3 or Cy5 
channel, a regression analysis was performed by fitting a parabola to the 
experimentally observed expression values. Because of the large number of 
genes that were found to be modulated in the present experiments, genes 
were selected for hierarchical clustering if their intensity ratios were inverse 
for the duplicate experiments and their averaged signal levels showed at 
least a twofold modulation in at least one of the time points measured. Prior 
to clustering, microarray data were log transformed (base 10) according 
to: logI = log(ICy3/ICy5) if ICy3 > ICy5  and logI = -log(ICy5/ICy3) if ICy5 > ICy3 , in 
which I is the intensity of each spot on microarray. Log values were averaged 
over duplicate experiments and were used for hierarchical clustering with J-
express software (MolMine AS) using the average linkage algorithm (UPGMA) 
with the standard correlation as distance measure. Using the hierarchical tree 
structure, clusters were selected by branching the tree at distinct levels.
Real-time quantitative RT-PCR
 For real-time quantitative RT-PCR, ABI Prism Sequence Detection 
System 5700 and Primer ExpressTM (PE Biosystems) were used. For each gene, 
a set of primers was designed using sequences obtained from GenbankTM and 
amplicons of 50-70 basepairs with TM between 58 and 60°C were selected. 
Prior to complementary DNA (cDNA) synthesis, 2 µg of total RNA were DNase 
treated for 15 min at 37ºC, after which RNA was reverse transcribed from 
random hexamer primers using the SUPERSCRIPTTM II reverse transcriptase kit 
(GibcoBRL). Subsequently, 0.08-0.2 μg of total RNA was amplified using SYBR 
Green® PCR Mastermix (Applied Biosystems) under the following conditions: 
initial denaturation for 10 min at 95ºC followed by 40 cycles consisting of 15 
sec at 94ºC and 1 min at 60ºC. Fold inductions and expression ratios were 
calculated from differences in threshold cycles at which an increase in reporter 
fluorescence above a baseline signal could first be detected (CT) between two 
samples, and averaged for duplicate experiments.
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Embryo preparation and in situ hybridization
 Embryos were collected from F1 females (Cba x C57Bl6) at embryonic 
day 16.5 (E16.5; E0.5 is midday of the day of the vaginal plug), dissected 
free from the uterus and membranes, fixed overnight at 40C in 4% 
paraformaldehyde, dehydrated, embedded in paraffin wax and sectioned (6 
μm) onto coated slides (Klinipath). The slides were dewaxed, rehydrated and 
pretreated with Proteinase K and acetic anhydride, and hybridized overnight 
at 550C essentially as described (13). Constructs were cloned into pSKII- in 
the antisense orientation in the T7 promoter. RNA probes were generated by 
transcription of the T7 RNA Polymerase in the presence of [α-35S]-UTP. After 
hybridization, the slides were washed at high stringency for 30 min at 620C, 
followed by treatment with RNase A for 30 min at 370C, washed again at high 
stringency, dehydrated and allowed to dry. Autoradiography was performed 
using Ilford G5 photo emulsion. The slides were exposed for 2 weeks at 40C. 
Photography consisted of combining brightfield (blue filter) and darkfield 
images (red filter).
RESULTS
Expression kinetics of bone markers in differentiating C2C12 cells
 To examine gene expression patterns during osteoblast differentiation, 
the murine mesenchymal progenitor cell line C2C12 was used as a model 
system. These cells have been described previously for their ability to 
undergo BMP2-induced differentiation into cells of the osteoblastic lineage 
(14). In this study, we have examined gene expression in a time course 
experiment in order to determine temporal expression patterns of groups of 
genes and to identify novel markers for mature osteoblasts. Expression of 
these marker genes in bone has subsequently been studied during mouse 
embryonic development by in situ hybridization.
When cultured in medium supporting low mitogenic activity, C2C12 
cells form multinucleated myotubes after reaching confluence. However, this 
process can be completely inhibited by culturing the cells in the presence of 
BMP2, resulting in the expression  of osteoblast genetic markers encoding 
Cbfa1, collagen type 1, alkaline phosphatase and osteocalcin (14, 15), each 
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with its own characteristic kinetics. To correlate gene expression with distinct 
stages of osteoblasts differentiation, we first analysed the kinetics of BMP2-
induced osteoblast differentiation by culturing the cells in presence or absence 
of rhBMP2 for different time intervals. As can be seen in figure 1, myotube 
formation was completely inhibited after 6 days of BMP2 treatment. Instead, 
a homogeneous population of cells with cuboidal morphology was formed, 
typical of osteoblastic cells (Fig. 1A). Northern blot analysis (Fig. 1B) revealed 
induction of the genes encoding alkaline phosphatase and osteocalcin, which 
are markers characteristic for osteoblasts in a late phase of differentiation 
(13). Alkaline phosphatase expression started on day 1, while osteocalcin 
mRNA was detectable from day 2 onwards, with both genes expressed at 
their highest level at day 6. Neither of these genes was detectably expressed 
in untreated cells. These data show that full induction of the differentiated 
phenotype in C2C12 cells requires at least a 6 days incubation period with 
BMP2.
Microarray analysis of osteoblast differentiation
 In order to study gene expression modulation as a function of the 
stage of osteoblast differentiation, we carried out microarray analyses on 
C2C12 cells after treatment for 1, 2, 3, and 6 days with BMP2. For the analysis 
of BMP2-induced genes, the mouse Unigene 1 array (Incyte Genomics) 
containing 9,596 uniquely annotated genes and ESTs was used. The diversity 
of genes spotted on this chip facilitates a comprehensive view of genetic 
responses caused by BMP2 treatment in these cells. Expression modulations 
were analysed by competitive hybridization of mRNA samples from BMP2-
treated cells at each of the four time points chosen, versus untreated samples 
at zero time as the universal control in all experiments. The dataset obtained 
therefore represents induction or repression levels of genes relative to their 
basal levels in undifferentiated C2C12 cells. Each experiment was carried 
out in duplicate with a fluor reversal to minimize possible bias caused by 
the molecular structure of the Cy3 and Cy5 labels. Genes were selected for 
further investigation if they exhibited inverse expression ratios per duplicate 
hybridization and if they exceeded a twofold positive or negative modulation 
level measured on the microarray. Since at least 10% of the genes on the chip 
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appeared to show some expression regulation in the present experiments 
(data not shown), this threshold value was chosen to focus the analysis on 
genes with relatively strong regulation levels. Of the genes present on the 
array, 342 genes met this prerequisite in at least one of the time points tested 
and this data set, consisting of 179 up-regulated and 163 down-regulated 
genes, was used for further analysis.
To obtain insight in the kinetics of the gene regulation during the 
differentiation process, genes were grouped according to similarities in the 
time course of their expression profiles. For this, hierarchical clustering with 
J-express software was carried out, using the average linkage algorithm 
(UPGMA) with the standard correlation as distance measure. Figure 2A 
shows the result of this clustering analysis, in which the 179 up-regulated 
genes are indicated in red and the 163 down-regulated genes in blue in 
the corresponding heatmap. Based on the dendrogram obtained, gene 
clusters were selected by branching the tree at distinct levels to discriminate 
between early, intermediate and late response genes. This resulted in the 
identification of six gene clusters that will be referred to as U1 to U4 and D1 
to D2, depending on the kinetics of their up (U)- or down (D)-regulation. In 
addition, for each cluster the averaged expression profile of all genes is shown 
on a scale normalized to 1.
Figure 1.
The effect of rhBMP2 on C2C12 cell 
differentiation. Cells were cultured 
in the presence or absence of 
rhBMP2 (300 ng/ml) as described 
in Materials and Methods. (A) 
Morphological changes induced 
by BMP2 treatment (+) for the 
indicated time points were analysed 
by phase contrast microscopy and 
compared with untreated cells (-). 
(B) Northern blot analysis of the 
expression of late phase osteoblast 
markers alkaline phosphatase 
(ALP) and osteocalcin (OC) and 
the housekeeping gene GAPDH. 
Ethidium bromide staining of RNA 
confirmed equal RNA loading, 
as represented by 18S and 28S 
ribosomal RNA.
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Cluster U1 represents a group of early response genes, with maximum 
Fig. 2
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up-regulation within the first 3 days of BMP2 treatment. In contrast, clusters 
U2, U3 and U4 reach their maximum levels only on day 6. Genes in cluster 
U2 are considerably up-regulated at day 1, but still less than 50% of their 
value on day 6. Expression of U3 genes is only very weakly regulated or even 
not regulated at all on day 1, but these genes become strongly up-regulated 
at later time points. Cluster U4 genes are not induced before day 3 of BMP2 
treatment. For the down-regulated genes, cluster D1 represents the early 
response genes for which down-regulation is maintained at later time points, 
while cluster D2 contains genes that show a delay in their down-regulation 
between day 2 and day 3. Figure 2B lists late response up-regulated genes 
and ESTs that may be representative for mature osteoblasts since they are 
co-regulated with osteocalcin and alkaline phosphatase. The complete set of 
genes within their characteristic clusters is available on our website (http:
//www.sci.kun.nl/celbi/aux1.htm).
The unique time dependent expression profiles of the groups of 
genes described here provide a proper characterization of different processes 
involved in osteoblast differentiation and identify subsets of genes that are 
co-regulated during the various phases of the differentiation process.
Figure 2 (opposite page). 
Cluster analysis of gene expression during BMP2-induced osteoblast differentiation. 
(A) Output of hierarchical clustering of 342 genes with the standard correlation 
of 10log transformed microarray data, as a heatmap with the corresponding 
dendrogram. The log transformed inductions levels are indicated with different colour 
intensities in blue and red representing down- and up-regulation respectively. In the 
heatmap, each gene is represented as a single column and measured time points 
are represented as rows. According to the dendrogram, 6 clusters were identified 
that are indicated with the coloured bars below the heatmap. For each cluster, the 
averaged expression pattern in the time course (normalized on a scale to 1) was 
calculated from log transformed microarray data of all genes within a cluster and 
shown as graphs. A number of 8 genes was not included in the clusters since their 
expression profiles were unique according to the dendrogram. (B) Representation 
of the genes within the clusters U3 and U4. The clusters are shown with the name 
and the GenbankTM accession numbers for each gene. Averaged microarray (MA) 
values of the duplicate experiments at each time point are indicated with different 
colour intensity on a red scale (for full colour figure, see page 241). 
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Functional analysis 
 Eisen and colleagues have previously reported that genes with 
similar expression profiles may share common functions (16). To explore 
the biological significance of the gene clusters described above, the protein 
functions of these clustered genes were determined according to Incyte 
Genomics functional classification. According to this classification genes 
can be categorized in seven functional classes, designated A to G, of which 
A and G can be further divided into various subclasses (see Fig. 3 for class 
specifications). In the table included in this figure, the number of genes per 
cluster was determined and analysed for deviation from random distribution 
when compared to the total number of genes in a particular class on the entire 
microarray. Figure 3A shows that based on Chi-square analysis, significant 
enrichment in at least one of the identified clusters was observed in six of the 
main seven classes. The data set was generally enriched in proteins belonging 
to class C (“protein modification and maintenance”) and class G (“localized 
and structural proteins”), but in addition cluster specific enrichment was 
observed for the classes A, B, D and E (see Fig. 3A). As shown in Fig. 3B, 
subclass specific enrichment of class A4 genes (“transcription factors”) was 
observed in category U1 consisting of up-regulated early response genes, and 
of class A1 genes (“extracellular messengers”) in category U3 consisting of 
up-regulated late response genes. Enrichment of G1.1 genes (“extracellular 
matrix”) was particularly significant in category U2 consisting of up-regulated 
intermediate response genes.
From this analysis it can be concluded that proteins with similar 
functions are co-regulated during differentiation. This description of the 
dynamics of osteoblast differentiation in terms of protein function provides 
therefore valuable information about osteoblast characteristics at distinct 
stages of the differentiation process.
Osteoblast specificity of BMP2-induced genes
 In order to identify putative new bone markers, we subsequently 
focussed on the clusters U3 and U4, which contain up-regulated late response 
genes. Alkaline phosphatase and osteocalcin are both found in cluster U3, and 
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therefore this cluster may also contain other genes associated with the matrix 
maturation and matrix mineralization phase of osteoblast differentiation. Late 
phase genes will most likely not be involved in general cell cycle and growth 
regulatory processes and may therefore well be specific for the osteoblast 
maturation process. In order to identify bone specific genes in the clusters 
U3 and U4, we first measured their expression level and induction by BMP2 
in C2C12 cells using real-time quantitative RT-PCR analysis. Subsequently 
Figure 3.
Analysis of protein functions of the clustered genes. The table shows the number 
of genes represented on microarray and determined in the clusters for the main 
functional classes (A-G) and their sub-classes. Enrichment of these classes was 
calculated as described in Results. Graphs are shown for main classes (A) and 
sub-classes (B) that were significantly enriched in one or more clusters (p<0.01 
according to a Chi-square test, and at least 4 observations) and significant 
enrichment is indicated with an asterisk.
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these expression and induction levels were compared with those in identically 
treated NIH3T3 cells, a non-osteoblastic murine fibroblast. Genes that were 
more strongly induced in C2C12 cells than in NIH3T3 cells were further 
examined for their BMP2-induced expression regulation in another murine 
preosteoblast cell line, MC3T3, to exclude C2C12 cell type specific effects.
Real time quantitative RT-PCR analysis on the 54 distinct genes 
present in U3 and U4 6 days after BMP2 treatment confirmed their up-
regulation in C2C12 cells, although the level of induction was generally 
higher than measured on microarray. This observation is in agreement with 
data published by others, reporting that the dynamic range of the RT-PCR 
technique is generally greater than that of microarray hybridizations (17). Of 
the genes tested only three showed less than twofold up-regulation by RT-
PCR, which most likely results from inappropriate cDNA sequences of these 
genes on microarray as was indicated by Incyte Genomics.
Table 1. Specific induction of late response genes
Accession 
number Description
Induction level
0-6d + BMP2
    C2C12       NIH3T3
W29228
AA517588
AA217902
AA794190
AA709999
AW210283
AA061047
AI197098
AA080270
AI117779
AA880440
AA037995
W53604
AA145454
AA755273
AA718392
AA222756
W17422
AA221794
AA237727
W08198
AI325603
osteocalcin
alkaline phosphatase 
Wnt inhibitory factor 1
EST
EST
lumican
stromal cell derived factor 5
EST
fatty acid binding protein 4
orosomucoid 1
hydroxyprostaglandin dehydrogenase 15 (D)
microfibrillar associated protein 5
procollagen type VI, alpha 2
insulin-like growth factor binding protein 4
protein related to DAN and cerberus
EST
EST
cathepsin H
regulator of G-protein signalling 2
EST
G-protein coupled receptor (edg-1)
apolipoprotein E
>1000
>1000
>1000
>1000
>1000
>1000
>1000
543
316
161
145
114
119
108
67.2
46.1
45.2
22.9
19.7
19.2
18.2
15.6
2.3
54.7
-15.1
-6.1
10.3
109
2.0
28.7
-1.4
11.0
1.0
3.3
1.8
2.1
-1.9
3.0
2.1
-6.0
-6.5
-3.5
-1.7
-5.4
A number of 54 late response genes was analysed by quantitative RT-PCR for their BMP2 
response in C2C12 cells and NIH3T3 fibroblasts. Inductions levels are shown after 6 days of 
BMP2 treatment relative to time point zero samples. Negative values represent repression. 
Listed are the 22 genes that were minimally tenfold stronger induced in C2C12 cells than in 
NIH3T3 fibroblasts.
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 Table 1 shows a survey of those genes that are at least 10-fold more 
induced in C2C12 cells than in NIH3T3 cells, when comparing mRNA levels of 
cells 6 days after BMP2 treatment with untreated cells at zero time. This list 
of 22 genes thus obtained contains the two well-known bone markers alkaline 
phosphatase and osteocalcin. In contrast to osteocalcin, alkaline phosphatase 
was also strongly induced in NIH3T3 cells, although still much less than in 
C2C12 cells. Specific regulation of these 22 genes was subsequently verified 
by comparing mRNA levels in C2C12 cells and MC3T3 cells at different time 
points after BMP2 treatment (Fig. 4). The late response of these genes in 
C2C12 observed on microarray was confirmed by quantitative RT-PCR. Of 
the genes tested, 11 were specifically up-regulated in both cell lines during 
BMP2-induced differentiation (Fig. 4, left hand panel). This group included 
the well-known marker genes osteocalcin and alkaline phosphatase. The 
other genes were either not induced in MC3T3 cells or already constitutively 
expressed in this cell line (Fig. 4, right hand panel). In conclusion, the 
approach of gene selection described here has enabled us to reduce a subset 
of 54 genes, expressed during the late phase of osteoblast differentiation as 
observed by microarray analysis, to 11 genes that were specifically induced 
during osteoblast differentiation. Table 2 lists the names and accession 
numbers of the 5 genes and 4 ESTs that in addition to osteocalcin and alkaline 
phosphatase have thus been found as potential new markers for osteoblast 
differentiation.
Table 2. List of markers for in vitro osteoblast 
             differentiation
Accession 
number Description
W29228
AA517588
AA217902
AA794190
AA709999
AA080270
AI117779
W53604
AA755273
AA222756
AA237727
osteocalcin
alkaline phosphatase 
Wnt inhibitory factor 1
EST
EST
fatty acid binding protein 4
orosomucoid 1
procollagen type VI, alpha 2
protein related to DAN and cerberus
EST
EST
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Figure 4.
Analysis of osteoblast specific BMP2-induced gene expression by quantitative RT-
PCR.Gene expression regulation of 22 selected genes with putative osteoblast 
specificity was analysed in C2C12 and MC3T3 cells at the same time points as used 
for microarray analysis. Inductions levels are shown relative to time point zero 
for BMP2-treated (patterned bars) and untreated cells (white bars). Genes were 
divided into two classes showing BMP2 specific induction in both cell types (left 
panel) or genes that did show specific induction in C2C12 but not in MC3T3 (right 
panel).
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Expression of genes identified by microarray during mouse embryonic 
development
 In the above study nine putative new markers have been found for in 
vitro bone cell differentiation using C2C12 cells as a model system. In vitro 
model systems are not without limitations, and therefore we analysed four 
of these genes, which showed highest induction levels by BMP2, for their 
expression in developing bone using mouse embryos at E16.5 of gestation 
by in situ hybridization. The expression patterns were compared with that 
of Cbfa1, a transcription factor that regulates osteoblast differentiation 
and is expressed early in skeletal development, in cells of mesenchymal 
condensations and the osteoblast lineage. In later development it is 
expressed in ossification centres of all bones, independent of their embryonic 
origin and mechanism of ossification (intramembranous or endochondral), 
but not in chondrocytes (4). At E16.5, ossification centres are present in most 
of the skeleton but not all bones are mineralized (18). We first confirmed the 
expression of Cbfa1 in bone in transverse sections of the head at the level of 
the jaws (Fig. 5A, F), and in the axial skeleton at the level of the lungs (Fig. 
5K, P). The ossification centres of the developing mandibular and maxilliary 
bones, frontal bone, nasal bone, ribs and vertebrae all showed clear expression 
of Cbfa1, as expected. We also observed high levels of Cbfa1 expression in 
the mandibular region/dental mesenchyme surrounding the developing tooth 
(Fig. 5F) as well as in developing enamel knots (not shown). The gene for 
Wnt inhibitory factor 1 (Wif1) showed a strikingly similar expression pattern 
to Cbfa1, with the osteoblastic regions of all bones in the head and axial 
skeleton, as well as the basisphenoid bone, showing high levels of expression. 
As described previously for Cbfa1 (2), expression of Wif1 was not detectable 
in Meckel’s cartilage (Fig. 5G). Again, Wif1 was detectable in the enamel knot 
of developing teeth in both the upper and lower jaw (Fig. 5G and insert) and 
the vibrissae of the whisker follicles (not shown); although these are not 
ossification centres, they are known targets of BMP signalling (19, 20). In 
addition, epithelium of the tongue expressed Wif1 but not Cbfa1.
The expression pattern of the 3 ESTs tested, however, differed 
significantly from Cbfa1, although in two of the three it was associated with 
bone. AA222756 at first appeared not to be expressed at all in comparable 
sections (Fig. 5C, H, M) but exceptionally and consistently we observed 
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highly restricted expression in the tips of the vertebrae (Fig. 5R and insert). 
AA709999, on the other hand, was expressed in all bones analysed but was 
restricted to the periosteum/compacted mesenchyme on the outside of the 
bone (Fig. 5D, I, N, S). As Wif1, this EST was also expressed in the epithelium 
of the tongue but, by contrast, not in the teeth. AA794190, however, was 
not expressed above background in bone (Fig. 5E, J, O, T) although it was 
Figure 5.
Expression of genes identified by microarray in the developing mouse skeleton at 
E16.5 by in situ hybridization.
A-J: transverse sections through the head at the level of the jaws for a control 
osteoblast marker Cbfa1 (A,F) and for Wif1 (B,G) and the three ESTs AA222756 
(C,H), AA709999 (D,I) and AA794190 (E,J). K-O: transverse sections through the 
body at the level of the midriff, showing expression in the ribs for Cbfa1 (K), Wif1 
(L), AA222756 (M), AA709999 (N) and AA794190 (O). P-T: transverse sections 
through the body showing expression in the vertebrae for Cbfa1 (P), Wif1 (Q), 
AA222756 (R), AA709999 (S) and AA794190 (T). Inserts are higher magnifications 
of structures in the main figures.
Abbreviations: bs, basisphenoid bone; fb, frontal bone; md, mandible; mx, maxilla; 
M, Meckel’s cartilage; nb, nasal bone; nc, nasal cavity; r, ribs; tg, tongue; to, tooth; 
v, vertebra; vi, vibrissa. (for full colour figure, see page 242).
Cbfa1 Wif1 AA222756 AA709999 AA794190
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expressed at various sites of BMP signalling, namely the tooth (Fig. 5J and 
inserts). These data show that several genes identified in this study are 
indeed markers for in vivo bone differentiation, with characteristic expression 
patterns for the individual genes.
DISCUSSION
 In this study, microarray technology was employed to examine gene 
expression patterns during osteoblast differentiation. Based on the analysis 
of 9,596 genes and ESTs, 342 transcripts were found to be at least twofold 
positively or negatively modulated during a time course experiment in which 
murine C2C12 cells differentiated from mesenchymal progenitor cells into 
mature osteoblasts. Hierarchical clustering of the genes regulated resulted in 
the identification of groups of early, intermediate and late response genes.
A subset of 54 late response genes was subsequently analysed for 
their BMP specific induction during osteoblast differentiation. Because of the 
similarity in expression behaviour with the well-established osteoblast markers 
alkaline phosphatase and osteocalcin, such genes may be characteristic for 
osteoblast function and activity and serve as markers for bone tissue. In 
our approach to examine expression levels in different cell types, alkaline 
phosphatase, osteocalcin and an additional 5 genes and 4 ESTs were found to 
exhibit specific induction by BMP2 in C2C12 cells and MC3T3 preosteoblasts, 
but much less so in NIH3T3 fibroblasts. Of these genes, those for fatty acid 
binding protein 4 (Fabp4), collagen type VI alpha 2, and orosomucoid 1 are 
well documented. Fabp4 is known as a marker for terminally differentiated 
adipocytes, and in vitro, its expression can be regulated by BMPs (21,22). 
Co-expression of Fabp4 with alkaline phosphatase and osteocalcin has also 
been found by others (23), suggesting that Fabp4 can indeed be a marker 
for osteoblast differentiation. Orosomucoid 1 is a natural anti-inflammatory 
agent and one of the major acute phase proteins in humans, but its precise 
biological function is still unknown. At the protein level, orosomucoid 1 is found 
in many tissues, but mRNA expression is mainly hepatic (24). Presence of the 
protein in bone has been observed previously (25), but mRNA expression in 
osteoblasts has not been described to date. Activation of expression of the 
collagen VI gene has been shown to play a role in the mineralization of human 
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osteoblast-like cells in vitro (26).
Induction levels of the genes tested in MC3T3 cells were generally 
lower than in C2C12 cells, which could be explained by differences in their 
basal expression levels. After 6 days of BMP2 treatment, expression levels 
were similar in both cell types, but basal levels in MC3T3 cells appeared to be 
higher than in C2C12 cells (data not shown). A similar effect in C2C12 cells 
and MC3T3 cells has been observed for osteocalcin by Shin et al. (27) who 
argued that MC3T3 cells, although immature, are already fully committed to 
the osteoblast lineage. Some of the genes that were not induced in MC3T3 
cells exhibited comparable expression levels with C2C12 cells at day 6 of 
BMP2 treatment, such as that for insulin-like growth factor binding protein 
4, which is known to be expressed by cells from various skeletal sites (28). 
Specific roles of such genes in osteoblast function can thus not be excluded, 
but the observed late response seems to be cell type specific.
The identified 55 late response genes identified were analysed for 
expression by quantitative RT-PCR in BMP2-treated C2C12 cells and NIH3T3 
fibroblasts. Most genes that were induced during osteoblast differentiation 
of C2C12 cells were already expressed in unstimulated fibroblasts (data 
not shown), but their BMP-responsiveness seems to be osteoblast specific. 
However, of the genes and ESTs specifically induced in both C2C12 cells and 
in MC3T3 cells, expression levels of Wif1, EST AA709999, EST AA794190 and 
EST AA222756 were very abundant in osteoblasts compared with NIH3T3 
cells. They thus behave similarly to osteocalcin, which could be indicative 
for a potential role of these genes in bone development. In addition, a DNA 
and protein homology search for EST AA709999 showed homology with 
tenascin, which has been demonstrated to play a role in supporting in vitro 
differentiation and maintaining the functional state of osteoblast-like cells 
(29).
Expression of these transcripts in bone during embryonic development 
was confirmed by in situ hybridization in mouse embryos at E16.5 of gestation. 
Expression was predominantly observed in bone, but also other tissues stained 
positively, including tooth primordium, tongue surface and vibrissae, which 
are BMP signalling targets (19,20,30). The difference in tissue specificity of 
the probes analysed, suggests involvement of factors other than BMPs in cell 
fate determination. Very interesting is the appearance of Wif1 expression in 
these tissues. Wif1 is an extracellular protein that inhibits Wnt signalling (31) 
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and to our knowledge this is the first report in which its expression has been 
correlated with osteoblast differentiation and bone development.
Other proteins that are known to interact with Wnt and thereby regulate 
Wnt-induced signalling, are Cerberus, Dickkopf, and secreted frizzled-related 
proteins. Remarkable is the presence in cluster U3 of the gene encoding the 
protein related to DAN and Cerberus, and for stromal cell-derived factor 5, 
of which the latter shows high homology to secreted frizzled-related protein 
2. In cluster U2, Dickkopf homolog 3 was present. This strongly suggests a 
relationship between BMP and Wnt signalling during bone development, which 
is in line with recent observations showing an important role for Wnt-mediated 
signalling in bone accrual during growth through LDL receptor-related protein 
5 (32). In addition, inhibition of Wnt signalling by Dickkopf has been shown to 
be mediated by interaction with LDL receptor-related protein 6 (33). Details 
of the mechanism whereby BMP and Wnt signalling interact during osteoblast 
differentiation awaits further investigation.
Although bone is a highly specialized tissue, osteoblasts are very similar 
with fibroblasts in terms of gene expression (5). A characteristic feature of 
osteoblasts is the secretion and processing of extracellular matrix. In general 
terms, strongest modulations were observed in our microarray experiments 
for extracellular matrix genes, with particularly striking up-regulation of 
small leucine-rich proteoglycans such as biglycan, osteomodulin, decorin and 
lumican. Proteoglycans play a role in matrix assembly and can promote in 
vitro matrix mineralization (34). Individual members of proteoglycans can 
function in inhibiting growth factors or in controlling cell proliferation, and 
apart from bone, they play a role in maintenance of connective tissue (35). 
Thus if expression of individual genes is not restricted to bone, the sequential 
expression of the combination of genes may ultimately specify an osteoblast. 
Of the up-regulated genes, 25% appear to encode for extracellularly localized 
proteins, while in addition regulation of extracellular matrix proteins (e.g. 
collagens) preceded regulation of extracellular proteases and messengers. 
This time dependent shift is in agreement with the model of osteoblast 
differentiation in which matrix deposition is followed by matrix maturation 
and mineralization (1). The genes listed here may thus extend our current 
knowledge about the mechanism whereby osteoblasts deposit bone matrix.
It is realized that a number of genes related to osteoblast differentiation 
such as that for osteoprotegerin and Cbfa1 were not included in the set of 
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342 genes regulated. The transcription factor Cbfa1 contains a C-terminal 
region that is constitutively expressed in C2C12 cells and an osteoblast 
specific N-terminal region that is specifically expressed during BMP2-
induced differentiation (36). The DNA sequence present on the microarray 
was complementary to the C-terminal part. No regulation of the C-terminal 
sequence was detected by quantitative RT-PCR, while strong up-regulation 
was observed of the N-terminal region (data not shown). Other genes, such 
as that for osteopontin and osteoprotegerin ligand, were significantly up-
regulated, but their induction level on microarray was less than twofold and 
therefore not included in our cluster analysis. Moreover, it is important to 
realize that unknown relevant osteoblast specific genes might not be present 
on the microarrays used here.
Other reports have appeared in which gene expression during 
osteoblast differentiation has been studied on a broad scale by using 
methods such as microarray or SAGE (37-41). It must be noted that accurate 
comparison of these studies is difficult for several reasons: 1) the Unigene 
1 array used in our study differs from the arrays used in other studies, so 
different gene populations are screened, 2) studies are performed in different 
cell lines, 3) different inducers of osteoblast differentiation such as BMP, 
ascorbic acid and β-glycerophosphate are used and 4) expression analysis 
is performed at different time points Of the 9 novel markers identified, only 
collagen type VI alpha 2 was found to be regulated in a microarray study of 
BMP2-induced differentiation of human marrow stromal cells (38).
In the present study we have focused on up-regulated late phase 
genes for identification of new bone markers. However, an important role 
in bone development could also be played by some of the down-regulated 
genes. For example, the gene for matrix Gla protein was found to be down-
regulated in the early phase. This protein inhibits matrix calcification and is not 
expressed in osteoblasts (42, 43). In addition, osteoblast specific regulatory 
suppressors might be found within the down-regulated genes. Forthcoming 
studies will focus on the characterization of the intermediate regulated genes, 
since they are both the targets of BMP signalling and the driving forces for the 
subsequent bone cell differentiation process.
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ABSTRACT
 Wnt signalling has been implicated in regulating bone formation 
by controlling osteoblast proliferation and function. Although stabilization 
of β-catenin by Wnt has been shown to increase alkaline phosphatase 
expression and osteoblast differentiation, the precise role of Wnt signalling 
during the process of osteoblast differentiation is largely unknown. In this 
study, we used microarray technology to investigate expression regulation 
of Wnt signalling components during in vitro osteoblast differentiation. 
Expression was analysed during bone morphogenetic protein 2 (BMP2)-
induced osteoblast differentiation of murine C2C12 and MC3T3 cells and data 
were compared with expression in BMP2-treated NIH3T3 fibroblasts. During 
osteoblast differentiation, particularly strong expression regulation of the 
Wnt antagonists Sfrp2 (secreted frizzled related protein 2) and Wif1 (Wnt 
inhibitory factor 1) was observed in the late phase of differentiation. In situ 
expression analysis in murine tail vertebrae supported Wif1 expression during 
late phase bone cell differentiation, since Wif1 was found to be expressed in 
vivo in trabecular, but not in cortical bone. We further analysed the effects 
of continuous activation of Wnt signalling by lithium chloride and observed 
that osteoblast differentiation was reduced, as measured by expression of 
osteoblast marker genes encoding alkaline phosphatase, osteocalcin and 
osterix, as well as by the amount of calcium release. Taken together, our 
data indicate that endogenous expression of Wnt antagonists by osteoblasts 
provides a negative Wnt feedback loop which is essential in controlling 
osteoblast maturation. 
INTRODUCTION
 Wnts form a family of secreted glycoproteins that control a diversity 
of biological processes including cell fate determination and polarity (5), cell 
proliferation (7) and apoptosis (24). Wnts mediate their signals by binding 
to receptors of the Frizzled family (31) and to the low-density lipoprotein 
receptor-related proteins Lrp5 and Lrp6 (20, 22, 27). Canonical Wnt signals 
are mediated to the nucleus via β-catenin. In unstimulated cells, β-catenin is 
phosphorylated by glycogen synthase kinase 3β (GSK-3β) in the cytosol and 
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targeted for degradation in the proteasome. Upon Wnt binding to its receptors 
GSK-3β activity is decreased, resulting in the accumulation and nuclear 
translocation of non-phosphorylated β-catenin, where it forms a complex 
with transcription factors of the TCF/LEF family to initiate transcription of Wnt 
responsive genes. This pathway is known to control a variety of developmental 
processes in relation to skeletal development, such as limb bud initiation, 
patterning and chondrocyte differentiation (see reference 32 for review).
Several reports have described a role for Wnt signalling in bone 
development and osteoblast differentiation. In vivo, canonical Wnt signalling 
via the Lrp5-mediated pathway controls particularly postnatal osteoblast 
proliferation, since Lrp5 deficient mice exhibit low bone mass due to a 
decreased numbers of osteoblasts (16). In humans, inactivating mutations 
in LRP5 result in reduced bone mass (13), whereas activating mutations that 
prevent its binding to the Wnt antagonist Dickkopf1 increase bone density 
(4, 19, 29). These observations indicate that bone mass is tightly regulated 
by the Wnt/LRP5 pathway. In vitro experiments have shown a stimulatory 
effect of the canonical Wnt pathway on alkaline phosphatase expression and 
osteoblast differentiation (3, 13, 16, 23). These studies have implicated a 
Wnt autocrine signal at the onset of osteoblast differentiation (23). However, 
a putative role of Wnt signalling during the full length of the osteoblast 
differentiation process has not been studied yet.
Control of Wnt activity is a complex process which is regulated 
at different levels by extracellular antagonists ((17) for review), receptor 
selectivity (25, 33) and interaction with other signalling pathways (1, 18). A 
detailed analysis of components in the Wnt network would facilitate a better 
understanding of the role of Wnt signalling during osteoblast differentiation. 
We have previously reported the use of gene expression microarray technology 
as a method to identify novel markers for osteoblast differentiation (28). 
One of the markers identified was Wif1 (Wnt inhibitory factor 1), a secreted 
protein that binds Wnts and antagonizes their activity (15).
In the present study we have used such microarray technology 
to investigate expression regulation of Wnt signalling components during 
BMP-induced osteoblast differentiation in vitro. We observed that of all 
components analysed, the antagonists of Wnt signalling showed strongest 
expression regulation, with strong upregulation particularly during late phase 
bone cell differentiation. In combination with results showing that continuous 
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Wnt signalling leads to decreased osteoblast differentiation, our data support 
an import role for Wnt antagonists as regulatory molecules in the progress of 
osteoblast maturation.  
MATERIALS AND METHODS
Cell culture 
 C2C12 murine mesenchymal progenitor cells and NIH3T3 murine 
fibroblasts, both obtained from the American Type Culture Collection, were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% newborn calf serum (NCS; HyClone®), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) at 37°C in a humidified atmosphere containing 
7.5% CO2. Murine MC3T3-E1 osteoblast precursor cells were maintained 
in α-MEM supplemented with 10% NCS. For differentiation experiments, 
cells were seeded at a density of 2.0x104 cells/cm2 and grown for 24 hrs. 
Subsequently, medium was replaced by DMEM (or α-MEM) containing 5% 
NCS in the presence or absence of recombinant human bone morphogenetic 
protein-2 (BMP2). BMP2 from different sources was used in this study, and 
each batch was calibrated for activity by measuring its dose-dependence 
of BMP-induced alkaline phosphatase activity in C2C12 cells, as described 
earlier by us (8). For the subsequent microarray experiments the lowest 
BMP concentration was applied that induced maximum alkaline phosphatase 
activity, corresponding to 300 ng/ml for BMP2 from Wyeth, Andover (for the 
C2C12 experiment) and 500 ng/ml for BMP2 from R&D Systems (for NIH3T3 
and MC3T3 experiments). The effects of lithium ions on C2C12 differentiation 
were studied in the presence of 250 ng/ml BMP2 (R&D Systems), which 
resulted in 70% of maximum alkaline phosphatase activity. For von Kossa 
and calcium deposition assays, the medium was supplemented with 12.5 mM 
β-glycerophosphate (Sigma). 
Human mesenchymal stem cells (hMSC) were obtained from Cambrex 
Bioproducts (Verviers, Belgium) and cultured either in proliferation medium or 
in osteogenic differentiation medium containing dexamethasone, ascorbic acid 
and β-glycerophosphate, as supplied by the manufacturer. For mineralization 
assays, hMSC cells were cultured in presence or absence of 100 ng/ml BMP2 
as indicated in the figure legends. Cells were seeded at a density of 1.0x104 
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cells/cm2 in proliferation medium. After 24 hrs medium was replaced by either 
proliferation or differentiation medium which was refreshed twice a week. 
Mineralization assays
 For calcium deposition measurements, calcium concentrations were 
measured in a colorimetric assay with o-cresolphtalein complexone as 
chromogenic agent (Sigma Diagnostics). C2C12 and hMSC cells were cultured 
in 24-wells culture dishes under osteogenic conditions as described above for 
different time intervals. Cells were washed twice with phosphate-buffered 
saline (PBS), after which calcium was extracted from the extracellular matrix 
with 150 µl of 0.5M HCl. After overnight incubation while shaking at room 
temperature, the extract was centrifuged to pellet cell debris. To quantify the 
amount of calcium, 50 µl of sample were mixed with 950 µl of calcium buffer 
(Sigma Diagnostics) and absorbance was measured in a spectrophotometer 
at 575 nm. Blank values were obtained by adding 50 µl of HCl to 950 μl of 
calcium buffer. Samples were measured in duplicate and obtained values 
averaged after background subtraction. 
For von Kossa staining, cells were washed twice with PBS and fixed for 10 
minutes in 3.7% formaline (J.T. Baker) in PBS. Subsequently cells were 
washed three times with water and incubated in 2% silvernitrate solution 
(Merck) for 10 minutes on a light source. After incubation silvernitrate was 
replaced by PBS.
RNA isolation
 Total RNA was extracted according to an acid guanidium thiocyanate-
phenol-chloroform method (TriPure® Isolation Reagent, Boehringer Mannheim) 
and RNA concentrations were determined by measuring the absorbance at 
260 nm. Poly(A)+ RNA was prepared from total RNA using the OligotexTM 
Method (Qiagen). Quantification of poly(A)+ RNA was carried out according to 
the RibogreenTM RNA quantitation assay (Molecular Probes). 
Array hybridization and data processing
 The generation of a microarray dataset describing the BMP2 response 
of C2C12 cells has previously been described by us (28). In that study gene 
expression profiles were studied at different time points in duplicate (with dye 
reversal) using cDNA from untreated cells at time zero as a  reference for all 
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time points. In addition, we analysed the BMP2 response of mouse MC3T3-
E1 and NIH3T3 cells by microarray analysis, using mouse brain cDNA as a 
common reference (6). Sample cDNA was labelled with Cy-5 and reference 
cDNA with Cy-3, and both were hybridized to Unigene 1 arrays (Incyte 
Genomics, Mountain View, CA) as described previously (34). In the case of 
human mesenchymal stem cells (hMSCs), universal human reference RNA 
(Stratagene, La Jolla, CA) was used as reference and samples hybridized to 
human Unigene 1 arrays. 
Hybridizations with RNA from samples obtained at time zero 
(unstimulated cells) were performed in triplicate to generate a robust 
estimation of basal gene expression. Individual gene expression profiles 
were corrected for array differences by exploiting the variation in intensity 
observed in the various reference samples. A basal normalized expression 
value of a gene g, denoted by , was computed at time zero by taking the 
average of the biological intensity corrected for the observed fluctuations in 
the reference intensity, as follows:
where  is the Cy5 intensity of the g-th gene on the i-th array,  is the 
Cy3 intensity of the g-th gene on the i-th array, and  is the mean Cy3 
intensity of the g-th gene averaged over the n replicate arrays corresponding 
to the unstimulated cells in which n=3 for our replicate experiment. Dynamic 
(normalized) gene expression profiles were determined to reflect gene 
induction in time during the differentiation process. The dynamic normalized 
expression value of gene g at array i, denoted by , was computed by 
taking a balanced ratio between biological intensity and mapped control 
intensity, according to:
where .  is the mean Cy3 intensity and  the 
mean Cy5 intensity of the g-th gene averaged over the 3 replicate arrays 
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corresponding to the unstimulated cells. In this way, the Cy3 intensity is 
mapped onto the average Cy5 intensity to relate the gene expression signals 
to the basal expression in unstimulated control cells. Data were visualized 
using the Spotfire Decision Site 7.0 package (Spotfire Inc., Somerville, MA). 
Real-time quantitative RT-PCR
 For real-time quantitative RT-PCR, ABI Prism Sequence Detection 
System 5700 and Primer ExpressTM (PE Biosystems) were used. For each gene, 
a set of primers was designed using sequences obtained from GenbankTM and 
amplicons of 50-70 basepairs with TM between 58 and 60°C were selected. 
Prior to complementary DNA (cDNA) synthesis, 2 µg of total RNA were DNase 
treated for 15 min at 37ºC, after which RNA was reverse transcribed from 
random hexamer primers using the SUPERSCRIPTTM II reverse transcriptase 
kit (GibcoBRL). Subsequently, 0.08-0.2 µg of total RNA was amplified using 
SYBR Green® PCR Mastermix (Applied Biosystems) under the following 
conditions: initial denaturation for 10 min at 95ºC, followed by 40 cycles 
consisting of 15 sec at 94ºC and 1 min at 60ºC. Expression values were 
calculated from threshold cycles at which an increase in reporter fluorescence 
above baseline signal could first be detected (CT).
In situ hybridization
 Neonatal mouse tails were collected from Swiss albino mice on day 
5 after birth and fixed in 4% paraformaldehyde, decalcified by incubation in 
12.5% sodium EDTA (pH 8.0) for 1 week at 4°C, embedded in paraffin wax 
and sectioned (5 µm) as described previously (9). The slides were dewaxed, 
rehydrated and pretreated with Proteinase K and acetic anhydride, and 
hybridized overnight at 55ºC as described previously (12). Constructs were 
cloned into pSKII- in the anti-sense orientation behind the T7 promoter. RNA 
probes were generated by transcription of the T7 RNA polymerase in the 
presence of (α-35S)-uridine triphosphate (UTP). After hybridization, the slides 
were washed at high stringency for 30 min at 62°C, treated with RNase A for 
30 min at 37°C, washed again at high stringency, dehydrated and allowed 
to dry. Autoradiography was performed using Ilford G5 photo emulsion. 
Slides were exposed for 2 weeks at 4°C and counterstained with Mayer’s 
haematoxylin. 
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RESULTS
Expression of Wnt signalling components during osteoblast 
differentiation
A proper understanding of the role of Wnt signalling on cellular 
differentiation requires a complete overview of the expression of Wnt 
signalling components during progression of the differentiation process. To 
study expression of such components on a broad scale during osteoblast 
differentiation, microarray technology was employed. The transcriptome 
of three different cell lines was studied using the mouse Unigene 1 array 
containing 9,596 uniquely annotated genes and expressed sequence tags 
(ESTs). Gene expression during time course experiments of BMP2-induced 
osteoblast differentiation was analysed in murine C2C12 and MC3T3 pre-
osteoblasts. To discriminate between general and osteoblast-specific gene 
expression regulation, mouse NIH3T3 fibroblasts were treated identically 
with BMP2 and used as a control. We previously described a set of 342 genes 
that respond to BMP2 in C2C12 cells (28). Using a 2.5-fold change cut-off 
value for differential expression, 420 genes were found to respond to BMP2 
in NIH3T3 cells and 194 genes in MC3T3 cells in at least one of the time 
points measured. This indicates that both MC3T3-E1 and NIH3T3 respond to 
BMP2 with a change in their transcriptional program. In this study, we limited 
the analysis of the expression data to the analysis of currently known Wnt 
signalling components.
 Figure 1A shows an overview of basal expression levels of the Wnt 
signalling components present on the array. Basal expression of the genes in 
the three cell lines studied is represented in a logarithmically based grey scale. 
The figure shows that many of the Wnt signalling components have relatively 
low basal expression levels in all three cell lines studied, when compared to 
a total of six housekeeping genes. Only Dkk3, Lrp5, Sfrp2 and Wnt4 show 
relatively high expression in MC3T3-E1 cells, whereas C2C12 and NIH3T3 
cells show high expression of Frzb (Sfrp3), Wnt6 and Wnt7b. Figure 1B shows 
a time course of gene expression levels from 0 to 144 hrs upon stimulation 
by BMP2. Here, transcript levels (D) are represented relative to that of the 
same gene in unstimulated cells at time point zero. Upon stimulation with 
BMP2, the C2C12 and MC3T3-E1 cells become committed towards osteoblast 
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differentiation, as evidenced by the expression of the osteoblast markers 
alkaline phosphatase (Akp2) and osteocalcin (Bglap1). Although NIH3T3 
cells show a transcriptional response to BMP2, they do not differentiate into 
osteoblasts, as indicated by the lack of induction of the alkaline phosphatase 
and osteocalcin genes. 
With respect to the Wnt signalling components, strong inductions 
were particularly measured for the extracellular Wnt modulators. The data 
show an induction after 48 hours of Sfrp2, Wif1 and Dkk3 in C2C12 cells. The 
induction of Sfrp2 and Wif1 was also observed in MC3T3-E1 cells, whereas 
Figure 1.
Expression of Wnt signalling components during osteoblast differentiation.
(A) Heat map of basal expression levels of the housekeeping genes Arbp (acidic 
ribosomal phosphoprotein); Gus (beta glucuronidase); B2m (beta-2 microglobulin); 
Tbp (TATA box binding protein); Tubb4 (tubulin beta 4) and Tubb5(tubulin beta 
5), as well as the osteoblast markers Akp2 (alkaline phosphatase 2) ; Bglap1 
(osteocalcin) and various Wnt signalling components in C2C12, MC3T3 and NIH3T3 
as measured by gene expression microarray. For each gene, basal expression levels 
were expressed relative to expression in the common reference control as described 
in Materials and Methods and subsequently log transformed. The resulting values 
are indicated with different colour intensities on a grey scale. (B) Expression 
dynamics of Wnt signalling components during osteoblast differentiation. Dynamic 
(normalized) expression values (D) were calculated as described in Materials and 
Methods and shown as a function of time in BMP-treated C2C12, MC3T3 and NIH3T3 
cells, and for the FRZB gene also in hMSCs treated with osteogenic differentiation 
medium (insert). 
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NIH3T3 but not MC3T3-E1 cells showed an induction of Dkk3. It should be 
noted, however, that the basal expression level of Dkk3 in MC3T3-E1 is high 
when compared to C2C12 and NIH3T3 (Figure 1A) Thus, Dkk3 is expressed 
in MC3T3 but not induced to higher expression levels by BMP2. Furthermore, 
BMP2 stimulation leads to a modest increase in expression of the Wnt4, 
Wnt10b and Tcf7 genes in C2C12 cells reaching a plateau phase at 24 hours 
after stimulation. The induction of these genes was confirmed by real time PCR 
(data not shown). In conclusion, of all Wnt signalling components particularly 
Sfrp2 and Wif1 are upregulated by BMP2 in C2C12 and MC3T3 cells, but not 
in NIH3T3 cells. Transcriptome analysis of human mesenchymal stem cell 
(hMSC) differentiation showed a similar result. Of all Wnt components only 
the antagonist hFRZB was strongly induced during dexamethasone-induced 
osteoblast differentiation (see insert Figure 1B). Induction of Wnt4, Wnt10b 
and Tcf7 within the first 24 hrs of differentiation is indicative for a Wnt 
autocrine loop during early osteoblast differentiation (23). Notably, our data 
show particularly strong induction of various Wnt antagonists in osteoblastic 
cells after 24 hrs of differentiation, suggesting a negative feedback loop 
during the late stages of osteoblast differentiation.
Effect of Wnt signalling on BMP2-induced osteoblast differentiation
To investigate if osteoblast differentiation is affected by the 
continuous activation of Wnt signalling pathways, we studied BMP2-induced 
differentiation of C2C12 cells in the presence or absence of LiCl. LiCl mimics 
activation of the canonical Wnt signalling pathway by inhibiting GSK-3β 
activity, resulting in significantly increased β-catenin levels (26). Based on the 
above results, we analysed the expression of a number of osteoblast marker 
genes as well as of the Wnt antagonists Wif1 and Sfrp2 in cells treated with 
BMP2 alone or with BMP2 in combination with LiCl. Expression levels were 
analysed by means of real-time quantitative RT-PCR during different stages of 
differentiation. Figure 2 shows that LiCl reduced the BMP2-induced expression 
of osteoblast differentiation genes Cbfa1, Osx (osterix), Akp2 (alkaline 
phosphatase) and Bglap1 (osteocalcin) at all time points tested. With respect 
to the Wnt signalling components tested, LiCl strongly reduced expression of 
sFrp2, but had a stimulatory effect on Wif1 expression, which suggests that 
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Wnt signalling itself regulates expression of its antagonist Wif1. LiCl had no 
significant effect on expression levels of Gapdh, indicating that the inhibitory 
effect of LiCl on BMP2-induced gene expression of the osteoblast markers did 
not result from a general negative effect of LiCl on gene expression. 
 We further investigated the effect of LiCl on mineral deposition by 
C2C12 and hMSC cells. Figure 3 shows that differentiating C2C12 and hMSC 
cells are capable of forming a mineralized matrix. As visualized by means 
of a von Kossa staining, culturing C2C12 for 8 days and hMSC for 21 days 
under osteogenic differentiation conditions revealed a strong accumulation 
of mineral in the matrix, which was not seen in the control (Figure 3A). 
To examine the effect of LiCl on mineral deposition in a quantitative way, 
calcium release assays were performed. In accordance with the Von Kossa 
staining, the amount of calcium that can be released from the extracellular 
matrix increases by treatment with BMP2 (Figure 3B). We subsequently 
Figure 2. 
The effect of LiCl on osteoblast marker gene expression in C2C12 cells.
Cells were either left untreated (black bars) or induced to differentiate into 
osteoblasts by treatment with BMP2 (250 ng/ml) in the presence (grey bars) or 
absence (white bars) of 4 mM LiCl. Gene expression levels of osteoblast markers 
and Wnt antagonists were analysed by real time RT-PCR over a differentiation 
period of 6 days. Expression values were calculated as described in Materials and 
Methods, and represented in relative units. 
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studied the effect of LiCl on the BMP2-dependent calcium deposition by 
C2C12 cells. The data presented in Figure 3B show that calcium release was 
completely inhibited when cells were cultured in the continuous presence of 
LiCl. However, when added at later times during the differentiation process 
(indicated after 2, 4 or 6 days), the inhibiting effect of LiCl was decreased. A 
neutral red assay revealed no significant effect on C2C12 cell number after 
6 days of continuous LiCl treatment, indicating that the observed inhibition 
of osteoblast function could not be attributed to toxic effects of LiCl (data 
not shown). To exclude cell type specificity, the experiment was repeated 
with hMSCs. Culturing these cells in dexamethasone-containing osteogenic 
differentiation medium for a period of 20 days resulted in a strong induction of 
calcium deposition. Similar to C2C12 cells, this induction was inhibited when 
Figure 3. 
The effect of LiCl on mineral deposition during osteoblast differentiation.
(A) Von Kossa staining of C2C12 and hMSC cells cultured in presence or absence of 
BMP2. Cells were cultured for a period of 8 (C2C12) or 21 days (hMSC) in medium 
supplemented with 100ng/ml BMP2 and 12.5 mM β-glycerophosphate or in medium 
only containing β-glycerophosphate (control).
(B) The amount of released calcium by C2C12 cells was measured after 6 and 
8 days in absence (-) or presence (BMP) of 250 ng/ml BMP2 and expressed as 
percentage of BMP control (100%). At different time points during differentiation, 
LiCl was added to the cultures. Calcium release levels are shown after 6 and 8 
days and represented as percentage of BMP control values (3.7 and 6.6 mg/dl 
respectively). (C) Calcium release by hMSCs, expressed as mg of calcium per 
deciliter of assay volume. Cells were cultured for a period of 20 days in osteogenic 
differentiation medium (n , control). LiCl was added either from time zero (t) or 
from day 10 (p). 
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cells were cultured in the continuous presence of LiCl (Figure 3C). These data 
show that continuous activation of Wnt signalling by LiCl inhibits late stage 
osteoblast differentiation independent of the inducing agent. 
Expression of Wif1 during bone development
 The microarray data show Wif1 expression during a late stage of 
osteoblast differentiation in vitro. In order to relate Wif1 expression with 
maturational stage during development in vivo, we analysed Wif1 expression 
by in situ hybridization analysis during bone development in newborn mouse 
tails, since in this system the primary centers of endochondral ossification are 
still developing in the most distal vertebrae. Cbfa1 was used as a control for 
osteoblast gene expression (Figure 4). 
 Cbfa1 mRNA expression was restricted to vertebral elements (Figure 
4A), while Wif1 mRNA was detected in vertebrae as well as in connective tissue 
surrounding the intervertebral discs (Figure 4B). Higher order magnifications 
of the vertebrae (Figure 4C) confirmed Cbfa1 expression in osteoblasts and 
proliferating chondrocytes, but not in hypertrophic chondrocytes, as described 
previously (10, 11). Expression of Cbfa1 was strong in trabecular as well as 
in periostal osteoblasts. The Wif1 expression pattern in the vertebrae differed 
from that of Cbfa1 (Figure 4D). Co-localization of Wif1 and Cbfa1 appeared 
to be restricted to osteoblasts, since no Wif1 signal above background was 
detected in chondrocytes. While Wif1 expression was strong in trabecular 
bone, only weak Wif1 expression was observed in the periosteum. Wif1 
expression in trabecular bone was restricted to regions of Cbfa1 expression, 
but not bone marrow. Taken together, of the Wnt antagonists studied, Wif1 is 
expressed in osteoblasts during in vivo bone development. 
DISCUSSION
In the present study we have analysed the expression patterns of 
various Wnt signalling components during osteoblast differentiation of C2C12 
and MC3T3 cells. Of all components tested, in particular the extracellular 
antagonists of Wnt activity were induced during the late phase of osteoblast 
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differentiation. Our results are indicative for a negative feedback loop of 
Wnt signalling during progression of osteoblast differentiation. Further, we 
examined the effect of Wnt signalling on osteoblast differentiation. The results 
presented in this study suggest that continuous activation of Wnt signalling 
by LiCl treatment decreases osteoblast extracellular calcium deposition and 
osteoblast differentiation, as characterized by reduced transcript levels of 
osteoblast marker genes.  Li+ mimics activation of the canonical Wnt signalling 
by increasing β-catenin levels (26), and therefore our results of a negative 
effect of Li+ on osteoblast markers support previous data  showing that Lef1, 
the nuclear effector of canonical Wnt signalling, inhibits osteocalcin gene 
expression by interacting with the DNA binding domain of Cbfa1, the main 
regulator of osteoblastic differentiation and function. Since this repression 
Figure 4. 
Expression of Wif1 in developing mouse vertebrae. 
(A-F) Expression in proximal tail vertebrae of Cbfa1 (A, C, E) and Wif1 (B, D, F). 
(C,D) Higher magnifications of dark field images of vertebrae shown in A and B. 
(E,F) Haematoxylin counterstaining. Pictures show bright field images of vertebrae 
shown in C and D. Abbreviations: id, intervertebral disc; bc, bone collar; pc, 
proliferating chondrocytes; hc, hypertrophic chondrocytes; tb, trabecular bone. 
(For full colour figure, see page 243).
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was enhanced by constitutively active β-catenin, these data also indicate 
a negative effect of continuous activation of Wnt signalling on osteoblast-
specific gene expression. 
In contrast to this negative effect of β-catenin-mediated signalling 
on osteocalcin, a positive effect of LiCl, as well as of activated β-catenin, 
has been observed on the expression level of the alkaline phosphatase 
gene  (3, 13). Moreover, BMP2-induced alkaline phosphatase expression in 
C3H10T1/2 is known to require activation of canonical Wnt signalling (23). 
We observed a negative effect of LiCl on BMP2-induced alkaline phosphatase 
expression, while in the absence of BMP2, LiCl was able to induce alkaline 
phosphatase gene expression in C2C12 cells 30-fold above control levels 
without affecting expression of Cbfa1, osterix, or osteocalcin (data not 
shown). These observations raise the possibility that the response of the 
alkaline phosphatase gene to Wnt activation is gene specific and not the result 
of an overall differentiation response. This notion is substantiated by other 
studies showing that Wnt activation results in increased alkaline phosphatase 
activity, but does not  necessarily lead to an increase in expression of other 
bone differentiation markers such as Cbfa1, osteocalcin and collagen type 
1 (3, 23). These data indicate that in the presence of BMP2 prolonged Wnt 
signalling results in an inhibition of differentiation.
Our observation that regulation of Wnt antagonists by BMP2 is 
restricted to a late phase of osteoblast differentiation parallels in vivo studies. 
During limb development, the Wnt antagonist Frzb is successively expressed 
in mesenchymal condensations, periochondrium and chondroblasts of 
cartilaginous anlagen from gestational stages E9.5 to E13.5 (14). Later, 
at E17.5, Frzb is expressed in osteoblasts of both endochondral and 
intramembranous bone, but not in chondrocytes (21). Similarly as observed 
for Frzb, our results also relate expression of Wif1 to a late phase of 
osteoblast differentiation. Expression of Wif1 in trabecular but not in cortical 
bone implicates expression in maturating osteoblasts. In addition, Wif1 is 
expressed in skeletal elements during embryonic development at E16.5 (28), 
but we found no expression in ribs and vertebrae at E14.5 when Cbfa1 is 
expressed (not shown). Thus in agreement with the in vitro expression data 
of the various Wnt antagonists, Wif1 and Frzb are expressed in osteoblasts 
during in vivo bone development. These data suggest an involvement of Wnt 
antagonists in (multiple) processes of skeletal development with their precise 
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function determined by temporal and spatial expression patterns. Similar to 
our observations in vitro, expression in vivo occurs during the late phase of 
differentiation, supporting the concept that suppression of Wnt signalling is 
essential for proceeding of osteoblast maturation. Our in vitro observation 
points to a strong synergystic induction of Wif1 expression by BMP2 and LiCl. 
This observation may indicate that Wif1 is part of a Wnt autoregulatory loop.
It is well realized that the effects of changes in LRP5/Wnt signalling 
on bone formation in vivo may be merely attributed to changes in osteoblast 
number rather than osteoblast differentiation (2, 16). These data are in 
concordance with studies that describe a role for Wnt signalling in expansion 
of cells with predefined fates (7, 30). Our data fit with a model in which Wnt 
maintains a proliferative signal in osteoblasts, which should be shut off by 
Wnt antagonists before terminal differentiation can proceed. Such a model 
is substantiated by studies that indeed show a proliferative response of 
osteoblasts to Wnt activation (23). We hypothesize that expression of Wnt 
antagonists during the later stages of osteoblast differentiation contributes to 
a block in proliferation that is necessary for differentiation to advance. Future 
studies on the presence and actions of Wnt signalling components in bone 
should shed further light on the precise mechanisms by which Wnt controls 
bone mass.
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MICRO ABSTRACT
 Key regulatory components of the BMP-induced osteoblast 
differentiation cascade remain to be established. Microarray and subsequent 
expression analyses in mice identified two transcription factors, Hey1 and 
Tcf7, with in vitro and in vivo expression characteristics very similar to Cbfa1. 
Transfection studies suggest that Tcf7 modulates BMP2-induced osteoblast 
differentiation. This study contributes to a better definition of the onset of 
BMP-induced osteoblast differentiation.   
ABSTRACT
Introduction: Elucidation of the genetic cascade guiding mesenchymal 
stem cells to become osteoblasts is of extreme importance for improving the 
treatment of bone-related diseases like osteoporosis. The aim of this study 
is to identify regulators of the early phases of BMP2-induced osteoblast 
differentiation.
Methods: Osteoblast differentiation of mouse C2C12 cells was induced 
by treatment with BMP2 and regulation of gene expression studied during 
the subsequent 24 hrs using high-density microarrays. The regulated genes 
were grouped by means of model-based clustering and protein functions were 
assigned. Real-time quantitative RT-PCR analysis was used to validate BMP2-
induced gene expression patterns in C2C12 cells. Osteoblast specificity was 
studied by comparing these expression patterns with those in C3H10T1/2 
and NIH3T3 cells under similar conditions. In situ hybridization of mRNA in 
embryos at embryonic day E14.5 and E16.5 of gestation and on newborn 
mouse tails were used to study in vivo expression patterns. Cells constitutively 
expressing the regulated gene Tcf7 were used to investigate its influence on 
BMP-induced osteoblast differentiation. 
Results and Conclusions: 184 genes and expressed sequence tags 
(ESTs) were differentially expressed in the first 24 hrs following BMP2 
treatment and grouped in subsets of immediate early, intermediate early 
and late early response genes. Signal transduction regulatory factors mainly 
represented the subset of immediate early genes. Regulation of expression 
of these genes was direct, independent of de novo protein synthesis and 
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independent of the cell-type studied. The intermediate early and late early 
genes consisted primarily of genes related to processes that modulate 
morphology, basement membrane formation and synthesis of extracellular 
calcified matrix. The late early genes require de novo protein synthesis and 
show osteoblast specificity. In vivo and in vitro experiments showed that the 
transcription factors Hey1 and Tcf7 exhibited expression characteristics and 
cell type specificity very similar to those of the osteoblast specific transcription 
factor Cbfa1, and constitutive expression of Tcf7 in C2C12 cells differentially 
regulated osteoblast differentiation marker genes.
INTRODUCTION
Mesenchymal stem cells have the potential to differentiate into various 
cell types that include osteoblasts, chondrocytes, adipocytes, myoblasts and 
fibroblasts (1, 2) depending on the signalling cascades activated during the 
initial phase of differentiation. Each of these signalling mechanisms is likely 
to regulate a specific set of early response genes that ultimately determine 
the final fate of the differentiation process. Bone is a highly specialized tissue, 
but osteoblasts are nevertheless very similar to fibroblasts in terms of gene 
expression and only a very limited number of osteoblast specific genes have 
been identified (3). 
Among the few established osteoblast specific genes are the 
transcription factors Core-binding factor 1 (Cbfa1) and Osterix (Osx). Cbfa1 
is a key regulator of osteoblast differentiation (4-6) and its regulation and 
function have been studied extensively over the last decade. Several isoforms 
of Cbfa1 have now been identified, of which the type II isoform is bone specific 
(7, 8). The activity of the Cbfa1 protein is modulated through post-translational 
modifications as well as through protein-protein interactions (9-12). Most of 
the well-established bone markers, such as Alkaline phosphatase, Collagen 
I, Bone Sialoprotein, Osteopontin and Osteocalcin, are known target genes 
of at least one of the Cbfa1 isoforms (4, 13-15). Moreover, the transcription 
factor Osx acts downstream of Cbfa1 and both Cbfa1 and Osx knock-out mice 
exhibit a complete absence of skeletal ossification (6, 16).
Osteoblast differentiation can be induced by various stimuli, but the 
most potent inducers are the Bone Morphogenetic Proteins (BMPs). Although 
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the BMPs were first identified for their ability to induce ectopic bone formation 
in vivo (17), these proteins appear to be multifunctional regulators of 
morphogenesis during embryonal development (18). In addition to the BMP-
induced Smad signal transduction pathway, several major signal transduction 
pathways, including the Wnt and Notch pathways, have been implicated in 
osteoblast differentiation. Nevertheless, only parts of the complete gene 
regulatory program guiding mesenchymal stem cells to become mature 
osteoblasts are currently known and many gaps still need to filling. 
Recently, we have shown that gene expression microarray analysis is 
a powerful approach to identifying late phase bone marker genes (19) and to 
examine differential responses induced by BMP2, TGFβ1 and activin A (20). 
The aim of the present study was to identify novel potential regulators of the 
osteoblast differentiation process that are regulated during the early phases 
(within 24 hrs) of BMP-induced osteoblast differentiation using high-density 
microarrays. Model-based clustering and functional analysis identified two 
osteoblast-related transcription factors, Hey1 and Tcf7, which exhibited very 
similar expression characteristics to the osteoblast-specific type II Cbfa1 
isoform. In addition, Tcf7 was shown to differentially regulate osteoblast 
differentiation marker genes.
MATERIALS AND METHODS
Tissue culture and growth factors
 The murine mesenchymal progenitor cell lines C2C12 and C3H10T1/2 
and the fibroblast cell line NIH3T3 (obtained from the American Type Culture 
Collection [ATCC]) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% newborn calf serum (NCS), penicillin (100 
U/ml) and streptomycin (100 µg/ml) as described previously (20). For the 
various experiments, cells were plated at a density of 2.0x104 cells/cm2 
and grown for 24 hrs in DMEM supplemented with 10% NCS. Subsequently, 
medium was replaced by DMEM containing 5% NCS either in the presence or 
in the absence of 300 ng/ml recombinant human BMP2 with or without 50 
µM cyclohexamide (CHX). Recombinant human BMP2 was kindly provided by 
Wyeth (Andover). Cyclohexamide was purchased from Sigma. 
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RNA isolation
Total RNA was extracted according to an acid guanidium thiocyanate-
phenol-chloroform method (TriPure® Isolation Reagent, Roche Diagnostics) 
and RNA concentrations were determined by measuring the absorbance at 
260 nm. Poly A+ RNA was prepared from total RNA using the Oligotex™ 
method (Qiagen). Quantification of poly A+ RNA was carried out according to 
the Ribogreen™ RNA quantitation assay (Molecular Probes).
Microarray and statistical analysis
Microarray analysis was performed as described before (20). For each 
time point, the BMP2-treated samples were hybridized versus control samples 
that were incubated for the same period in DMEM supplemented with 5% 
NCS. For the hybridization experiments, the mouse Unigene 1 array from 
Incyte Genomics (Palo Alto) was used, and the experiments were performed 
in duplicate with a fluor reversal to minimize possible bias caused by the 
molecular structure of the Cy3 and Cy5 dyes. Background-subtracted element 
signals were used to calculate Cy3/Cy5 ratios. Genes were selected for further 
analysis if the signal to background ratio for a particular gene was > 2.5 
and at least 40% of the area on chip could be used for signal computation 
in at least one of the two channels. To account for systematic errors caused 
by non-linear differences in signal intensities of the Cy3 and Cy5 channel, 
statistical analysis was performed as described before (20). Genes with 
significant (p<0.01) differential expression regulation for at least one of the 
time points were selected for further analysis. Prior to clustering, microarray 
data were log transformed (base 10) according to: logI = log (ICy3/ICy5) if ICy3 
> ICy5 and logI = -log (ICy5/ICy3) if ICy5 > ICy3, in which I is the intensity of each 
spot on microarray. Log values were averaged over duplicate experiments 
and scaled to unit vector length (normalization). Subsequently, normalized 
log values were clustered using model-based clustering (21). Briefly, in this 
method clusters are considered to be groups displaying multivariate normal 
distributions. Various models were fitted to the data and an estimation was 
made of the accuracy of the model describing the data by assuming that 
underlying probability distributions occur for each model. Subsequently, a 
selection was made based on maximizing Bayesian Information Criterion 
(BIC) values for the specific model and number of clusters that represented 
the data best. Optimal clustering was obtained using a clustering method 
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in which the distribution of the expression ratios within a cluster were 
ellipsoidal, the cluster volumes variable, the cluster shapes equal and the 
cluster orientations variable (VEV-model). Protein functions of the genes were 
identified according to Incytes Protein Function Hierarchy. 
Real-time RT-PCR
For real-time RT-PCR, the ABI Prism Sequence Detection System 5700 
and Primer ExpressTM Software (PE Biosystems) were used. For each gene, 
a set of primers was designed using sequences obtained from GenbankTM 
and amplicons of 50-100 base pairs with TM between 58 and 60°C were 
selected. Prior to complementary DNA (cDNA) synthesis, 2 µg of total RNA 
were DNase (Invitrogen) treated for 15 min at 37ºC, after which RNA was 
reverse-transcribed using random hexamer primers (Amersham Pharmacia) 
in a total volume of 50 μl using the SUPERSCRIPTTM II reverse transcriptase 
kit (Invitrogen). Subsequently, aliquots of first-strand cDNA (2 µl) were 
amplified using SYBR Green® PCR Master mix (Applied Biosystems) under 
the following conditions: initial denaturation for 10 min at 95ºC followed by 
40 cycles consisting of 15 sec at 94ºC and 1 min at 60ºC. Fold inductions 
and expression ratios were calculated from differences in threshold cycles 
at which an increase in reporter fluorescence above a baseline signal could 
first be detected (CT) between two samples, and averaged for duplicate 
experiments.
In situ hybridization
 Mouse embryos were collected from F1 females (Cba x C57B16) at 
embryonic day 14.5 and 16.5 (E14.5 and E16.5), dissected free from the uterus 
and membranes, fixed overnight at 4oC in 4% paraformaldehyde, dehydrated, 
embedded in paraffin wax and sectioned (6 µm) onto coated slides (Klinipath, 
Duiven, the Netherlands). Neonatal mouse tails that were kindly provided by 
dr. Marcel Karperien (Leiden University, the Netherlands) were collected from 
Swiss albino mice on day 5 after birth and fixed in 4% paraformaldehyde, 
decalcified by incubation in 12.5% sodium EDTA (pH 8.0) for 1 week at 4oC, 
embedded in paraffin wax and sectioned (5 µm) as described previously (22). 
The slides were dewaxed, rehydrated and pretreated with Proteinase K and 
acetic anhydride, and hybridized overnight at 55oC essentially as described 
previously (23). Constructs were cloned into pSKII- in the anti-sense 
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orientation in the T7 promoter. RNA probes were generated by transcription 
of the T7 RNA polymerase in the presence of [α-35S]-uridine triphosphate 
(UTP). After hybridization, the slides were washed at high stringency for 30 
min at 62oC, treated with RNase A for 30 min at 37oC, washed again at high 
stringency, dehydrated and allowed to dry. Autoradiography was performed 
using Ilford G5 photo emulsion. The slides were exposed for 2 weeks at 4oC. 
Photographs were made from combined bright-field (blue filter) and dark-field 
images (red filter).
Plasmids and transfections 
 The mouse Tcf7 cDNA cloned in pcDNA1 was kindly provided by dr. 
Hans Clevers (Hubrecht Laboratory, the Netherlands), while the mouse Cbfa1 
cDNA cloned in pBluescript and the p6OSE2 luciferase reporter construct 
were kindly provided by dr. Patricia Ducy (Baylor College of Medicine, 
Houston, TX). The renilla reporter construct pRL-SV40 was purchased from 
Promega. The Tcf7 coding region was excised from the plasmid by HindIII / 
XbaI digestion and ligated into HindIII / XbaI-digested pcDNA3.1. The Cbfa1 
coding region was excised from the plasmid by EcoRV / XbaI digestion and 
ligated into EcoRV / XbaI-digested pcDNA3.1. The integrity of the resulting 
pTcf7-3.1 and pCbfa1-3.1 plasmids was verified by DNA sequence analysis. 
For stable transfections, pTcf7-3.1 was introduced into C2C12 cells using the 
Lipofectamin method according to the manufacturer’s specifications (Gibco/
BRL). Monoclonal stable transfectants were selected on G418 (400 μg/ml) 
and Tcf7 expression levels were analyzed by real-time RT-PCR. For transient 
transfections, pCbfa1-3.1, pTcf7-3.1, p6OSE2 and pRL-SV40 (Promega) 
were introduced into C2C12 cells using the Lipofectamin method according 
to the manufacturer’s specifications (Gibco/BRL). Twenty four hours after 
transfection, luciferase levels were measured.
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RESULTS
BMP2 induced expression profiles
Upon BMP2 treatment, C2C12 mesenchymal progenitor cells 
differentiate into osteoblastic cells, whereas they form myotubes in response 
to low serum conditions (24). Previously, we have shown that under identical 
experimental conditions as used here, C2C12 cells differentiate into osteoblasts 
which strongly express bone markers such as Alkaline phosphatase (ALP) 
and Osteocalcin (OCN) 2 days after BMP2 treatment (19). To identify novel 
potential regulators of BMP2-induced differentiation, we studied the onset 
of the differentiation process by microarray analysis (shown in Figure 1). Of 
the 9,330 genes spotted on the array, 184 sequences were found to exhibit 
significant (p<0.01) differential expression in the first 24 hours following 
BMP2 treatment.
Model-based clustering, a method recently described for efficient 
handling of microarray data (25, 26), was used to group the 184 genes by 
similarities in their expression profiles resulting in the identification of 10 
distinct clusters. When classified into functional groups according to the 
function of their cognate protein (Table 1 supplemental data), the majority 
(94%) of the genes in our data set fell in the groups “Signal Transduction”, 
“Localized and Structural Proteins”, or “Expressed Sequence Tags” (ESTs). 
Figure 1 shows an overview of the clustering results and the distribution 
of the genes over the functional categories is indicated per cluster. Figure 
1A shows the 6 clusters with genes for which the most notable differential 
expression is positive and Figure 1B shows the 4 clusters with genes for 
which this is negative. Globally, genes from clusters 2, 3, 4, 7 and 10 can be 
categorized as immediate early genes that display distinct regulation 2 hrs 
after BMP2 treatment. Clusters 5, 6 and 9 represent intermediate early genes 
that were regulated from 6 hrs onwards, and clusters 1 and 8 represent late 
early genes for which no expression regulation was observed until 24 hrs after 
BMP2 treatment. 
Of the immediate early genes 90% (clusters 2, 3, 4 and 7) showed 
increased expression, while only 10% (cluster 10) exhibited decreased 
expression following BMP2 treatment. In contrast, the intermediate early 
responses showed a balance in up- and down-regulated genes (clusters 5, 6 
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and cluster 9 respectively). This indicates that the initial response to BMP2 
is a transcriptional activation response. Furthermore, a time-dependent shift 
could be observed in the distribution of gene functions. Specifically, 65% (34 
of 52) of the immediate early genes could be classified as Signal Transduction 
proteins, while only 12% (6 of 52) of these genes represented Structural 
proteins. During proceeding differentiation, less Signal Transduction related 
genes were regulated (17% and 28% for intermediate early and late early 
genes respectively), while an increasing number of Structural proteins were 
regulated (19% and 38% respectively). These Structural proteins include 
cell morphology-related genes such as the Troponins C and T and keratin 
complex genes, and matrix-related genes such as Procollagen IV α1 (Col4a1), 
Matrix gla protein, Nidogen1 and the Laminins α5 and β3. Using model-based 
clustering we have thus been able to distinguish different time-dependent 
Table 1. Protein functions represented on the microarray
Group Subgroup Group Subgroup
Signal transduction and 
regulation
Extracellular messengers
Receptors
Intracellular signalling
Transcription factors
Adhesion and molecular 
recognition
Adhesion
Antigen recognition
Membrane Transport Channels and porins
Transporters and pumps
Electron transfer Cytochromes
Iron-sulphur 
proteins
Flavoproteins
Other
Protein modification 
and maintenance
Proteases
Protease inhibitors
Protein glycosyl transferases
Protein lipid transferases
Protein acetyl transferases
Protein isomerases
Chaperones
Localized and structural 
proteins
Extracellular matrix
Cell wall
Surface structure
Membrane
Periplasm
Cytoplasm
Cytoskeleton
Ribosome
Chromatin
Organelle
Nucleic acid synthesis 
and modification
Polymerases
Ligases
Nucleases
Methylases
Helicases
Topoisomerases
Recombinases
Splicing factors
Single stranded binding proteins
Other
EST
Protein functions of the regulated genes were categorized according to subgroups (Incyte Protein 
Function Hierarchy). Per gene only 1 functional group was assigned.
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Figure 1. 
Expression profiles of the significantly (p<0.01) regulated BMP2-responsive genes. 
Genes regulated within 24 hrs after BMP2 treatment are shown, grouped according 
to Model-based clustering of 10log transformed microarray data (normalized on a 
scale to 1). Induction levels are indicated with different colour intensities in red and 
blue, representing up-and down-regulation respectively. (For full colour figure, see 
page 244).
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Figure 1, continued.
Protein function profile graphs show the number of genes within each cluster with a 
particular function. Genes with unknown function or other functions were labelled as 
“Other”. EST: Expressed Sequence Tag, TF: transcription factor, EMe: Extracellular 
messenger, IS: Intracellular signalling protein, Rec: Receptor, EMa: Extracellular 
matrix protein, CPl: Cytoplasmatic protein and CSk: Cytoskeletal protein. (For full 
colour figure, see page 245).
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expression profiles of the regulated genes that coincide with specific functions 
of the genes present in each cluster. 
Validation of the microarray data 
We and others have shown previously that microarray data are highly 
comparable with results obtained using other methods such as real-time 
RT-PCR and Northern blotting, but that the ratio of expression regulation 
measured with these other methods vary probably due to the distinct 
hybridization conditions of the various methodologies (20, 27). To validate 
the expression profiles measured in this microarray experiment, 52 genes 
were tested as representatives of all 10 clusters both in original RNA material 
used for the microarray and in RNA material obtained from an identical but 
independent experiment by real-time RT-PCR. The expression profiles of 92% 
(48 out of 52) of the genes tested was confirmed (supplemental materials, 
Table 2). Only the expression pattern of genes present in cluster 4, which were 
relatively weakly regulated and reached a maximum of 1.4-fold expression 
regulation, could not be confirmed. In conclusion, using real-time RT-PCR, we 
have been able to confirm both the pattern of the expression profiles as well 
as the level of differential expression regulation for the majority of the genes 
in this microarray experiment. 
Transcriptional regulators of osteoblast differentiation
To identify novel potential regulators of osteoblast differentiation, 
we primarily focused on the transcription factors with altered expression 
during differentiation. In the complete set of 184 regulated sequences, 17 
transcription factors were identified (Table 3). The real-time RT-PCR analysis 
described above, confirmed the BMP2-induced differential expression for 15 
out of the 17 transcription factors. It should be noted that on the microarray, 
sequences uniquely representing the bone-specific Cbfa1 isoform (Type II) 
were not present. Hence, type II Cbfa1 was not included in our microarray 
data set. 
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Accesion 
number
Description Cluster Expression 
profile
Accesion 
number
Description Cluster Expression 
profile
AI552130 Hey1 1 + AW210425 Slc20a1 3 +
AI386062 Car3 1 + W18822 Gadd45γ 3 +
AA450795 CCK 1 + AA517353 Nfkbia 3 +
AA667906 Cyr2 1 + AA982549 Placental 
Growth factor
3 +
AA958693 Tcf7 1 + AA895566 Gadd45β 3 +
W81878 Osf2 (fasciclin) 1 + AA036380 Snail 3 +
AI510076 OASIS 2 + AA733791 Ddr1 3 +
W97877 Prx2 2 + AA162153 MCSF 3 +
AA145784 Timp3 2 + AA427234 VEGF 3 +
AA833402 Similar to Ier3 2 + AA879919 Tissue factor 3 +
W08321 Id1 2 + AA536836 bHLHB2 4 -
AI322367 Id2 2 + AI595201 HB-EGF 4 -
AA066816 Id3 2 + AA832598 EST 4 -
AA733600 Klf4 2 + AA271866 Pla2γ 4 -
AA466979 Similar  to CoA 
dehydrogenase 
2 + AA238037 Imap38 5 +
AI427265 Smad6 2 + AA796818 Isg15 5 +
AA545284 Smad7 2 + AA549591 Exportin 1 6 +
AA028420 Sprr1a 2 + AA108600 CPO 6 +
AI551955 EST 2 + AA152636 Int4a 6 +
AI587984 GPR97 2 + AA796822 Siat4c 7 +
AA646509 Tieg 2 + AA501052 Xin 7 +
AI604159 Similar to 
frizzled
2 + AI323202 Scya2 7 +
AA415211 Musk 2 + AA437694 MyoD 7 +
AI430581 Cytidine 
deaminase
2 + AA606331 L-myc 7 +
AA197529 Lunatic fringe 2 + AA067083 Hmga1 8 +
W34122 Bin1 9 +
W14224 Ndr1 10 +
Expression profiles identified by microarray analysis were tested for confirmation by real-time 
RT-PCR. +, expression pattern confirmed; -, expression pattern not confirmed; Hey1, hairy/
enhancer-of-split related with YRPW motif; Car3, carbonic anhydrase 3; CCK, cholecystokinin; 
Cyr2, cysteine-rich protein 2; Tcf7, T-cell specific transcription factor 7; Osf2 (fasciclin), fasciclin 
I like osteoblast specific factor 2; OASIS, old astrocyte specifically induced substance; Prrx2, 
paired related homeobox 2; Timp3, tissue inhibitor of metalloproteinase 3; Ier3, immediate early 
response 3; Id1, inhibitor of DNA binding 1; Id2, inhibitor of DNA binding 2; Id3, inhibitor of DNA 
binding 3; Klf4, kruppel like factor 4 (gut); CoA dehydrogenase, coenzyme A dehydrogenase; 
Smad6, MAD homolog 6; Smad7, MAD homolog 7; Sprr1a, small proline-rich protein 1A; EST, 
expressed sequence tag; GPR97, Gprotein coupled receptor 97; Tieg, TGFβ−inducible early 
growth response; Musk, neural fold/somite kinase 2; Slc20a1, solute carrier family 20 member 
1; Gadd45β, growth arrest and DNA damage inducible β; Ddr1, cell adhesion kinase 1; Mcsf, 
macrophage colony stimulating factor; Vegf, vascular endothelial growth factor; bHLHB2, basic 
helix-loop-helix domain containing class B2; HB-EGF, heparin binging epidermal growth factor; 
Pla2γ, Ca2+-independent phospholipase A2 gamma; Imap38, immunity associated protein 38kDa; 
Isg15, ubiquitin cross reactive protein 15kDa; CPO, coproporphyrinogen oxidase; Int4a, integrin 
4a; Siat4C, sialyltransferase 4C; Xin, caridac myogenesis 1; Scya2, small inducible cytokine 2; 
MyoD, myogenic differentiation 1; L-myc, lung carcinoma myc related oncogene 1; Hmga1, high 
mobility group protein 1; Bin1, bridging integrator 1; Ndr1, N-myc downstream regulated 1.
Table 2. Validation of the microarray data
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Transcription factors that are specifically expressed in osteoblasts but 
not in other cell types are likely to be regulators of osteoblast differentiation. 
We analyzed the cell type specificity for 13 transcription factors that showed 
a robust response to BMP2 treatment compared to control medium (Table 
3). To this end, gene expression regulation by BMP2 was assessed in mouse 
C2C12 and C3H10T1/2 mesenchymal progenitor cell lines, which both can 
differentiate into osteoblasts, and for comparison, in NIH3T3 fibroblasts, 
which can not differentiate into osteoblasts (Figure 2). To test the validity 
of this approach, expression regulation of the bone-specific isoform of Cbfa1 
(Cbfa1, type II) was analyzed by real-time RT-PCR in all three cell types 
and compared to expression regulation of sequences correlating with all 
isoforms (Cbfa1, bipartite sequences). Figure 2A shows a 5-fold BMP-specific 
induction for Cbfa1 type II in the osteoblastic cell types after 24 hrs, while no 
expression regulation was detected in the NIH3T3 fibroblasts. In contrast, the 
Cbfa1 bipartite sequences displayed low levels of BMP2-induced expression 
in the C2C12 cells, while no differential expression was observed in the 
C3H10T1/2 or NIH3T3 cells. These data show that this approach enables us 
to discriminate between osteoblast-restricted and common BMP responses.
Subsequently, the expression regulation of the 13 transcription factors 
was tested for cell type specificity (Figure 2B and Table 3). Nine of these 
transcription factors were regulated in response to BMP2 treatment in all three 
cell lines to approximately the same extent and will further be referred to as 
“general BMP-response transcription factors”. The genes L-myc and MyoD 
were only expressed in C2C12 cells. C2C12 cells differentiate into myoblasts 
under low serum conditions whereas C3H10T1/2 cells do not, therefore these 
transcription factors could be characteristic for the pre-myoblastic phenotype 
of C2C12 cells. Finally, the transcription factors Hey1 and Tcf7 showed specific 
BMP2-induced up-regulation in both C2C12 and C3H10T1/2 cells, similar to 
the osteoblast specific transcription factor Cbfa1 type II, but were not or 
very weakly regulated in NIH3T3 cells. These results suggest that the BMP2-
induced regulation of Hey1 and Tcf7 is osteoblast specific.
To be able to distinguish between direct and indirect effects in 
response to BMP2, we analyzed gene expression in the presence or absence 
of cyclohexamide (Chx), an inhibitor of de novo protein synthesis. The data 
summarized in Table 3 shows that the immediate early general BMP-response 
transcription factors were not dependent on protein synthesis for their BMP2-
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Table 3. Gene expression characteristics of osteoblast differentiation related 
transcription factors
Accession
number Description Type
Cluster
number Category
Expression 
profile
Cell type 
specificity
CHX 
dependent
Cbfa1, type IIa late early osteoblast yes
AI552130 Hey1 Helix-loop-helix 1 late early + osteoblast partly
AA958693 Tcf7 HMG box 1 late early + osteoblast yes
AI510076 OASIS Leucine zipper 2 immediate early + no no
W97877 Prx2 Homeo domain 2 immediate early + no no
W08321 Id1 Helix-loop-helix 2 immediate early + no no
AI322367 Id2 Helix-loop-helix 2 immediate early + no no
AA066816 Id3 Helix-loop-helix 2 immediate early + no no
AI427265 Smad6 MH domain 2 immediate early + no no
AA545284 Smad7 MH domain 2 immediate early + no no
AA646509 Tieg Zinc finger 2 immediate early + no no
AA036380 Sna1 Zinc finger 3 immediate early + no no
AI549669 TSC22 Leucine zipper 2 immediate early - n.d. n.d.
AA536836 bHLHB2 Helix-loop-helix 4 immediate early - n.d. n.d.
AA606331 L-myc Helix-loop-helix + Leucine zipper 7 immediate early + myoblast n.d.
AA437694 MyoD Helix-loop-helix 7 immediate early + myoblast n.d.
AA733600 Klf4 Zinc finger 2 immediate early +b no n.d.
AA067083 Hmga1 HMG box 8 late early +b no n.d.
Data on the 17 transcription factors modulated by BMP in the microarray experiments were 
compared with type II Cbfa1. Type of transcription factor, cluster number and cluster category are 
listed. Expression profiles identified by microarray analysis were verified by real-time RT-PCR, +: 
expression pattern confirmed, -: expression pattern not confirmed. Cell type specific expression 
regulation (Figure 2) and dependence on de novo protein synthesis indicated. For the de novo 
protein synthesis experiment, cells were pretreated for half an hour with DMEM containing 5% NCS 
in the absence or the presence of cyclohexamide (CHX, 50μM) after which cells were stimulated 
with BMP2 (300 ng/ml) in the absence or presence of cyclohexamide. Expression regulation was 
analyzed by real-time RT-PCR, n.d.: not done. Abbreviations used: Cbfa1, type II: Core binding 
factor 1, type II isoforms, Hey1: Hairy/enhancer-of-split related with YRPW motif 1, Tcf7: T-Cell 
specific transcription factor 7, OASIS: Old astrocyte specifically induced substance, Prx2: Paired 
related homeobox 2, Id1: Inhibitor of DNA binding 1, Id2: Inhibitor of DNA binding 2, Id3: Inhibitor 
of DNA binding 3, Smad6: MAD homologue 6, Smad7: MAD homologue 7, Tieg: TGFβ-inducible 
early growth response, Sna1: Snail homologue, TSC22: TGFβ stimulated protein 22, bHLHB2: 
Basic helix-loop-helix domain containing class B2, L-myc: lung carcinoma myc related oncogene 
1, MyoD: Myogenic differentiation 1, Klf4: Kruppel like factor 4 (gut), Hmga1: High mobility group 
protein 1. a: not identified in the microarray experiment, but used as a positive control, b: very 
low levels of expression regulation. 
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induced gene expression, at least at the 2 hr and 6 hr time points. Messenger 
RNA of some of these genes was actually superinduced in the presence of 
BMP2 and Chx, probably as a result of an increase in mRNA stability or loss 
of transcriptional repressors by Chx as previously reported for Smad7 (28). 
Furthermore, the late early genes Tcf7 and Cbfa1 type II were fully impaired 
in their BMP2-induced expression in the presence of cyclohexamide. Induction 
of Hey1 was severely repressed due to Chx treatment, but its expression was 
still induced over 13 fold at 24 hrs in the presence of the protein synthesis 
inhibitor, which suggests that regulation of Hey1 might be both direct and 
indirect. These results indicate that the classification of the genes based on 
our clustering method correlates with de novo protein synthesis-dependent 
transcription regulation.
Figure 2. 
BMP-induced expression profiles in osteoblastic and non-osteoblastic cell lines.
Expression profiles of the transcription factors in C2C12, C3H10T1/2 and NIH3T3 
cells. Cells were seeded and grown for 24 hrs upon which the medium was replaced 
by DMEM containing 5% NCS in the presence or absence of BMP2 (300 ng/ml). 
RNA was isolated 0 hr, 2 hrs, 6 hrs and 24 hrs after stimulation. Subsequently, 
expression levels were measured by quantitative real time RT-PCR.
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Expression of Hey1 and Tcf7 during mouse development
 Results obtained from the above described experiments, indicate 
that Hey1 and Tcf7 could be potential novel regulators of osteoblast 
differentiation. To study the involvement of both genes in embryonic bone 
development, expression of these genes was analyzed in mouse embryos 
at E14.5 and E16.5 of gestation and in neonatal mouse tails by the use of 
in situ hybridization. Neonatal mouse tails were used because their primary 
centers of endochondral ossification are still developing in the most distal 
vertebrae. These vertebrae consist of alkaline phosphatase-negative cartilage 
whereas the most proximal vertebrae are alkaline phosphatase-positive and 
mineralized (22). The expression patterns of Tcf7 and Hey1 were compared 
with that of Cbfa1, which has previously been shown to be expressed during 
early skeletal development, in cells of mesenchymal condensations, and in 
the osteoblast lineage. In later development it is expressed in ossification 
centers of all bones, independent of their embryonic origin and mechanism 
of ossification (intramembranous or endochondral), but not in hypertrophic 
chondrocytes (4). We first confirmed the expression of Cbfa1 at E14.5 in 
bone in transverse sections of the head at the level of the jaws (Figure 3A), at 
E16.5 in sagital sections of the head at the level of the nasal cavities (Figure 
3D) and in proximal vertebrae of the mouse neonatal tail (Figure 3G). The 
ossification centers of the developing mandibular and maxillary bones, nasal 
bone, clavicle, humurus, and scapula as well as proliferating chondroblasts, 
periosteal osteoblasts and trabecular osteoblasts all showed clear expression 
of Cbfa1, as expected (4). In agreement with previous data, high levels 
of Cbfa1 expression were also observed in the mandibular region/dental 
mesenchyme surrounding the developing tooth (19). 
The Tcf7 gene showed an expression pattern remarkably similar to 
that of Cbfa1 in embryos at E14.5 and E16.5 of gestation (Figures 3B and 
3E). Except for the C1 vertebra, expression of Tcf7 was observed in all bones 
analyzed, although restricted to the periosteum/compacted mesenchyme of 
these bones. In the mouse neonatal tail vertebrae, both the periosteal and 
trabecular osteoblasts showed high levels of Tcf7 expression similar to Cbfa1, 
but no expression of Tcf7 was observed in proliferating chondroblasts (Figure 
3H). With respect to the Hey1 gene, no expression could be detected in the 
clavicle, humurus, scapula or C1 vertebra. However, low but significant levels 
124
Chapter 4
125
Novel regulators of early osteoblast differentiation
of expression were observed in the mandibular and maxillary bones (Figures 
3C and 3F). Specifically, Hey1 expression was restricted to the central parts of 
the bones (trabecular bone) and was absent in the periosteum. In the newborn 
tail vertebrae, the Hey1 gene showed specific expression in trabecular 
osteoblasts, albeit somewhat weaker than the Cbfa1 and Tcf7 genes (Figure 
3I). These data show that the two osteoblastic transcription factors identified 
in this study are expressed during in vivo bone differentiation, with individual 
expression patterns similar but not equal to Cbfa1. 
Figure 3. 
In vivo expression of Hey1 and Tcf7 in the developing mouse skeleton. 
(A-C) Transverse sections of E14.5 mouse embryos at the level of the jaws for the 
control osteoblast marker Cbfa1 (A), Tcf7 (B) and Hey1 (C), (D-F) Sagital sections 
of E16.5 mouse embryos at the level of the nasal cavities for Cbfa1 (D), Tcf7 (E) and 
Hey1 (F), (G-I) Mouse proximal tail vertebrae for Cbfa1(G), Tcf7 (H) and Hey1 (I). 
Abbreviations used: bm, bone marrow; C1v, cartilage primordium of C1 vertebra; 
cl, clavicle; h, cartilage primordium of humurus; hc, hypertrophic chondroblasts; id, 
intervertebral disc; Jo, Jacobson’s organ; M, Meckel’s cartilage; md, mandible; mx, 
maxilla; nc, nasal cavity; nca, nasal capsule; P, periosteal bone; pc, proliferating 
chondroblasts; sc, scapula; T, trabecular bone; tg, tongue; to, tooth; vb, vertebral 
body. (For full colour figure, see page 246).
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Tcf7 differentially affects BMP2-induced osteoblast differentiation
To further investigate the role of Tcf7 and Hey1 expression during 
osteoblast development, we introduced expression vectors for their cognate 
genes into C2C12. We identified cells expressing high levels of Tcf7 (Figure 
4A), but were unable to isolate clones over-expressing Hey1 (results not 
shown). The differentiation capacity of Tcf7-overexpressing cells (C2C12-
Tcf7) was assessed by measuring ALP activity, as well as the expression of the 
myogenic differentiation markers Myogenin and MyoD and of the osteogenic 
differentiation markers ALP, Wnt inhibitory factor 1 (Wif1) (19), Cbfa1 and 
OCN following BMP2 treatment. The data represented in Figures 4B and 4C 
show that the C2C12-Tcf7 cells were still able to differentiate to the osteoblast 
lineage as evidenced by the induction of ALP activity and transcripts as well 
as the induction of the late phase differentiation marker Wif1. The levels of 
these markers were slightly elevated in the C2C12-Tcf7 cells compared to the 
control cells. 
Figure 4.  
BMP2-induced osteoblast differentiation in 
C2C12-Tcf7 cells.
(A) Expression of Tcf7 in C2C12-Tcf7 
cells. Expression levels were measured by 
quantitative real-time RT-PCR. (B) Dose-
dependent induction of ALP activity 48 hrs 
after BMP2-treatment, (■) C2C12 cells, 
(●) C2C12-Tcf7 cells. (C) BMP2-induced 
expression profiles. Messenger RNA was used 
to measure the expression of two myogenic 
and 4 osteoblast marker genes at the 
indicated time points.  Mean expression levels 
were corrected for GAPDH and are expressed 
relative to the basal expression level in un-
stimulated C2C12 cells. Error bars indicate 
differences between duplicate experiments. 
(D) Tcf7 represses Cbfa1-mediated activation 
of the osteocalcin promoter in C2C12 cells. 
Cells were transfected with p6OSE2 (100 ng), 
pCbfa1-3.1 (50 ng) and/or pTcf7-3.1 (100 ng) 
as indicated. Luciferase activation levels were 
corrected for renilla levels and are represented 
as fold activation over control. The luciferase 
values represent the means of triplicate 
samples ± S.E.
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In contrast, the expression of Cbfa1 was slightly lower in C2C12-Tcf7 
cells whereas the expression of OCN was completely abrogated. These data 
suggest that Tcf7 differentially affects osteoblast differentiation. In control 
C2C12 cells, the expression of the myogenic differentiation markers Myogenin 
and MyoD was induced during conditions that favor myoblast differentiation 
and repressed upon BMP2 treatment. In contrast, the C2C12-Tcf7 cells failed 
to induce Myogenin and MyoD transcription under myogenic differentiation 
conditions, indicating that differentiation was impaired. The abrogation of 
OCN expression in the C2C12-Tcf7 cells could be a result of the slightly 
reduced Cbfa1 levels in these cells or from a direct action of Tcf7 on OCN 
transcription. The latter notion is in line with published data that show that 
Lymphoid enhancer binding factor 1 (Lef1), a functional homologue of Tcf7, 
represses Cbfa1-dependent transcription from the OCN gene promoter (29). 
The repression of Lef1 is mediated through direct interaction with Cbfa1 and 
could be visualized on p6OSE2, which contains an artificial promoter consisting 
of 6 Cbfa1 recognition sites upstream of the basal osteocalcin promoter (-
34/+13), and a luciferase reporter gene. To investigate whether a similar 
mechanism could play a role in our system, we co-transfected combinations 
of Tcf7, Cbfa1 and p6OSE2 into C2C12 cells. As expected, Cbfa1 but not 
Tcf7 induced activity of the luciferase reporter (Figure 4D). Interestingly, 
co-expression of Tcf7 significantly reduced the Cbfa1-induced activity of the 
reporter. The SV40 promoter driven expression of the renilla-reporter gene 
that was co-transfected to monitor differences in transfection efficiency was 
not affected by Tcf7 (results not shown), indicating that the observed effect is 
specific for Cbfa1 driven transcription. 
 
DISCUSSION
Genetic cascades regulated during the initial phase of differentiation 
guide mesenchymal stem cells to become osteoblasts, and activating 
and repressing transcription factors are very important in directing this 
differentiation process. In our data set of 184 regulated genes and ESTs, we 
observed an immediate up-regulation of transcription factors and other Signal 
Transduction proteins (2 hrs), but a slight delay in the repression of genes 
such as those related to myoblast differentiation (6 hrs). The near absence 
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of repression of gene expression 2 hrs after BMP treatment observed in this 
study might be a reflection of the observation that Smads are transcriptional 
activators that first need to activate transcriptional repressors to inhibit 
gene expression (30). In accordance with this, a number of transcription 
factors have been identified among the immediate early genes, such as the 
inhibitor of differentiation (Id) genes (Id1, Id2 and Id3) and the Transforming 
growth factor β1-induced transcript 4 (TSC-22) gene, that can function as 
transcriptional repressors (31, 32). The immediate early transcription factors 
may subsequently regulate the expression of genes involved in remodelling 
of cell architecture (between 6 and 24 hrs). However, commitment to the 
osteogenic lineage was not apparent until 24 hrs, when the osteoblast 
specific transcription factor Cbfa1 and the novel osteoblast-related genes 
Hey1 and Tcf7 were found to be regulated. Previously, we have shown that 
the onset of regulation of bone markers such as ALP and OCN starts around 
48 hrs of BMP treatment (19). These results are slightly different from data 
reported recently by Balint and coworkers who showed both activation and 
repression of differentiation-related genes within the first hours of osteoblast 
differentiation, followed by commitment and establishment of the bone 
phenotype in C2C12 cells within 24 hrs of BMP treatment (33). It should be 
noted here, that there are substantial differences in the experimental design, 
such as the cell density at the onset of BMP treatment and the absence of 
serum in their experiments that might explain the observed differences. 
Our study identified 15 transcription factors that are induced within the 
first 24 hours of BMP2 induced osteoblast differentiation. We investigated 
whether additional osteoblast related transcription factors might be identified 
among the 3 immediate early ESTs identified in this study. However, in silico 
sequence analysis did not reveal specific DNA binding domains or characteristic 
transcription activating domains, suggesting that these ESTs are not novel 
transcription factors (results not shown). Of the 15 known transcription factors 
in our dataset, 9 immediate early general BMP-response transcription factors 
did not display osteoblast specific expression regulation, but were specifically 
induced by BMP2 and therefore might have a function in the regulation of 
osteoblast differentiation. Indeed, 8 out of these 9 transcription factors 
have previously been reported to be involved in osteoblast differentiation or 
function. OASIS has been described to be expressed in pre-osteoblasts in 
vivo and its expression pattern coincides with that of Osteopontin (34). Prx2 
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cooperates with Prx1 in regulating skeletogenesis in the craniofacial region, 
inner ear and limbs, as was shown in knock-out experiments (35). Transient 
induction of the Id genes by BMP has previously been described in osteoblastic 
cells (24, 36-38) and Id1 was found to be able to inhibit OCN gene expression 
(39). Furthermore, Smad6 and Smad7 are negative regulators of the BMP 
signal transduction pathway capable of repressing BMP-induced osteoblast 
differentiation (40, 41). Tieg was first identified in human osteoblastic cells 
(42) and is able to induce ALP expression and inhibit OCN expression in 
human osteoblasts similar to TGFβ (43). Until now, direct involvement of 
Sna1 in osteoblast differentiation has not been reported. However, Sna1 has 
been described to be an inhibitor of E-cadherin expression in different cell 
types (44-46), and E-cadherin itself has been reported to be essential for 
optimal BMP-induced osteoblast differentiation (47), suggesting that Sna1 
might be indirectly involved in osteoblast differentiation. 
Although bone is a highly specialized tissue, osteoblasts have previously 
been described as sophisticated fibroblasts, exhibiting only a few osteoblast 
specific transcription factors and marker genes, such as Cbfa1, Osx and OCN 
(3). It could be postulated that to establish a highly specialized tissue such as 
bone, the action of several specific key regulatory transcription factors might 
not be required. Instead, a limited set of osteoblast-specific transcription 
factors in combination with general BMP-responsive transcription factors 
might be sufficient for guiding a mesenchymal stem cell to become a mature 
osteoblast. In our experiments, BMP2-induced transcription of Hey1 and 
Tcf7 was restricted to osteoblastic cells, suggesting that these factors may 
contribute to further specifying osteoblast fate delineated by bone specific 
transcription factors like Cbfa1 and Osx. This notion is further substantiated 
by our observation that both Hey1 and Tcf7 are expressed in developing bone 
tissues in vivo. 
Hey1 belongs to the Hairy and enhancer of split (Hes1) family of 
transcription factors and is a primary target of Notch (48), which has been 
reported to inhibit osteoblast differentiation (49, 50). Hey1 functions as an 
inhibitor of myoblast differentiation in C2C12 cells (51) and is able to associate 
to its family member Hes1 and form stable heterodimers with Hes1 upon DNA 
binding (48). Hes1 has been reported to be a negative regulator of osteoblast 
differentiation (52), but it can also stimulate the trans-activating function 
of the osteoblast specific transcription factor Cbfa1 (9). To the best of our 
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knowledge Hey1 knock-out mice have not been reported and Hey1 has not 
previously been reported to be involved in osteoblast differentiation. Our in 
vitro data indicate that Hey1 expression by BMP2 is restricted to osteoblasts 
and not observed in fibroblasts. Furthermore, Hey1 is expressed during in 
vivo bone formation with an expression pattern that partially overlaps with 
that of Cbfa1 and Tcf7. We speculate that Hey1 might affect osteoblast 
differentiation in a comparable manner to or in association with Hes1. This 
putative mechanism is the subject of our current studies.
Tcf7 is a member of the T lymphocyte-specific enhancer / Lymphoid 
enhancer binding factor (Tcf/Lef) family and an effector of Wnt signalling (53). 
The canonical Wnt pathway has been implicated in the control of bone mass 
and osteoblast differentiation. Inactivating mutations in the Wnt co-receptor 
LRP5 decrease bone accrual during growth whereas activating mutations lead 
to a high bone mass phenotype (54), and stabilized β-catenin in osteoblasts 
enhances their differentiation capacity (55, 56). However, the downstream 
effectors of Wnt/β-catenin in osteoblasts remain to be established. Our data 
indicate that Tcf7 is a BMP2 target gene in osteoblasts but not in fibroblasts. 
In vivo, expression of Tcf7 has been reported during embryonic bone 
development up to embryonic day E14.5 (57). Our data confirm and extend 
these results and show that Tcf7 expression at E14.5 and E16.5 of gestation 
is highly but not completely similar to Cbfa1 expression. In the developing 
mouse tail, Tcf7 expression is limited to osteoblasts and, unlike Cbfa1, not 
seen in hypertrophic chondrocytes. It is tempting to speculate that Tcf7 
plays a role as a downstream effector of BMP2/Wnt signalling and provides 
a molecular access point where these two signalling pathways integrate. 
In C2C12 cells that over-express Tcf7, we observed a down-regulation of 
Myogenin and MyoD similar to the down-regulation mediated by Cbfa1 
(58), suggesting a role of Tcf7 in suppression of myogenic differentiation. 
In addition, we observed a BMP2-dependent differential effect on expression 
of genes that mark osteoblast differentiation. Our observation that Tcf7 
suppresses Cbfa1-induced transcriptional activity of the p6OSE2 reporter is 
in perfect agreement with published work that showed that the Tcf7 family 
member Lef1 exerts an identical effect on Cbfa1-mediated transcription (29). 
The exact mechanisms by which Tcf7 modulates osteoblast and/or myogenic 
differentiation are not clear and the subject of our current investigations.
In conclusion, our results show that BMP-induced osteoblast differentiation 
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employs a cascade in which the initial phase of differentiation is based 
on general BMP-response genes. During the progression of osteoblast 
differentiation, osteoblast commitment genes and osteoblast specific genes 
are regulated in concert with general BMP-response genes, which ultimately 
leads to a functional osteoblast. In addition, Hey1 and Tcf7 have been identified 
with similar expression characteristics as the osteoblast specific transcription 
factor Cbfa1, and Tcf7 was shown to modulate BMP2-induced osteoblast 
differentiation. Further elucidation of the function of these transcription 
factors in osteoblast differentiation may contribute to drug target research to 
treat bone diseases such as osteoporosis.
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ABSTRACT
Motivation: We propose a reverse engineering scheme to discover genetic 
regulation from genome-wide transcription data that monitors the dynamic 
transcriptional response after a change in cellular environment. The interaction 
network is estimated by solving a linear model using simultaneous shrinking 
of the least absolute weights and the prediction error.
Results: The proposed scheme has been applied to the murine C2C12 cell 
line stimulated to undergo osteoblast differentiation. Results show that our 
method discovers genetic interactions that display significant enrichment of 
co-citation in literature. More detailed study showed that the inferred network 
exhibits properties and hypotheses that are consistent with current biological 
knowledge. 
INTRODUCTION
The development of cells is largely determined by the past and current 
states of transcription of a relevant set of genes. The transcription levels 
themselves are the result of a complex network of influences exerted by 
the genes on each other through gene products and signalling pathways. In 
order to understand any developmental process, it is imperative to unravel 
the underlying genetic interaction network. This understanding might lead 
to the development of novel (therapeutic) intervention strategies. Although 
techniques like genome-wide location analysis (Lee et al., 2002) and promoter 
analysis (Tavazoie et al., 1999) may reveal some of the direct transcriptional 
interactions, the outcome of developmental events is still difficult to explain 
from sequence information and location data alone. 
Alternatively, microarray measurements sampled over time present 
a global view on transcriptional changes during development and allows 
to elucidate the regulatory network in a complementary manner, i.e. from 
transcript data to regulatory influences. Current successful methodologies 
to infer genetic interactions from microarray data, however, have primarily 
been restricted to the use of perturbation (e.g. knockout) microarray data 
(Gardner et al., 2003; Segal et al., 2003; Rung et al., 2002; Pe’er et al., 2001; 
Hartemink et al., 2001) or learn interactions between representatives of gene 
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clusters (Guthke et al., 2005; Wahde and Hertz, 2001). 
Here, we present the Least Absolute Regression Network Algorithm 
(LARNA), an efficient and robust method to infer a sparse genetic regulatory 
network structure from microarray data sampled over time. In our 
framework, a generative linear model is learned to predict the expression 
values of a target gene, based on a linear combination of the past expression 
values of an automatically selected set of genes, denoted as its regulators. 
The main advantage of our method is the automatic determination of the 
network structure from the data. We applied our method on a time-course 
microarray data set of the mouse C2C12 cell-line with and without stimulation 
to undergo osteoblast differentiation. Results show that LARNA discovered 
genetic interactions that are significantly more co-cited in literature than can 
be expected by chance. To a large extent LARNA shows higher enrichment 
of co-citation than hierarchical clustering. This exemplifies the fact that our 
network inference methodology presents a complementary approach to 
the more popular clustering methods, by aiming at discovering regulatory 
behaviour instead of functional units. 
The final network that was discovered presents a global view on 
the genes and influences involved in driving mesenchymal stem cells into 
osteoblastic or myoblastic differentiation. The network also poses hypotheses 
consistent with biological knowledge of which at least two were confirmed by 
literature study. 
MATERIALS AND METHODS
 The complete pre-processing procedure consisted of 1) growing the 
cell cultures, harvesting samples and RNA isolation, 2) hybridization and 
read-out of micro-arrays, 3) removing array outliers, 4) array normalization, 
5) gene selection and interpolation. This resulted in a single data set, on 
which different clustering and regression methods were applied. Each method 
results in a different network. All networks structures were tested for co-
citation enrichment by comparing them to a co-citation network obtained 
from PubMed. A single regression network was chosen based on co-citation 
enrichment and its structure was visualized (using clustering results). 
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Cell culture and RNA isolation
 C2C12 murine mesenchymal progenitor cells (obtained from the 
American Type Culture Collection) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% newborn calf serum 
(HyClone®), penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37 °C in a 
humidified atmosphere containing 7.5% CO2. For differentiation experiments, 
cells were seeded at a density of 2.0·104 cells/cm2 and grown for 24 hrs. From 
this culture, cells were harvested in triplicate and this time point is denoted as 
time zero. Subsequently, medium was replaced by DMEM containing 5% NCS. 
One subculture received no treatment and another subculture was treated with 
500 ng/ml BMP2 (R&D Systems) and 12.5 mM β-glycerophosphate (Sigma) 
to induce osteoblast differentiation. Cells were subsequently harvested 
from both sub-cultures at one, two, six and ten days after time zero. As 
expected, untreated cells developed into myoblasts, whereas the treated 
cells differentiated into osteoblasts which was confirmed by monitoring cell 
morphology and marker gene expression as described previously (Vaes et al., 
2002; de Jong et al., 2004b). 
Total RNA was extracted according to an acid guanidium 
thiocyanatephenol- chloroform method (TriPure® Isolation Reagent, Boehringer 
Mannheim) and RNA concentrations were determined by measuring the 
absorbance at 260 nm. Poly(A)+ RNA was prepared from total RNA using the 
OligotexTM Method (Qiagen). Quantification of poly(A)+ RNA was carried out 
according to the RibogreenTM RNA quantitation assay (Molecular Probes). 
Array hybridization
 A microarray dataset was generated from the aforementioned 
11 samples. We employed an experimental design based on a common 
reference sample as described previously (Churchill, 2002). To this end, Cy5 
labelled cDNA was synthesized from mRNA purified from the cell cultures 
and hybridized to Unigene 1 arrays (Incyte Genomics, Mountain View, CA) 
as described previously (Yue et al., 2001). Cy3 labelled cDNA derived from 
mouse brain was used as a control in these hybridizations.  
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Data pre-processing
 Taking the proper pre-preprocessing steps is important as it may 
heavily influence the outcome. In the supplementary materials, the chosen 
preprocessing steps and their motivations are described in more detail. Here, 
we briefly describe the pre-processing steps that were taken. 
After read-out, array outlier detection was performed on the arrays. 
One array (24h after treatment) was found to be aberrant and after manually 
being confirmed to be contaminated, it was removed from further analysis. 
The common reference approach allowed us to employ the Cy3 
intensities as a gene-specific way to compensate for array differences. Gene 
inductions in time were expressed as a balanced ratio between biological and 
control intensities after both were scaled to the initial untreated intensities. 
This results in the normalized expression value of gene g on array a:
         
(1)
Here, Cy5ag denotes the spot intensity in the Cy5 channel of the g-th gene 
on the a-th array, whereas Cy50g denotes the Cy5 intensity of the g-th gene, 
averaged over the three untreated arrays at time zero. A similar notation is 
used for Cy3. Using Eq. 1, a normalized gene profile is constant zero if the 
spot intensities measured in the biological sample show the same deviation 
from its initial intensity level as its corresponding spot in the control sample. 
After normalization, a set of significantly expressed genes was selected 
based on whether or not they showed an absolute gene expression value in 
any of the remaining arrays that exceeds a preset threshold α = 3.052. This 
threshold was determined by taking the maximal observed absolute gene 
expression values of a list of known housekeeping genes. 
Having a non-uniform sampling, the data is augmented with a series of 
synthetic microarray results by using linear interpolation between subsequent 
arrays. Using a one-day interval, Δt = 24h, the final data set resulted in 21 
“measurements”, i.e. two series of 10 ”measurements” at days 1, 2, ..,10 and 
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one measurement at zero. The choice of Δt had minor effect on the overall 
performance (see supplementary materials).
Regression networks
 We inferred a genetic network by learning a mathematical model to 
predict future gene expression values based on past gene expression values. 
One of the simplest models is a linear genetic network model (D’Haeseleer 
et al., 1999; Gardner et al., 2003). The linear model assumes that the gene 
expression level of each gene is the result of a weighted sum of all other gene 
expression levels at the previous time-point, or in vector notation: 
ŷq =W · xq + ε     q ∈ 1, 2, . . . , Q     (2) 
Here, ε models the error and Q is the number of microarray transition 
pairs, < xq, yq >, that are available for learning and are indexed by q. If xq 
represents a measurement at time t, e.g. xq = x(t), then yq = x(t+Δt). The 
interaction parameter, wij ∈W, represents the existence (wij ≠ 0) or absence 
(wij = 0) of a controlling action of regulator gene j on target gene i, whether it 
is activating (wij > 0) or inhibiting (wij < 0), as well as the strength (|wij |) of 
the relation. Note that all genes are target genes as well as possible regulator 
genes, i.e. i, j ∈ 1, . . . ,N. Furthermore, a bias and a treatment node were 
included in W by adding two artificial inputs to xq that are treated as if they 
were normal genes, i.e. a “bias gene” with expression value equal to one for 
all arrays and a “treatment gene” with zero expression in untreated and one 
in treated arrays. 
A standard approach to obtain an estimate of the complete set of 
model parameters, Ŵ, from data, is to minimize the squared error between 
the predicted ŷq and measured yq gene expression levels, i.e.: 
 (3) 
However, standard linear algebra techniques will not be sufficient, because 
the number of microarray pairs is far less than the number of selected genes, 
resulting in a highly under-determined problem. Due to the resulting problems 
140
Chapter 5
141
Network analysis of murine osteoblast differentiation 
of co-linearity and over-fitting, it is impossible to unambiguously determine 
the best parameter set for the complete set of regulators and it becomes 
essential to constrain the solution space appropriately (Liao et al., 2003). 
Restricting the number of regulators follows the biological intuition that 
only a limited number of genes will directly influence a gene’s transcription 
during the process under consideration (Guelzim et al., 2002). Even if this 
assumption is violated in some cases, it makes sense to apply Occam’s 
razor and infer only the most prominent influences when insufficient data 
is available (Hashimoto et al., 2004). Also, to function stably in a stochastic 
environment, the global regulatory system needs to react robustly against 
small perturbations in the regulatory influences and signalling pathways 
that feed it. Ensuring that the inferred models are robust against noise will 
therefore regularize the inference process and direct it towards more plausible 
models. 
We obtained a combination of data-fit, robustness and limited 
connectivity by augmenting the standard squared error with a penalty term 
that sums the absolute values of the weights (van Someren et al., 2003):
         (4) 
        
Here, λ provides a trade-off between data-fit versus robustness and limited 
connectivity. Note that robustness implies that small changes in the input 
result in small changes in the output, i.e. δyi/δxj = wij are small. A solution 
to this equation is, generally, found using only a few iterations of the EM-
algorithm (Grandvalet, 1998). In statistical learning, this method is called 
Least Absolute Shrinkage and Selection Operator (LASSO) (Tibshirani, 
1994), because it tends to shrink the weights (robustness) such that only 
a few weights remain non-zero (limited connectivity). As a result, LARNA 
automatically selects from among all genes that set of genes (called 
regulators) that, in combination, provides the best prediction of that gene’s 
future gene expression levels. The use of LASSO to infer genetic interactions 
was first introduced in (van Someren et al., 2002) and shown to outperform 
other algorithms on synthetic data. 
To test how well our method compares to other approaches, we 
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have also implemented three linear models (i.e. sparse QR (SQR), backward 
search (B) and forward beamsearch (F)), three non-linear approaches (i.e. 
Discrete Dynamic Bayesian Network (DDBN), Sigmoidal Gradient Ascent 
(SGA) and Sigmoidal Least Absolute Penalization (SLAP)) and two time-
lagged correlation based methods (i.e. Correlation Metric Construction (CMC) 
and Significant Time-Lagged Correlation (STLC)). SQR is a standard linear 
algebra method based on Gaussian Elimination and QR decomposition that 
returns a (zero-error) matrix that consists completely of zeroes except for R 
columns which contain non-zero values (R equals the rank of the system). B 
is a method that finds sparse network solutions based on a greedy backward 
search algorithm that for each target gene keeps removing the regulator 
with the lowest weight until a given minimal number of regulators, Kmax, is 
reached or the error becomes non-zero (Weaver et al., 1999). F is a method 
that finds sparse network solutions based on a forward beam-search, with 
beam-size K = 5 (van Someren et al., 2001). For each target gene, this 
method starts by checking all single-regulator networks. Then it checks all 
two-regulator networks that can be constructed by adding a regulator to each 
of the best K single-regulator networks. This recursively repeats with more 
regulators until the prediction error is below a desired level Emax. The DDBN 
uses greedy hill-climbing with 100 restarts to find the best structure (with 
maximal connectivity Kmax) of a dynamic Bayesian network (van Berlo et al., 
2003). Before learning, data was discretized into three gene expression levels 
using K-means clustering (as in (Pe’er et al., 2001)). SGA uses 100 restarts 
of gradient ascent to learn a linear model augmented with a sigmoidal dose-
response curve (similar to (Weaver et al., 1999; Wahde and Hertz, 2001)) 
and recursively sets the lowest weights to zero until Zmax non-zeros remain. 
SLAP is similar to SGA with the addition of the sum of absolute weights to the 
cost function. STLC first computes a matrix of the most significant correlation 
found between each pair of genes over all possible time-lags and returns 
different networks by thresholding the correlations in this matrix based on 
significance. CMC is an implementation of Arkin et al. (1997) which constructs 
a directed network from a single linked tree that connects genes that have 
similar correlation profiles. Such a profile consists of the correlations to all 
other genes, individually maximized for all possible time-lags. All regression 
and cluster methods were applied to the same outlier-removed normalized 
interpolated data. More detailed descriptions of all methods are published as 
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supplementary materials.
Co-citation network and enrichment
 Jenssen (Jenssen et al., 2001) has shown that a co-citation network 
reflects biologically meaningful relationships. One way to validate the network 
results is, therefore, to compare them against a co-citation network. To this 
end, a list of gene abbreviations was constructed by extracting symbol name 
and synonyms from the gene detail pages of MGI (Blake et al., 2003). For 
each gene abbreviation, PubMed was searched for publications that mention 
this term and a list of identifiers (PMID) referring to these publications was 
extracted. A pair is said to be co-cited when there exists at least one paper 
that mentions both: 
(5) 
Here, k(i) is the list of gene abbreviations of gene i and ps is the list of PubMed 
IDs corresponding to term s. 
For each network result, the number of true positives was determined 
as the number of gene pairs for which the inferred network predicts an 
interaction and that are co-cited: 
 (6) 
Because TP depends on the connectivity of the co-citation matrix as well as 
on the connectivity of the inferred matrix, two complementary performance 
measures were computed. Specificity (SP) indicates how often a proposed 
interaction concerns genes that are related and is defined as TP divided by 
the number of predicted interactions. Sensitivity (SE) indicates how much of 
the ‘ground truth’ is discovered and is defined as TP divided by the number of 
pairs that are co-cited. 
(7) 
Here, FP stands for false positives and FN for false negatives.
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RESULTS
Clustering and co-expression networks
 C2C12 cells are myoblasts that form myotubes when cultured under 
low serum conditions. Upon treatment with BMP2, the cells differentiate to 
an osteoblast phenotype (Vaes et al., 2002). We studied gene expression at 
several time points during myoblast and osteoblast differentiation. Figure 1 
shows an overview of the microarray data. A total of 101 genes (out of the 
9596) showed significant changes in expression with respect to zero under 
our experimental conditions. To give a meaningful description of the data, 
these genes were grouped by hierarchical clustering into three main clusters. 
Cluster one consists of genes that are down-regulated during either osteoblast 
or myoblast differentiation. This cluster contains many genes related to 
control of proliferation (e.g. Plf, Mcm5, Hmga1). See supplementary materials 
for a complete list of gene symbols, gene names and accession numbers of all 
genes mentioned in this paper. The second cluster visible in Figure 1, consists 
of genes induced during osteoblast differentiation and contains typical 
osteoblast markers such as Akp2, Bglap1 and Col1a1. Cluster three consists 
of genes that are induced during myoblast differentiation but do not change 
in expression in BMP2-treated cells. Many well-known muscle-related genes, 
(e.g. Myh1, Tncc, Myom1, Casq1, Ckm) reside in this cluster. 
Clustering is known to place functionally related genes into the 
same group. The results of the hierarchical clustering could, therefore, be 
interpreted as if it represents a network of fully connected modules (one 
module for each cluster) without any connections between modules. Such a 
co-expression network is illustrated in Figure 2 for a small subset of genes 
(chosen arbitrarily just for visualization purposes).
Enrichment for co-citation in inferred networks
 
 If the inferred networks express relationships that are biologically 
meaningful, it is expected that these networks also show enrichment for 
co-citation compared to random networks. Therefore, we constructed a co-
citation matrix for the 101 selected genes. 
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Figure 1. 
Gene expression values from eleven microarrays (columns) of the 101 genes that 
were significantly differentially expressed (rows) visualized as a heatmap. Black values 
represent positive expression, white values negative expression, whereas gray values 
correspond the absence of expression (see colour bar at the right). Arrays consist of an 
untreated triplicate (ZE), an untreated subseries (UN) and a treated subseries (BB). Both 
subseries were sampled at one (24), two (48), six (144) and ten days (244) after ZE. 
Array BB24 was found to be contaminated and removed from further analysis. The bar to 
the right of the heatmap indicates the clustering result using hierarchical clustering with 
the cosine distance and complete linkage at a selection of three clusters. Before clustering 
and network inference, the triplicate at ZE was averaged and linear interpolation was 
used to obtain a virtual data set that is (uniformly) sampled at every day, e.g. expression 
values at UN72, UN96 and UN120 were obtained by linear interpolation between UN48 
and UN144. 
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This matrix is represented in Figure 3. In this matrix, genes are ordered 
and grouped according to the clustering described in Figure 1.We expect 
that co-expression networks obtained from clustering will tend to show a 
strong enrichment for co-citation and that the co-citation enrichment scores 
of clustering may serve well as reference performance. Figure 3 already 
indicates that large clusters will not show a particularly strong enrichment 
for co-citation (only the cluster of osteoblast markers is slightly enriched). 
Instead, the occurrence of several small white triangles close to the diagonal 
suggests that enrichment is stronger for small clusters. Alternatively, we 
found that genes in close hierarchical proximity share similar row and column 
patterns, indicating that co-expressed genes tend to share the same pattern 
of co-citation with other genes (Chaussabel and Sher, 2002). 
 A systematic analysis of co-citation enrichment for different distance 
measures, linkage types and cluster sizes using hierarchical clustering shows 
that most co-expression networks resulting from small cluster sizes (i.e. a 
large number of clusters) are significantly enriched for co-citation. A cosine 
distance measure and single linkage combination was found to score best 
(See supplementary materials). Therefore, we have used this “best-scoring” 
combination as a method of reference to compare co-citation enrichment of 
co-expression networks with regression networks. 
Networks derived from clustering of genes show full connectivity within 
clusters (See Figure 2) whereas true genetic networks are likely to be sparsely 
connected. Furthermore, the clustering algorithms do not reveal the causal 
relationships within the genetic network. Therefore, we devised a method for 
Least Absolute Regression Network Analysis (LARNA) that can unravel genetic 
Figure 2. 
Illustration of co-expression network 
between a small arbitrarily chosen subset of 
genes based on the same clustering as was 
used in Figure 1. There are three clusters, 
i.e. one cluster of four genes, one cluster 
of six genes and one cluster of one gene. 
The corresponding co-expression network 
contains links between all genes in the 
same cluster, but no links between genes in 
different clusters. The position of the genes 
is based on a Sammon projection which 
places genes closer together when their 
expression profiles are more similar. 
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network structure from microarray data sampled in time. LARNA distinguishes 
itself from other regression network models as it provides a unique trade-off 
between data-fit versus robustness and limited connectivity. 
Figure 3. 
Co-citation matrix extracted from PubMed between the 101 selected genes. 
Because the matrix is symmetric, only the lower triangular part is visualized. 
White patches indicate pairs of genes that are co-cited at least once, black patches 
indicate no co-citation. The main diagonal indicates whether single genes are cited 
at least once (white) or not at all (black). The upper triangle visualizes the same 
clustering result as was used in Figure 1. Pairs of genes that are in the same cluster 
are indicated by a common colour, white patches indicate pairs of genes that are in 
different clusters. Note that a clustering in N clusters that is strongly enriched in co-
citation would show up as N triangular structures below the diagonal that contain 
more white patches than elsewhere.
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Repeated application of all methods on synthetic data generated using 
a linear model with random structure shows that HC, F, STLC and LARNA 
perform on average significantly better than random, whereas SQR, B and 
CMC do not or only marginally (Published as supplementary materials). 
Because synthetic data may not reflect the actual characteristics of 
the data, Figure 4 shows the performance of LARNA applied to the C2C12 
differentiation data and compared to other network models. The specificity 
of the networks with random connections (Random) indicates that the prior 
probability of randomly selecting a pair of co-cited genes is approximately 
6% on average with roughly 2% standard deviation. The results show that 
standard linear approaches that search for limited connectivity (B, F and 
SQR) perform significantly better than random if the inferred networks are 
sufficiently connected (SE > .04). Moreover, in the current setting, recursively 
Figure 4. 
The specificity (SP) versus sensitivity (SE) for the network methods with respect to 
the co-citation network from Figure 3. Dotted lines depict performance of random 
networks plus and minus one standard deviation. Lines with markers depict the 
performance of network inference methods for different parameter settings (the 
parameter is depicted in the legend after the method’s name). Parameter-less 
methods are depicted with a single marker. The upper-right corner specifies optimal 
performance. For each method, one solution is chosen manually as a possible ”best” 
solution and indicated by an arrow with the corresponding parameter setting.
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adding possible regulators (F) seems a more fruitful search strategy than 
recursive elimination (B). The probabilistic and non-linear model (DDBN) 
is able to outperform randomly connected network structures, but is very 
sensitive to its parameter. 
The need to discretize the data prior to learning in combination with 
the severely limited number of samples may have contributed to DDBN’s bad 
performance. The non-linear SGA does outperform the randomly connected 
structures, but not its linear equivalent (B). More strikingly, SLAP is not able 
to return networks that are significantly better than random. Finally, STLC 
outperforms HC at larger sensitivity ranges and performs similarly when 
returning more sparsely connected networks. In contrast, CMC (located at 
1.6% sensitivity) which is also based on time-lagged correlations, but which 
was not originally intended for genetic network reconstruction, performs only 
marginally better than random. All of these methods aim to infer networks 
of limited connectivity, but they do not provide measures against noise on 
the data. LARNA is able to outperform these methods by incorporating both 
criteria simultaneously.
LARNA shows highest enrichment in co-citation
 The best overall performance of all network inference methods 
was obtained by LARNA, which outperformed the best clustering method 
particularly at intermediate levels of sensitivity and to a lesser extent at 
high levels of sensitivity. The λ parameter of LARNA determines the trade-off 
between fitting the data versus robustness and limited connectivity. When 
data-fit is less emphasized, the inferred networks become less sensitive to 
noise and more sparsely connected, resulting in higher specificity (sometimes 
at the cost of sensitivity). This pronounced effect is exemplified by LARNA’s 
performance in Figure 4 around 6.5% sensitivity. While data-fit is relaxed, 
the sensitivity remains approximately 6.5%, but the specificity increases from 
15% to almost 32%. Here, LARNA removes unnecessary regulators from the 
network thereby removing a significant number of false positives. 
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Analysis of a single inferred network
 To further illustrate the consistency of the networks inferred by LARNA 
with current biological expertise, a single network of interest was selected 
to be analyzed in more detail. Because, the best setting of λ cannot be 
reliably determined from the already limited amount of data (e.g. by cross-
validation), we propose to utilize the literature enrichment scores to select 
a single network solution. We have selected the LARNA solution that scored 
best in specificity (32%), while giving sufficiently high sensitivity (6%). 
The selected network depicted in Figure 5 is indeed quite sparse, with 
genes having mostly one or two, but maximally four, regulators. Note that 
the sparseness constraint effects the number of regulators only, the number 
of targeted genes can still vary from none (e.g. Ogn) to many (e.g. Dcn). 
Obviously, the position of the genes within the network is also of importance, 
i.e. we expect genes with regulating roles (e.g. Tnnc2) to be network 
initiators (i.e. influencing many but being influenced by few) and known 
(osteoblast) differentiation markers to be more downstream in the network 
(e.g. Bglap1). 
Furthermore, regulatory networks are expected to have a modular 
architecture (Featherstone and Broadie, 2002), consisting of highly 
interconnected modules where inter-module influences are exerted through 
only a few “hub” genes. Indeed, four modules can be recognized in the 
selected network, i.e. 1) the ”muscle development” module (M1) that is 
related to the normal differentiation of untreated C2C12 precursor cells to 
myoblasts, containing Tnnc2 as a main regulator and many muscle-related 
genes, 2) a module related to proliferation (M2 containing o.a. Mrpplf3, 
Hmga1 and Igfbp2) regulated primarily by proliferin (Plf ), 3) a module with 
genes related to extra-cellular matrix formation and processing (M3) with 
decorin (Dcn) and periostin (Postn) as main regulators and 4) a module of 
genes related to osteoblast maturation and mineralization (M4 containing o.a. 
Bglap1 and Ogn). To provide a better visualization of the network structure, 
we utilized clustering and domain knowledge to organize the genes into these 
four modules. These modules correspond to the clusters/modules recognized 
by hierarchical clustering and which were depicted in Figure 1. An exception is 
formed by the osteoblast differentiation module (cluster 2) that we split into 
a matrix formation module (M3) and a mineralization module (M4) according 
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to the phases that are recognized in the osteoblast differentiation process 
(Franceschi, 1999). 
Consistent with a modular structure, connections from one module 
to another are established only through one of the few “hub” genes (i.e. 
Tnnc2, Plf, Dcn and Postn). Furthermore, these regulating influences from 
one module to another are consistently positive or negative, i.e. all influences 
have the same sign. These influences (large arrows in Figure 5) are indicative 
of the global regulatory behaviour. 
Figure 5. 
Diagram of the network inferred by LARNA. Each node (black box, white edge) 
represents a set of the genes with the same inferred input and output connections. 
For illustrative purposes, the genes that were not connected to any other gene were 
left out of the diagram. Arrows represent an inferred positive interaction (activation) 
from a regulating gene to its target(s), where the arrow head ↑ is positioned at the 
target. Similarly, a directed negative interaction (inhibition) is indicated by a  
marker at the target. Self-regulations are not shown. The genes were grouped into 
four modules (large grey boxes) based on the clustering and known osteoblast 
differentiation phases (see text). Large arrows indicate interaction between 
modules. Numbers indicate TP per link.
Genes that had exactly the same ingoing and outgoing influences were 
grouped together into a single node (black boxes in Figure 5). A node consists 
of genes with the same pattern of positive and negative (non-zero) weights 
on its row and column (main diagonal excluded). Figure 6 shows the gene 
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expression profiles of all 101 genes, where genes within the same node are 
plotted in the same subplot. This assignment of genes into nodes can be seen 
as an alternative way of clustering, where genes are grouped according to 
how they influence and how they are influenced by other genes. This property 
of received and exerted influences may potentially give a better reflection of 
a gene’s function than its expression profile alone. Obviously, both properties 
are strongly related, i.e. genes with very similar expression profiles will 
probably receive similar incoming connections. Figure 6 shows that genes 
in the same node tend to have similar expression profiles, although some 
expression profiles that seem similar can be found in different nodes.
DISCUSSION
 
 We have presented a method to infer genetic interactions from 
timecourse microarray data. Given the large number of genes and the 
low number of microarrays it is critical that the complexity of the model 
is sufficiently regularized and additional information is incorporated in the 
inference process. To this end, a simple linear model was chosen as the core 
of our approach and the model was constrained to be robust against noise and 
sparsely connected. We have shown how LARNA provides a balance between 
these properties and data-fit. 
We have applied several approaches to a C2C12 microarray data set 
with 101 selected genes measured at eight different biological states available 
for learning. The interactions inferred by LARNA were significantly more 
frequent between genes that are mentioned together in literature than could 
be expected by chance. Obviously, the literature network is not a very accurate 
reflection of the true underlying network (which is not known). Co-citation 
networks contain a substantial amount of false connections (e.g. genes that 
are co-cited but do not influence each other) and missing connections (i.e. 
interactions that are not yet known). The sensitivity and specificity values 
are, therefore, only meaningful in a relative way. Nevertheless, literature 
enrichment is still useful as a measure to compare different methods, since 
1) these errors are unbiased (i.e. they modify the score of any method in 
the same way) and 2) the number of co-cited genes that do truly interact is 
sufficiently high to show difference in performance. 
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The performance of LARNA was found to be superior to all other 
genetic network models. Search strategies may return significantly 
enriched structures, but are hampered by the substantial noise in the data. 
Alternatively, the non-linear models may potentially allow for more realistic 
model behaviour, but they suffer too severely from unreliably parameter 
identification, due to the limited number of measurements. To a large extent, 
LARNA showed a higher enrichment of co-citation than could be obtained 
with the best setting of hierarchical clustering. This makes network inference 
a valid and interesting method to analyze micorarray data in a way that 
is complementary to clustering. Whereas clustering obtains groups of co-
regulated genes, network inference goes one step further and unravels the 
causal relationships between them. 
More detailed study showed that many inferred interactions and 
network properties are consistent with current biological knowledge and 
expertise. In our opinion, the selected network seems to capture the more 
Figure 6. 
Expression profiles of all 101 genes grouped into 18 different subplots. In each 
subplot, normalized gene expression is depicted on the Y-axis versus time (in days) 
on the X-axis for treated (solid line) and untreated cells (dotted line with marker). 
Genes in the same node are plotted in the same subplot. The subplots correspond 
to the 17 nodes depicted in Figure 5, except for one subplot (row 2, column 3) 
which corresponds to all unconnected genes.
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global inter-relationships corresponding to osteoblast differentiation, but 
some important parts are still missing and many inferred interactions are 
likely to reflect indirect effects. This is exemplified by the fact that the selected 
network contains only one known transcription factor (Hmga1). Furthermore, 
some well-known regulators of the myogenic and osteogenic pathways are 
missing. With respect to the osteogenic regulator Runx2 this is explained 
by the fact that the bone-specific transcript is not represented on the array 
(de Jong et al., 2004a), whereas others did not show significant expression. 
Nevertheless, some missing elements are to be expected of a network that is 
generated ‘ab initio’ and from such an extremely low number of arrays. 
It seems, however, that the global inter-relationships between genes 
and modules revealed by the network fit extremely well with current knowledge 
of differentiation of mesenchymal cells. Differentiation of mesenchymal cells 
occurs with a concurrent decline in proliferative capacity (Aubin, 1998; Peng 
et al., 2004). Accordingly, the network shows negative feedback from the 
muscle and osteoblast differentiation modules to the proliferation module. 
In addition, it reveals negative feedback from the proliferation module to 
the osteoblast differentiation module. This is in line with experimental data 
that show a mutually exclusive relation between proliferation and terminal 
differentiation of mesenchymal cells (Ying et al., 2003; Marzia et al., 2000). 
Within the discovered network, a central role is found for periostin 
and decorin, both extra-cellular genes involved in cell-matrix interactions 
(Horiuchi et al., 1999; Danielson et al., 1997). They initiate the forming of an 
extra-cellular matrix (Col1a1 and Timp3) and eventually initiate osteoblast 
maturation genes (Bglap1 and Ogn). Such a proposed stimulation of the 
differentiation process by matrix-cell interactions is in line with published 
data. Disruption of the decorin gene leads to abnormal collagenous matrix 
formation (Danielson et al., 1997). Under normal conditions, formation of 
the extracellular matrix drives the differentiation of osteoblasts. Disruption 
of the matrix leads to impaired differentiation and an osteopenic phenotype 
in vivo (Franceschi et al., 1994; Lai et al., 2001; Corsi et al., 2002). The 
interactions between matrix-associated genes and terminal differentiation 
markers predicted by our computer-learned network are in good agreement 
with these experimental data. 
In conclusion, we presented LARNA, a regression algorithm to infer 
sparse genetic networks from microarray data sampled over time. Interacting 
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gene pairs identified by LARNA are enriched for co-cited genes. In this respect, 
LARNA outperforms standard network inference methods and clustering 
algorithms. Importantly, two global hypothesis raised by LARNA conform 
to current biological knowledge, i.e. 1) osteoblast maturation is induced by 
extra-cellular matrix formation and 2) proliferation and differentiation are two 
mutually exclusive modes of operation. The interactions revealed by LARNA 
on the current limited set of microarrays are of a global character and do 
not reflect all details. Preliminary in-silico studies support the intuition that 
samples should be taken more frequent at moments when the dynamics of 
the gene expression signals increases (results not shown). The enrichment 
scores were not sensitive to changes in the interpolation interval, but the 
interval at which measurements are obtained as well as the number of 
different treatments will be much more important. Future studies with more 
arrays sampled at smaller intervals are likely to provide a network map with 
higher resolution. It would also prove interesting to compare the results of 
the different regression networks with different publicly available co-citation 
networks and other global co-expression networks.
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ABSTRACT 
 A major challenge in developmental biology is to correlate genome-
wide gene expression modulations with developmental processes in vivo. 
In this study, we analyzed the role of Runx2 during intramembranous and 
endochondral bone development, by comparing gene expression profiles 
in 14.5 dpc wild-type and Runx2 (-/-) mice. A total of 1277, 606 and 492 
transcripts were found to be significantly modulated by Runx2 in calvaria, 
forelimbs and hindlimbs, respectively. Bioinformatics analysis indicated 
that Runx2 not only controls the processes of osteoblast differentiation 
and chondrocyte maturation, but may also play a role in axon formation 
and hematopoietic cell commitment during bone development. A total of 
41 genes are affected by the Runx2 deletion in both intramembranous 
and endochondral bone, indicating common pathways between these two 
developmental modes of bone formation. In addition, we identified genes 
that are specifically involved in endochondral ossification. In conclusion, our 
data show that a comparative genome-wide expression analysis of wild-type 
and mutant mouse models allows the examination of mutant phenotypes in 
complex tissues.
INTRODUCTION
 During skeletogenesis, bone is formed by two different processes, 
intramembranous ossification (flat bones) and endochondral ossification 
(long bones) (5). Both processes require the condensation of mesenchymal 
stem cells in order to form the shape of the future skeletal elements. During 
intramembranous ossification, the condensed mesenchymal cells differentiate 
directly into preosteoblasts and subsequently into osteoblasts. By this 
process, the flat bones of the skull and parts of the mandible and clavicle are 
formed (35, 38). During endochondral ossification, long bones in the skeleton 
develop by a two-step process in which the mesenchymal cells in the centre 
of the condensation first differentiate into chondrocytes and thereby form 
a cartilage template which is subsequently replaced by bone. In the central 
region of the cartilage, chondrocytes mature to hypertrophic chondrocytes 
and secrete cartilage matrix. Subsequently, the hypertrophic chondrocytes 
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undergo apoptosis and the cartilage template is invaded by blood vessels 
accompanied by osteoblasts from the periostal mesenchyme layer and 
osteoclasts. The cartilage matrix is then degraded by osteoclasts and replaced 
by bone matrix deposited by osteoblasts (5, 48). 
 The runt-related transcription factor Runx2 (Cbfa1/Osf2/Pepb2αA) is 
known to have a key function in skeletogenesis. In Runx2 (-/-) mice, both 
intramembranous and endochondral bone formation is blocked and as a result 
their endochondral skeleton is made of cartilage (47, 54). Runx2 (-/-) mice 
lack expression of the osteoblast marker genes Spp1 (secreted phosphoprotein 
1 or osteopontin) and Bglap1 (bone gamma-carboxyglutamate protein 1 or 
osteocalcin) (47), and therefore their phenotype has been attributed to an 
absence of mature osteoblasts. Runx2 overexpression in non-osteoblastic 
cells induces the expression of the osteoblast marker genes Col1a1 (collagen 
type I, alpha 1), Ibsp (integrin binding  sialoprotein, or bone sialoprotein), 
Spp1 and Bglap1 (3, 28, 36, 44), indicating that it acts as a transcriptional 
regulator of the osteoblast phenotype.
During development the strongest expression of Runx2 is observed 
in the osteoblasts (28, 39, 45, 75), but low expression levels have also been 
detected in pre-hypertrophic and hypertrophic chondrocytes (39, 45, 75). 
In line with this expression in chondrocytes, Runx2 (-/-) mice do not only 
show a lack of osteoblasts, but also reduced mRNA levels of the hypertrophic 
chondrocyte genes Col10a1 (procollagen, type X, alpha 1), Ihh (Indian 
hedgehog), Bmp6 (bone morphogenetic protein 6), Ibsp and Spp1 (39, 45, 
47). This indicates that Runx2 also plays a central role in the maturation from 
chondrocytes to hypertrophic chondrocytes. Detailed analysis of Runx2 (-/-) 
embryos indeed showed a lack of hypertrophic chondrocytes in the proximal 
limbs (humerus and femur), although less severe effects were observed in 
the distal limbs (radius, ulna, tibia, fibula) (39, 45). Evidence for a direct role 
of Runx2 in chondrocyte hypertrophy comes from studies with transgenic 
mice, in which overexpression of Runx2 resulted in premature chondrocyte 
maturation (75), while introduction of a dominant negative form of Runx2 
inhibited chondrocyte hypertrophy (79). During skeletal development 
Runx2 therefore acts as a regulator of both osteoblast differentiation and 
chondrocyte maturation. 
 In addition to osteoblasts and chondrocytes, expression of Runx2 
has further been observed in tendon and fibroblasts of the dermis (47), in 
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primary mammary epithelial cells (40, 54), in T cells of the thymus (63), 
endothelial cells, vascular smooth muscle cells and differentiating fat cells 
(15), although in all cases only at low levels. A role for Runx2 in mammary 
gland development has been proposed (68), but it remains to be established 
whether endogenously expressed Runx2 indeed has a developmental function 
in non-skeletal cell types. Finally, Runx2 is ectopically expressed in tumours, 
including breast cancer (4) and prostate cancer (17) and in lymphoma cells 
(73).
In order to study the role of Runx2 in bone and chondrocyte 
differentiation in more detail, we have used microarray expression profiling 
to identify genes that are specifically expressed in intramembranous and 
endochondral bone. Microarray technology has been used before to identify 
early mediators of osteoblast differentiation (21, 55, 57) as well as late 
osteoblast marker genes (58, 60, 80) and osteoblast-related transcription 
factors (70), but all these studies have been carried out on in vitro model 
systems. Despite the promising results obtained, such studies on in vitro cell 
lines may have limited predictive value for in vivo gene function, while results 
acquired with exogenous inducers of cellular differentiation may strongly 
depend on the choice of experimental conditions. 
In this study we combined Runx2 (-/-) mice and microarray technology 
to identify Runx2-mediated processes during skeletal development. We 
compared gene expression in calvaria, as a model system for intramembranous 
ossification, with that in whole forelimbs and hindlimbs, as model systems 
for endochondral ossification. By studying both wild-type and Runx2 (-/-) 
embryos, the specificity of Runx2-induced gene expression during these 
two processes was analysed. Bioinformatics analyses of the microarray data 
showed that Runx2 plays common and distinct roles during intramembranous 
and endochondral bone formation. In particular, we identified a number of 
novel genes that are genetically downstream of Runx2 in calvaria and limbs. 
Altogether, the analysis presented here reveals a novel in vivo approach for 
characterising the mechanism whereby Runx2 induces bone formation. 
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EXPERIMENTAL PROCEDURES
Embryonic tissue collection
 Animals with disrupted Runx2 function were generated by insertion 
of a LacZ-neo cassette into the third exon of Runx2 as described previously 
(54). Since the Runx2 (-/-) mutation is lethal immediately after birth, wild-
type and mutant embryos were obtained from crossing Runx2 (+/-) animals. 
In the morning, vaginal plugs were determined as evidence for mating. 
Females with a plug were separated from males and when pregnant, embryos 
were collected at 14.5 dpc (0.5 is midday of the day of observation of a 
vaginal plug). Dissection of embryos was carried out in cold sterile phosphate-
buffered saline (Invitrogen). After dissection, calvaria and hindlimbs were 
immediately transferred into an individual well of a 24-well plate that was 
kept on a block of dry ice. In this way, the samples were frozen quickly after 
which they were stored at -80ºC. Genomic DNA was isolated from brain or 
yolk sac for PCR genotyping. 
RNA isolation
 For RNA analysis, samples of interest were taken up in TRIzol® while 
still frozen (Invitrogen). For analysis on calvaria, a total of 31 wild-type 
calvaria were pooled in 1 ml of TRIzol® and homogenized using a Ultra-Turrax 
homogenizer (T25 basic, IKA-Werke). A total of 39 knockout calvaria were 
pooled and treated similarly. For isolation of RNA from limbs, 20 pairs of 
forelimbs and 20 pairs of hindlimbs, of both wild-type and knockout samples, 
were individually homogenized in 1 ml of TRIzol®. After incubation at room 
temperature for 5 min, the mixture was transferred into an Eppendorf tube 
and centrifuged for 10 min, 12000 rpm at 4ºC in order to remove debris. The 
supernatant was transferred to a fresh tube and RNA was extracted according 
to the manufacturer’s protocol. RNA was precipitated by treatment with sodium 
acetate 0.8M / NaCl 1.2M and isopropanol and after air drying dissolved in 50 
µl of DEPC-treated H2O. RNA concentrations were determined by measuring 
absorbance at 260 nm. From each individual isolation of limb RNA, an equal 
amount of was pooled to generate a total of 150 μg of RNA from each of the 
four samples to be tested (i.e. WT/forelimb, WT/hindlimb, KO/forelimb and 
KO/hindlimb). The quality of the RNA samples was evaluated by capillary 
electrophoresis on an Agilent 2100 Bioanalyzer (Agilent Technologies).
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Microarray processing and data analysis
 From a total of 5 μg of RNA, double-stranded cDNA was synthesized 
using the SUPERSCRIPT™ II system (Invitrogen) in combination with a 
T7(dT)24 cDNA Primer (Ambion). The cDNA was then used as a template 
for the preparation of biotin-labelled cRNA using the BioArray High Yield RNA 
Transcript Labelling Kit (Enzo Diagnostics). Subsequently, 10 µg of biotin-
labelled cRNA were hybridized to the MOE430A Array (Affymetrix), washed, 
stained with phycoerythrin-streptavidin conjugate (Molecular Probes), after 
which the signals were amplified by staining the array with biotin-labelled 
anti-streptavidin antibody (Vector Laboratories) followed by phycoerythrin-
streptavidin. The arrays were scanned with an Agilent GeneArray Scanner 
2500 laser according to the manufacturer’s instructions. In order to obtain 
data with sufficient statistical power, calvaria samples were hybridized in 
four-fold on arrays, while limb samples were hybridized in ten-fold. Data 
were saved as raw image file and quantified using Microarray Suite 5.0 
(Affymetrix). Statistical analysis of the data was performed using Rosetta 
Resolver Version 3.2. The required normalization was carried out using the 
so-called error model developed for Affymetrix GeneChips. For each tissue, a 
ratio of gene expression in wild-type versus knock-out tissue was calculated. 
Genes were included for analysis if the p-value calculated for this ratio was 
less than 0.01. For the calvaria data, the additional criterion was applied that 
expression above background had to be measured in all 4 wild-type or knock-
out measurements on the array. 
For a functional analysis of the set of significantly modulated genes, 
the web-based platform Gene Ontology Tree Machine (GOTM) was used to 
identify so-called GO terms with relatively enriched gene numbers. The 
results were expressed as enrichment ratio for GO categories with a p-value 
to indicate significance of deviation from random distribution (88). From each 
data-set, the genes were ranked according to the microarray p-value whereby 
for the calvaria and forelimbs 500 transcripts with smallest p-values were 
selected without discriminating between up- or down-regulation, while for 
the hindlimbs all 492 significantly modulated transcripts were included in the 
analysis.  
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Real-time quantitative RT-PCR
 Real-time quantitative RT-PCR was essentially done as described 
previously (81). Briefly, complementary DNA (cDNA) was obtained by reverse 
transcription of RNA from random hexamer primers using SUPERSCRIPT™ II 
reverse transcriptase (Invitrogen). Subsequently, cDNA was amplified using 
SYBR Green® PCR Mastermix (Applied Biosystems) on a ABI Prism Sequence 
Detection System under the following conditions: initial denaturation for 10 
min at 95°C, followed by 40 cycles consisting of 15 s at 94°C and 1 min at 
60°. Expression values were subsequently determined according to threshold 
cycles (Ct values), indicating the increase of reporter fluorescence above 
baseline levels. For each gene, PCR was carried out in triplicate and mean 
expression values were corrected for mean Gapdh expression levels. 
Promoter analysis
 Promoter analysis was performed to examine whether promoters of 
the genes that were significantly downregulated in all three datasets showed 
enrichment of potential Runx2 binding sites. To this end, the Perl module 
TFBS-0.5.0 (49) was used to search for exact occurrences of the motif 
AACCACA (26) in the promoter sequences of all genes in the genome up to 
5000 nucleotides upstream of the transcriptional start site. Enrichment for 
Runx2 binding sites in the selected gene set was computed using the hyper-
geometric distribution for varying settings of a threshold, p, on the promoter 
length (10 ≤p≤ 10000 nucleotides) and a threshold, t, on the number of 
binding sites (1 ≤t ≤5). The resulting p-values reflect the likelihood of finding 
at least t or more Runx2 binding sites within p nucleotides upstream of the 
transcriptional start site in a random subset of k genes from the genome 
(where k equals the number of genes in the selected set of Runx2-dependent 
genes).
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RESULTS
Microarray analysis of WT and Runx2 mutant calvaria and limbs 
To examine genes of which expression is modulated by Runx2 during 
skeletogenesis on a genome-wide basis, microarray expression profiling was 
carried out on skeletal tissues (calvaria, forelimbs and hindlimbs) of wild-type 
and Runx2 (-/-) mouse embryos at 14.5 dpc. At this developmental stage, the 
function of Runx2 in the osteoblasts of the calvaria is activated by release of 
Twist inhibition, resulting in the expression of Ibsp (9). Similarly, in 14.5 dpc 
limbs the osteoblasts present in the bone marrow and the bone collar strongly 
express Runx2 (39) and its target genes Ibsp and Spp1 (67). 
 Calvaria were dissected including the skin layer on top of the calvaria 
and gene expression levels were analysed in pools of calvaria (CAL), whole 
forelimbs (FL) and whole hindlimbs (HL) of both wild type (WT) and Runx2 
(-/-) (KO) embryos, as described in Experimental Procedures. Based on a p-
value cut-off of 0.01, 1277 transcripts out of the total of 22,625 present on the 
array were found to be modulated in CAL, 606 in FL and 492 HL. Of the 1277 
modulated transcripts in calvaria, 531 transcripts showed lower expression 
values in KO than in WT and will therefore be referred to as downregulated 
transcripts. The 746 transcripts with higher expression values in KO than 
in WT calvaria will be referred to as upregulated transcripts. Similarly, the 
forelimb data contained 296 downregulated and 310 upregulated transcripts, 
while the hindlimb data contained 172 downregulated and 320 upregulated 
transcripts. These data indicate that the Runx2 deletion leads to both up- and 
downregulation of gene expression in bone tissue. 
Functional analysis of differentially expressed genes
In order to analyse these expression data in terms of processes 
disrupted in the Runx2 (-/-) mice, we performed a functional analysis based on 
the so-called Gene Ontology (GO) classification. Each gene on the microarray 
corresponds to one or more specific GO-terms according to the function of its 
proteins. In the analysis we compared the number of modulated genes with 
the total number of genes on microarray in each GO-term, with restriction to 
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the main GO-class Biological Process.  
 The GO analysis was carried out on the 500 modulated CAL and FL 
transcripts with the lowest p-value and on all 492 modulated HL transcripts, 
without discriminating between up- or downregulation. Out of the 500 
calvaria transcripts analyzed, 307 unique genes had an annotation within the 
main category Biological Process. Out of these 307 genes, 127 unique genes 
contributed to significant enrichment of one or more GO-terms. Within the 
500 selected forelimb genes, 290 unique genes were annotated, of which 127 
genes contributed to enriched GO-terms, while for the hindlimbs 288 out of 
306 annotated genes gave rise to enrichment of GO-terms. These data show 
that at least 40% of the genes regulated by Runx2 belong to specifically 
enriched GO-terms. 
As shown in figure 1, significant enrichment (p<0.01) was observed 
for 42 distinct GO-terms in the case of calvaria (Fig. 1A), 30 for forelimbs 
(Fig. 1B) and 20 for hindlimbs (Fig. 1C). Table 1 surveys which of these 
GO-terms are specifically enriched in a single tissue and which in multiple 
tissues. All three tissues appear to be enriched for genes with the annotation 
skeletal development, an expected result that validates our approach. 
Similar enrichment was observed for the term phosphate transport, which 
includes different types of procollagens, thus reflecting the relevance of 
matrix formation during skeletogenesis. Genes of the classes cell adhesion, 
cytoskeletal oganization and biogenesis and gliogenesis were also found to be 
over-represented in the three data sets, implicating that these processes are 
dependent on Runx2.
Other functional classes related to skeletal development, such as 
bone remodelling, ossification and biomineral formation, showed enrichment 
in calvaria and hindlimbs but not in forelimbs, while cartilage development 
and peptidyl proline modification were only enriched in calvaria and forelimbs. 
Particularly strong enrichment was further observed for collagen catabolism in 
calvaria, and collagen fibril organization in forelimbs. These data indicate that 
formation and processing of the collagenous matrix are Runx2-dependent 
processes.
Intriguingly, GO-terms that were enriched for differentially modulated 
genes only in calvaria and not in fore- and hindlimbs, included cell migration, 
cell motility, axon guidance, axonogenesis and glial cell differentiation 
(Fig. 1A), suggesting that either Runx2 has a cell autonomous function in 
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Fig. 1B
Figure 1, continued.
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cell migration, or that neuronal development is associated with calvaria 
development. Conversely, the fore- and hindlimb, but not the calvaria, data 
showed consistent enrichment for genes involved in gas transport, oxygen 
transport, muscle contraction and muscle development (Fig. 1B and 1C), 
which may relate to the observed lack of blood vessel formation during 
endochondral ossification in Runx2 (-/-) mice (39, 54). Together, the data 
indicate a distinct role for Runx2 during intramembranous and endochondral 
ossification.
  
Global analysis of differentially expressed genes
We next examined to what extent genes that were differentially 
expressed (p<0.01) in at least one of the three tissues, showed similar levels 
of modulation in calvaria, forelimbs and hindlimbs. Expression modulations 
of the three experiments were expressed as log-transformed ratios, and 
subsequently plotted against each other, in the following way: log(FL) versus 
log(CAL); log(HL) versus log(CAL); and log(FL) versus log(HL), whereby 
the linear regression coefficient (R) was used as a measure for expression 
similarity (figure 2). The best similarity was observed between log(FL) and 
log(HL) (R=0.503, Fig. 2C), while interestingly the similarity between log(HL) 
and log(CAL) (R=0.458, Fig. 2B) was markedly higher than between log(FL) 
Fig. 1C
Figure 1, continued.
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and log(CAL) (R=0.105, Fig. 2A). In spite of the low R-values, these results 
indicate that the differential gene expression in CAL is more comparable with 
that of HL than of FL. 
 A markedly increased correlation was observed when genes were 
selected that were significantly modulated (p<0.01) in all three experiments 
(Fig. 2D-F). In particular a strong correlation was obtained between log(HL) 
and log(CAL) (R = 0.910) and between log(FL) and log(HL) (R=0.938). 
Data-sets Enriched GO-terms
calvaria +
forelimbs +
hindlimbs
Cell adhesion; Cell organization and biogenesis; Organelle 
organization and biogenesis; Cytoskeleton organization 
and biogenesis;  Phosphate transport; Development; 
Gliogenesis; Skeletal development; Organ development
calvaria +
hindlimbs
Biomineral formation; Ossification; Bone remodelling
calvaria +
forelimbs
Cellular morphogenesis; Actin filament-based process; 
Actin cytoskeleton organization and biogenesis; 
4-Hydroxyproline metabolism; Peptidyl-proline 
hydroxylation to 4-hydroxy-L-proline; Peptidyl-
proline modification; Peptidyl-proline hydroxylation; 
Morphogenesis; Histogenesis; Cartilage development
forelimbs +
hindlimbs
Muscle contraction; Muscle development; Oxygen 
transport; Gas transport
calvaria Behaviour; Locomotory behaviour; Locomotion; Cell 
motility; Cell migration; Axon guidance; Activation 
of MAPKK activity; Cellular morphogenesis during 
differentiation; Axonogenesis; Regulation of 
axonogenesis; Glial cell  differentiation; Collagen 
catabolism; Organ morphogenesis; Odontogenesis; 
Odontogenesis (sensu Vertebrata); Positive regulation 
of development; Regulation of heart contraction rate; 
Antigen presentation\, exogenous antigen via MHC class 
II; Antigen processing; Antigen processing\, exogenous 
antigen via MHC class II
forelimbs Extracellular structure organization and biogenesis; 
Cartilage condensation; Collagen fibril organization; 
Extracellular matrix organization and biogenesis; 
Proteoglycan metabolism; Peptidyl-amino acid 
modification; Germ cell development
hindlimbs Cellular process; Cell communication; Phosphagen 
metabolism; Protein folding
Table 1. Significantly enriched GO-terms for each data-set
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Again, a better correlation between hindlimbs and calvaria was observed than 
between forelimbs and calvaria. Altogether, these results show that a large 
discrepancy exists in individual gene expression between forelimbs, hindlimbs 
and calvaria, reflecting the observation that distinct genes are modulated, 
while in addition genes can be differentially modulated between the three 
tissues (i.e. up- or downregulated). Runx2 thus modulates different sets of 
genes in forelimbs, hindlimbs and calvaria. However, a subset of genes can be 
identified of which expression modulation is controlled by Runx2 in a similar 
fashion during development of calvaria as well as limbs. 
Identification of genes downstream of Runx2 in calvaria and limbs
To identify the commonality between intramembranous and 
endochondral ossification we searched for genes that were similarly modulated 
(i.e. up- or downregulated) in calvaria and limb tissues. Table 2 lists the 
genes that were significantly (p<0.01) modulated in calvaria, forelimbs and 
hindlimbs. A total of 41 different genes were identified, including 35 known 
genes and 6 ESTs. 
A total of 22 genes and 3 ESTs showed downregulation in all three 
datasets. Among these are the well-known osteoblast expressed genes 
Ibsp (integrin binding sialoprotein), Spp1 (secreted phosphoprotein), Akp2 
(alkaline phosphatase), Runx2 itself and Dlx5 (distall-less homeobox 5). Five 
additional genes are known to be expressed in skeletal tissue: Matn4 (matrilin 
4) (46), Mmp9 (matrix metalloproteinase 9) (30), Col9a1 (procollagen, type 
IX, alpha 1) (2, 77), Scgf (stem cell growth factor) (37) and Agc1 (aggrecan) 
(34). Besides these 10 genes previously associated with skeletal development, 
we thus identified 15 genes with currently unknown expression and function 
in bone, which are putative in vivo target genes of Runx2. The putative role of 
some of these genes in bone development will be discussed below. 
Promoter analysis of genes commonly regulated in limbs and calvaria
The genes that are commonly regulated in limbs and calvaria may 
be either direct targets of Runx2 or associated with a common process 
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that is genetically downstream of Runx2. To investigate the possibility that 
genes are direct Runx2 targets we searched for Runx2 binding sites in their 
cognate promoter sequences. To this end, we calculated the frequencies of 
Runx2 binding sites in the promoters of the genes listed in table 2 and for 
comparison, the frequency of Runx2 binding sites in the genome. The results 
presented in figure 3 show that the promoters of the genes listed in table 
2 are enriched for specific Runx2 binding sites. Notably, the occurrence of 
a single motif showed enrichment near significance (p = 0.054) within the 
first 250 nucleotides upstream of the transcriptional start site. However, the 
data show strong enrichment of multiple motifs per promoter sequence. The 
most significant enrichment was found for the occurrence of four motifs per 
Figure 2.
Global gene expression similarity in calvaria, forelimbs and hindlimbs. Genes were 
selected if they were significantly modulated (p<0.01) in at least one data-set 
(A-C), or in all three data-sets (D-F). Log transformed expression ratios (Lograt) 
were plotted to determine similarity in Runx2-modulated gene expression between 
forelimbs and calvaria (A, D), hindlimbs and calvaria (B, E) and forelimbs and 
hindlimbs (C, F). Each spot represents a unique transcript. Linear regression was 
performed to calculate regression coefficients, which were used to compare gene 
expression behaviour among the different data-sets. Abbreviations : FL, forelimbs; 
HL, hindlimbs; CAL, calvaria.
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promoter (p = 0.0014). Eighteen out of the 25 genes analysed have at least 
one Runx2 binding site within these first 5000 nucleotides (table 2). Among 
these are the known Runx2 targets Ibsp (6, 41), Spp1 (64), Mmp9 (56) and 
Runx2 itself (27). The latter genes all have two or more Runx2 binding sites 
in their promoters. These data indicate that the promoters of the group of 
genes that are commonly regulated in calvaria and limbs are significantly 
enriched for multiple Runx2 binding motifs. Whether these promoters indeed 
bind Runx2 in vivo remains to be established.
Figure 3.
Enrichment of Runx2 binding sites in promoters of genes commonly downregulated 
in Runx2 (-/-) calvaria and limbs. The promoters of the 25 downregulated 
genes listed in table 2 were searched for the AACCACA Runx2 binding motif. 
For comparison, the occurrence of this motif in the genome was examined. The 
analysis was done for the occurrence of 1 to 5 motifs as a function of the length 
of the sequence upstream of the transcriptional start site of the gene. The p-value 
indicated on the y axis indicates whether the Runx2 binding motif was significantly 
enriched in the set of 25 genes in comparison to the genome. The figure shows that 
the occurrence of 1 motif is enriched near significance (p= 0.054) within the first 
250 basepairs upstream of the transcriptional start sites. The occurrence of 2, 3, 
4 and 5 motifs is significant within the first 2000, 2600, 3000 and 4200 basepairs, 
respectively (p-values 0.037, 0.035, 0.0014 and 0.018, respectively). There was no 
significant enrichment beyond 4200 basepairs or for >5 motifs (not shown). 
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Runx2-controlled gene expression during endochondral bone formation
Given that Runx2 controls chondrocyte maturation, we next aimed 
to identify genes whose expression modulation is particularly related to 
endochondral bone formation. We extracted genes of which expression 
modulation was significant in fore- and hindlimb data-sets (p<0.01), but 
not in calvaria (p>=0.01). This selection resulted in the recognition of 95 
distinct transcripts, of which 80 established genes and 15 ESTs (table 3). A 
subset of 31 genes was found to be downregulated in both FL and HL. This set 
included genes that are known to be expressed and to function in cartilage, 
such as Comp (cartilage oligomeric matrix protein) (53), Matn1 (matrilin 
1), Matn3 (matrilin 3) (22), Col9a3 (procollagen type IX, alpha 3) (13), 
Pcolce2 (procollagen C-endopeptidase enhancer 2) (71) and the regulator 
of chondrocyte differentiation Sox9 (SRY-box containing gene 9) (1). These 
results underscore the direct role of Runx2 during in vivo cartilage formation. 
Table 3. Genes significantly modulated in forelimbs and hindlimbs 
Probe ID
Fold 
Change
FL
Fold 
Change
HL
Gene Gene titel
FL↓
HL↓
1416298_at
1426921_at
1460734_at
1419527_at
1437810_a_at
1451527_at
1422148_at
1449614_s_at
1418477_at
1417348_at
1449005_at
1448145_at
1416810_at
1453089_at
1425195_a_at
1448486_at
1448716_at
1423271_at
1427323_s_at
1415871_at
1425993_a_at
1426529_a_at
1426600_at
1417427_at
1437621_x_at
1451538_at
1416939_at
1448685_at
1450621_a_at
1420842_at
1416335_at
-2.08
-1.88
-1.83
-1.81
-1.75
-1.73
-1.71
-1.42
-1.4
-1.31
-1.31
-1.29
-1.28
-1.25
-1.24
-1.22
-1.2
-1.18
-1.17
-1.17
-1.16
-1.16
-1.15
-1.13
-1.13
-1.11
-1.1
-1.1
-1.09
-1.09
-1.07
-1.55
-1.67
-1.19
-1.55
-1.51
-1.24
-1.29
-1.37
-1.29
-1.2
-1.22
-1.09
-1.2
-1.37
-1.18
-1.24
-1.28
-1.09
-1.19
-1.06
-1.12
-1.12
-1.2
-1.13
-1.09
-1.11
-1.14
-1.1
-1.22
-1.08
-1.05
Mmp9
Abcf1
Col9a3
Comp
Hbb-bh1
Pcolce2
Matn3
AI314976
Matn1
2310039H08Rik
Slc16a3
Wwp2
Mea1
3110079O15Rik
Acat2
Mut
Hba-x
Gjb2
D11Ertd498e
Tgfbi
Hsp105
Tagln2
Slc2a1
1500026D16Rik
---
Sox9
Pyp
2900010M23Rik
Hbb-y
Ptprf
Mif
matrix metalloproteinase 9
ATP-binding cassette, sub-family F (GCN20), member 1
procollagen, type IX, alpha 3
cartilage oligomeric matrix protein
hemoglobin Z, beta-like embryonic chain
procollagen C-endopeptidase enhancer 2
matrilin 3
expressed sequence AI314976
matrilin 1, cartilage matrix protein 1
RIKEN cDNA 2310039H08 gene
solute carrier family 16, member 3
WW domain containing E3 ubiquitin protein ligase 2
male enhanced antigen 1
RIKEN cDNA 3110079O15 gene
acetyl-Coenzyme A acetyltransferase 2
methylmalonyl-Coenzyme A mutase
hemoglobin X, alpha-like embryonic chain in Hba complex
gap junction membrane channel protein beta 2
DNA segment, Chr 11, ERATO Doi 498, expressed
transforming growth factor, beta induced
heat shock protein 105
transgelin 2
solute carrier family 2, member 1
RIKEN cDNA 1500026D16 gene
Similar to SERA_MOUSE D-3-phosphoglycerate dehydrogenase
SRY-box containing gene 9
pyrophosphatase
RIKEN cDNA 2900010M23 gene
hemoglobin Y, beta-like embryonic chain
protein tyrosine phosphatase, receptor type, F
macrophage migration inhibitory factor
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Probe ID
Fold 
Change
FL
Fold 
Change
HL
Gene Gene titel
FL↑
HL↑
1454713_s_at
1449456_a_at
1429379_at
1448730_at
1425145_at
1449347_a_at
1421344_a_at
1417426_at
1417614_at
1428455_at
1448117_at
1418511_at
1434975_x_at
1429159_at
1417889_at
1432466_a_at
1417552_at
1450430_at
1426387_x_at
1452141_a_at
1419442_at
1417466_at
1419186_a_at
1450883_a_at
1449368_at
1426938_at
1423584_at
1435493_at
1448995_at
1451204_at
1433916_at
1416203_at
1460409_at
1450333_a_at
1417962_s_at
1423547_at
1448228_at
1416211_a_at
1421840_at
1460666_a_at
1423091_a_at
1419663_at
1448823_at
1452398_at
1427040_at
1454735_at
1420884_at
1415723_at
1419584_at
1434620_s_at
1418892_at
1419273_at
1437401_at
1454708_at
1416405_at
1429514_at
1421917_at
1416805_at
1452143_at
1450839_at
1417818_at
1448392_at
1452197_at
1450641_at
2.86
2.54
1.81
1.79
1.64
1.51
1.49
1.48
1.42
1.33
1.31
1.29
1.28
1.27
1.26
1.25
1.25
1.25
1.24
1.24
1.23
1.22
1.22
1.21
1.21
1.21
1.2
1.2
1.17
1.17
1.17
1.16
1.16
1.16
1.16
1.16
1.16
1.16
1.15
1.14
1.14
1.14
1.13
1.13
1.12
1.11
1.11
1.1
1.1
1.1
1.1
1.09
1.09
1.08
1.08
1.08
1.08
1.08
1.08
1.07
1.07
1.07
1.07
1.07
2.54
1.71
1.53
1.43
1.48
1.61
1.41
1.3
1.53
1.22
1.31
1.26
1.41
1.25
1.49
1.19
1.18
1.19
1.34
1.17
1.24
1.28
1.21
1.22
1.12
1.31
1.14
1.14
1.13
1.18
1.17
1.17
1.16
1.13
1.14
1.18
1.16
1.19
1.15
1.13
1.14
1.17
1.07
1.11
1.11
1.24
1.23
1.07
1.17
1.12
1.09
1.1
1.13
1.12
1.08
1.07
1.12
1.11
1.09
1.07
1.09
1.08
1.07
1.07
Hdc
Mcpt5
Xlkd1
Cpa3
Il1rl1
Xlr4
Jub
Prg
Ckm
Col14a1
Kitl
Dpt
9030221M09Rik
4631408O11Rik
Apobec2
Apoe
Fap
Mrc1
9030221M09Rik
Sepp1
Matn2
Rgs5
Siat8d
Cd36
Dcn
Nova1
Igfbp7
5730453H04Rik
Cxcl4
4933425F03Rik
Vamp3
Aqp1
Cpt1a
Gata2
Ghr
Lyzs
Lox
Ptn
Abca1
Ebf3
Gpm6b
Ogn
Cxcl12
Plce1
Kdt1
Odf2
Sln
Eif5
AI428795
AW060714
Rhoj
C80913
Igf1
Ablim1
Bgn
Ppap2b
Pdgfra
1110032E23Rik
Spnb2
D0H4S114
2310058J06Rik
Sparc
Smc4l1
Vim
histidine decarboxylase
mast cell protease 5
extracellular link domain-containing 1
carboxypeptidase A3, mast cell
interleukin 1 receptor-like 1
X-linked lymphocyte-regulated 4
ajuba
proteoglycan, secretory granule
creatine kinase, muscle
procollagen, type XIV, alpha 1
kit ligand
dermatopontin
RIKEN cDNA 9030221M09 gene
RIKEN cDNA 4631408O11 gene
apolipoprotein B editing complex 2
apolipoprotein E
fibroblast activation protein
mannose receptor, C type 1
RIKEN cDNA 9030221M09 gene
selenoprotein P, plasma, 1
matrilin 2
regulator of G-protein signalling 5
sialyltransferase 8 (alpha-2, 8-sialyltransferase) D
CD36 antigen
decorin
neuro-oncological ventral antigen 1
insulin-like growth factor binding protein 7
RIKEN cDNA 5730453H04 gene
chemokine (C-X-C motif) ligand 4
RIKEN cDNA 4933425F03 gene
vesicle-associated membrane protein 3
aquaporin 1
carnitine palmitoyltransferase 1a, liver
GATA binding protein 2
growth hormone receptor
lysozyme
lysyl oxidase
pleiotrophin
ATP-binding cassette, sub-family A (ABC1), member 1
early B-cell factor 3
glycoprotein m6b
osteoglycin
chemokine (C-X-C motif) ligand 12
phospholipase C, epsilon 1
kidney cell line derived transcript 1
outer dense fiber of sperm tails 2
sarcolipin
eukaryotic translation initiation factor 5
expressed sequence AI428795
expressed sequence AW060714
ras homolog gene family, member J
expressed sequence C80913
insulin-like growth factor 1
actin-binding LIM protein 1
biglycan
phosphatidic acid phosphatase type 2B
platelet derived growth factor receptor, alpha polypeptide
RIKEN cDNA 1110032E23 gene
spectrin beta 2
DNA segment, human D4S114
RIKEN cDNA 2310058J06 gene
secreted acidic cysteine rich glycoprotein
SMC4 structural maintenance of chromosomes 4-like 1 (yeast)
Vimentin
Table 3. Continued
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Given the cellular heterogeneity of the endochondral bone it is well 
realized, however, that the genes presented here can be functional in other 
cell types than osteoblasts and chondrocytes. This is illustrated e.g. by the 
differential expression of Tagln2 (transgelin 2 or SM22β), which is known to 
be expressed in smooth muscle cells of the arteries, and has been detected 
in cartilaginous primordia during embryonic development, as well as in 
the periosteum during later development (89). Additionally, a number of 
genes encoding hemoglobins were found to be downregulated. Differential 
expression of these genes may reflect the lack of blood vessel invasion 
observed in cartilage of Runx2 (-/-) embryos (39, 54). 
Considering the up-regulated genes, the strongest modulations were 
observed for genes of which expression is related to mast cell development, 
such as Hdc (histidine decarboxylase), Mcpt5 (mast cell protease 5), Cpa3 
(carboxypeptidase A3) and Kitl (Kit ligand). This possibility of ectopic mast 
cell gene expression in Runx2 (-/-) mice will be discussed below.  
Validation of microarray data by real time RT-PCR
 The modulation of genes that are suggestive for ectopic mast cell 
gene expression in Runx2 (-/-) mice, and the enrichment for genes related 
to axon guidance and glial cell differentiation, are indicative for previously 
unrecognized functions of Runx2. To validate the microarray data, quantitative 
RT-PCR (Q-PCR) for genes of these particular processes was carried out on 
the calvaria, forelimb and hindlimb RNA samples (Fig. 4). In addition, the 
expression of the Runx2 target gene Spp1 and of the cartilage-associated 
gene Comp was analysed. As can be seen in figure 4, the Runx2 target gene 
Spp1 was downregulated in calvaria, forelimbs and hindlimbs, and similar 
to the microarray data the strongest modulation was observed in calvaria. 
As expected, expression of the cartilage associated gene Comp was higher 
in limbs than in calvaria (Fig. 4). In agreement with the microarray data, 
expression of Comp was lower in knockout limb samples than in wild-type 
samples. Expression modulation of Slit2 (slit homolog 2) and Reln (reelin) 
was examined since these genes contributed to the enrichment of the GO-
terms axon guidance and glial cell differentiation respectively. The gene 
Reln showed significant upregulation in forelimbs, hindlimbs and calvaria on 
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microarray, which could be confirmed by PCR in the forelimbs and calvaria. 
The modulation on microarray was 1.27 and 1.53 in forelimbs and calvaria 
respectively. In the PCR, Reln showed a 1.7 and a 1.5 fold induction in 
forelimbs and calvaria. For Slit2 a 1.6 fold increase was measured by PCR 
in knockout calvaria in comparison to wild-type. On microarray, Slit2 was 
1.28 fold upregulated in knockout calvaria, while no significant regulation 
was observed in the limbs. To confirm the induction of mast cell related gene 
expression in Runx2 (-/-) embryos, we analyzed expression of Hdc and Mcpt7. 
A very strong upregulation in the knockout samples was observed for Mcpt7. 
Similarly, Hdc showed significant higher expression in the knockout forelimbs 
and hindlimbs in comparison to wild-type, while no significant difference was 
observed for Hdc expression in calvaria. These data are thus in agreement 
with the microarray data, implying that expression of mast cell genes are 
induced in Runx2 (-/-) embryos. Together, these data confirm that Runx2 
ablation leads to altered expression of genes related to mast cells and axon 
guidance. 
Figure 4.
Validation of gene expression 
by quantitative RT-PCR. Gene 
expression levels of selected 
genes were determined by 
real-time PCR in RNA samples 
of forelimbs (FL), hindlimbs 
(HL) and calvaria (CAL) of 
wild-type (WT) and Runx2 
(-/-) mice (KO) that were 
also used for microarray 
analysis. Measurements were 
performed in triplicate, after 
which the calculated mean 
expression was corrected 
for Gapdh expression levels. 
Error bars indicate standard 
deviations. 
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DISCUSSION
In the present study we performed microarray expression analysis 
on  a mutant mouse model to analyze gene expression modulations during 
intramembranous and endochondral bone development. Expression analysis 
of 22,625 gene probes in bone tissue of wild-type and Runx2 (-/-) murine 
embryos resulted in the recognition of 1277, 606 and 492 genes respectively 
that were differentially modulated by Runx2 in calvaria, forelimbs and 
hindlimb. Subsets of genes were identified that were regulated by Runx2 
during both intramembranous and endochondral ossification, or specifically 
only during endochondral bone formation. Our results demonstrate that 
comparative genome-wide expression analysis of wild-type and mutant mouse 
models enables the identification of specific gene expression patterns during 
complex developmental processes such as bone development. Moreover, by 
GO annotation analysis we identified multiple processes that are affected by 
Runx2 deficiency, but that have so far escaped attention during phenotype 
analysis. 
Our data indicate that Runx2 plays distinct roles during 
intramembranous and endochondral ossification. In particular, the calvaria 
data were found to be enriched for genes with a presumptive function in 
cell migration, a result not observed in fore- or hindlimbs. According to GO 
annotation, a group of 14 genes belonged to this functional classes, of which 
the following 8 genes were downregulated in Runx2 (-/-) calvaria: Alcam 
(activated leukocyte cell adhesion molecule), Bmp7 (bone morphogenetic 
protein 7), Cap1 (CAP adenylate-associated protein 1), Cdh2 (cadherin2), 
Foxd1 (forkhead box D1), Cxcl12 (chemokine (C-X-C motif) ligand 12), 
Sema3a (semaphorin 3A) and Rtn4 (reticulon 4), while the following 6 genes 
were upregulated: Cdh4 (cadherin 4), Lama1 (laminin alpha 1), Reln (reelin), 
Slit2 (slit homolog 2), Tie1 (tyrosine kinase receptor 1) and Tns1 (tensin 1). 
Of these genes, expression and a function during osteoblast differentiation 
or bone development had already been published for Alcam (18), Bmp7, 
Cap1 (8), Cdh 2, Cdh 4 (20), Cxcl12 (65) and Sema3a (78). The precise 
role of these genes in calvaria development remains to be established, but 
it is reasonable to assume that these genes function in Runx2-controlled 
migration of mesenchymal cells during formation of the calvaria, since Runx2 
increases cell migration of C3H10T1/2 and MC3T3 immature osteoblast in 
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culture (32). 
Alternatively the products of these migration genes may participate in 
the recruitment of other cell types to the bone microenvironment, as has been 
demonstrated for Cxcl12 which acts as a chemotactic molecule for osteoclasts 
(85). The GO-terms axonogenesis and axon guidance are also overrepresented 
in the calvaria data-set, and some of the identified cell migration genes are 
also known to play a role in axon guidance, including Alcam, Bmp7, Cdh4, 
Foxd1, Sema3a and Slit2. In particular the membrane-associated secreted 
molecule Sema3a is expressed in both osteoblasts and osteoclasts during rat 
development, and is as such involved in the formation of synapses between 
bone cells and axons (78, 84). Our data showed enrichment for the GO-class 
gliogenesis in calvaria, forelimbs and hindlimbs. Regulation of glia cell related 
genes by Runx2 has also been observed in a microarray experiment on 
human dental pulp cells of cleidocranial dysplasia (CCD) patients, a disease 
associated with RUNX2 mutations (19). Moreover, the GO-class gliogenesis 
contains the gene Reln which showed consistent upregulation in Runx2 (-/-) 
calvaria, forelimbs and hindlimbs. Mutational analysis in mice has shown 
that the extracellular matrix protein reelin affects neuronal migration outside 
the brain by forming a barrier for neuronal migration, with the result that 
reelin is absent from regions where neurons are present (86). In addition 
to the upregulation of Reln expression in knockout tissue, we observed an 
upregulation of the Slit2 transcript. The product of this gene has a repulsive 
function in axon guidance (16). Together, these data indicate that genes 
involved in neuronal migration are genetically downstream of Runx2, 
although this regulation is likely to be indirect, involving for instance a cross-
talk between differentiating osteoblasts and adjacent non-skeletal cells. This 
observation fits with the knowledge that bone is an innervated tissue (66) and 
that bone mass is under control of the sympathetic nervous system (25, 29, 
76). On the basis of our data it is tempting to speculate that Runx2 controls 
signals that are necessary for proper innervation of bone tissue. 
Our microarray studies on gene expression during endochondral 
bone formation were carried out on whole limbs, of which the skeletal tissue 
constitutes only a small fraction. The observation that osteoblast genes, 
such as Ibsp and Spp1, are strongly downregulated in limbs of Runx2 (-/-) 
mice, indicates that the microarray data primarily detect gene expression 
modulations in skeletal cells. This agrees with the observation that in contrast 
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to the skeletal elements, the soft tissues in limbs of Runx2 (-/-) mice do not 
show a phenotype (47, 54). We therefore hypothesize that the processes that 
are affected in these knock-out limbs according to the GO analysis, reflect the 
effects of altered skeletal cells on other cellular processes in these tissues. 
Endochondral ossification of long bones is controlled by chondrocytes 
and osteoblasts, and development of both cell types is controlled by Runx2. 
A subset of 97 genes appeared to be significantly modulated in forelimbs and 
hindlimbs, but not in calvaria. Since the common genes downstream of Runx2 
were subtracted by excluding genes that were also significantly modulated 
in calvaria, these data represent genes that are specific for endochondral 
bone development. The genes that were downregulated in both forelimbs 
and hindlimbs of the knock-out mice, were predominantly associated with 
cartilage formation, but were also related to blood vessel development. This 
observation agrees with our current knowledge that blood vessel invasion in 
the cartilage matrix is essential for subsequent bone formation. Runx2 has 
been shown to induce Vegf (vascular endothelial growth factor) expression in 
vitro, and Runx2 (-/-) mice lack Vegf expression in hypertrophic cartilage (87). 
The data are thus representative for indirect processes that are controlled by 
Runx2 during endochondral bone formation.
 Typically, the genes that were most strongly upregulated in forelimbs 
and hindlimbs of Runx2 (-/-) mice are related to mast cells, such as Mcpt5 
(mast cell protease 5), Hdc (histidine decarboxylase), Cpa3 (carboxypeptidase 
A3) and Kitl (Kit ligand or stem cell factor). Similarly, Mcpt6 (mast cell 
protease 6) and Mcpt7 (mast cell protease 7) were also strongly up-regulated 
in calvaria (table 2). An explanation for these results could be that ectopic 
mast cell formation occurs in Runx2 (-/-) mice. Mcpt5 (50), Mcpt6 (59) and 
Mcpt7 (51) have been described to be expressed in immature bone marrow-
derived mast cells. A functional relationship between bone remodelling and 
mast cells is indicated by the observation that an absence of mast cells leads 
to lower rates of bone matrix formation in mice (69). Furthermore, mast 
cells are induced in hyperparathyroid bone as a result of increased Kitl levels 
in osteoblasts (10, 11). Kitl is a hematopoietic growth factor that induces 
development of mast cells from bone marrow cells (42, 82), but has also 
been shown to promote multinucleated osteoclast differentiation in vitro (23, 
83). The effect of Kitl on preosteoclasts is supposed to be dependent on cell 
contact-dependent interaction with Kitl-expressing osteoblasts (33). It can 
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be speculated that the described absence of osteoclasts in Runx2 (-/-) mice 
results from a Kitl-induced differentiation of common precursor cells into mast 
cells. The induced expression of mast cell genes in Runx2 (-/-) mice indicates 
that genes identified in this study may be indirectly regulated by Runx2, such 
that their expression regulation is dependent on the presence of functional 
osteoblasts.  
In addition to the description of Runx2-mediated processes, novel in 
vivo genes downstream of Runx2 were identified which were downregulated in 
Runx2 (-/-) calvaria, forelimbs and hindlimbs. The consistent downregulation 
in all three different tissues strongly suggests that these genes are common 
Runx2-controlled genes that can be regulated either directly or indirectly 
by Runx2. Out of the 22 genes thus identified, 12 had not previously been 
associated with expression or function in bone. Among the 12 genes identified 
are the intracellular signalling molecules Snf1lk, Pim1 and Satb2. The serine/
threonine kinase Snf1lk (Snf1 like kinase) has been shown to be expressed 
during cardiogenesis (61) where it is supposed to play a role in cell cycle 
control (72).The proto-oncogene Pim1 (proviral integration site 1) encodes a 
serine/threonine kinase (62) that is involved in proliferation of hematopoietic 
cells (7, 52) and vascular smooth muscle cells (43). Mice lacking functional 
Pim1 have reduced body size (52), but a bone phenotype in these mice has not 
been studied. Pim1 expression in osteoblasts has not been described to date, 
but its expression has been shown in lymphoma cells where it acts in synergy 
with Runx2 (12). Based on the observation that 10 of the identified 22 Runx2-
induced genes are expressed during bone cell development, we propose that 
also Pim1 and Snf1lk are involved in osteoblast proliferation. However, since 
no Runx2 binding site was found in the Snf1lk promoter, control of Snf1lk by 
Runx2 is likely to be indirect. The transcription factor gene Satb2 is expressed 
in neurons (14) and pre-B cells (24). Haploinsufficiency of SATB2 has been 
shown to cause a cleft palate in humans and murine Satb2 is expressed in 
mesenchyme of the developing palate (31), which is indicative for a functional 
role of Satb2 in development of mesenchymal tissues. The consistent 
downregulation of these genes in both intramembranous and endochondral 
bone of Runx2 (-/-) embryos implies that they might be important regulators 
in the formation of skeletal elements. 
In a study by Stock et al. (74), 15 putative Runx2 target genes were 
identified by microarray analysis in C3H10T1/2 cells. A number of these genes 
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was found to be modulated in our data. In the Stock study, Mglap (matrix 
gamma-carboxyglutamate protein) and Postn (periostin) were identified as 
positively regulated by Runx2, which is in agreement with our observation 
that these genes were down-regulated in Runx2 (-/-) calvaria. Furthermore, 
Fbln5 (fibulin 5) was identified as a negative target of Runx2, which was 
significantly upregulated in the calvaria in our experiments. This difference 
may arise from the different models and experimental schemes that were 
used. In our study, gene expression was studied on the organismal level. It can 
be expected that many of the genes identified are related to developmental 
processes that are dependent on proper osteoblast differentiation and whose 
expression is regulated for instance by Runx2-dependent factors that are 
secreted by differentiating osteoblasts. 
 In summary, the present study shows that genome-wide expression 
analysis of mutant mouse models has great potency in understanding gene 
function during development and organogenesis. We observed novel gene 
expression downstream of Runx2 and functional properties of Runx2 in 
vivo that are relevant for the process of skeletal development. The results 
presented may contribute to better knowledge of the complex role that Runx2 
has during skeletogenesis and embryonic development. 
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ABSTRACT
Runx2 is a key transcription factor during bone development and 
mice lacking functional Runx2 are characterized by an absence of mature 
osteoblasts. Although Runx2 target genes have been identified, the exact 
mechanisms by which Runx2 controls osteoblast differentiation in vivo 
are poorly understood. In this study, we analyzed Runx2-controlled gene 
expression on a genomic scale during embryonic bone development. Gene 
expression levels were compared between developing calvaria of wild-type 
and Runx2 (-/-) embryos at gestational stage 14.5 dpc. Microarray analyses 
indicated that ablation of Runx2 expression leads to reduced expression of 
well-known osteoblast markers and of a large set of genes that have previously 
not been associated with calvaria development. Expression of genes encoding 
the homeobox proteins Dlx5 and Msx2 was reduced in Runx2 (-/-) calvaria. 
In situ hybridization experiments suggested that Runx2 is part of a feed-
forward loop that leads to an increased number of cells expressing Msx2 in 
the calvaria. Surprisingly, genes encoding typical keratinocyte genes, such as 
loricrin and keratins, were found to be strongly downregulated in Runx2 (-/-) 
mice. Since the skin layer adjacent to calvaria was included for the microarray 
analyses, these observations suggest that skin development is impaired in 
Runx2 (-/-) embryos. Together, our data provide a comprehensive overview 
of genes downstream of Runx2 in the developing calvaria. Furthermore, they 
suggest that formation of the skeletal mesenchyme and induction of osteoblast 
differentiation is a prerequisite for proper development of skin tissue. 
INTRODUCTION
A major challenge in developmental biology is to correlate modifications 
of genome-wide gene expression with developmental processes in vivo. 
Although candidate gene approaches have resulted in the identification of 
major factors that control patterning or cell differentiation processes, a full 
understanding of the more complex changes associated with fundamental 
multicellular processes such as organogenesis requires more global and 
systematic analyses in vivo. The combination of large scale gene expression 
profiling by microarray analysis with mouse genetics is a a powerful approach 
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to understand such in vivo processes.
Ossification of the developing calvaria is controlled by the transcription 
factor Runx2. Inactivation of Runx2 in mice leads to an arrest of osteoblast 
differentiation at an early stage of skeletogenesis, and as a result a complete 
lack of mineralized bone in newborn mice (23, 36). Both in mice and human, 
Runx2 haploinsufficiency causes cleidocranial dysplasia (CCD), a syndrome 
with impaired ossification, agenesis of the clavicle and delayed closure of 
the fontanelles (24, 34). The existence of such a haploinsufficient phenotype 
emphasizes the key role that Runx2 is playing during osteoblast differentiation. 
It also validates the use of murine models to study relevant mechanisms of 
human bone physiology and pathology. Moreover, Runx2 has also been shown 
to regulate postnatal osteoblast function, i.e. bone matrix deposition (14). 
This function is carried out in part by controlling the expression of structural 
genes that mark the osteoblast phenotype such as Col1a1 (procollagen type 
I, alpha 1) Bglap1 (bone gamma carboxyglutamate protein 1, or osteocalcin), 
Ibsp (integrin binding sialoprotein, or bone sialoprotein) and Spp1 (secreted 
phosphoprotein 1, or osteopontin) (14, 15, 21). Given the role of Runx2 in 
bone development and homeostasis, genes controlled by Runx2 might be 
interesting candidates for novel therapeutics to target bone-related disorders 
such as osteoporosis.
The purpose of the present study was to explore in vivo gene 
expression patterns during early steps of skeletogenesis, with the aim of better 
understanding the molecular events controlling osteoblast differentiation and 
thereby bone formation. Considering that Runx2 is the earliest known specific 
determinant of osteoblast differentiation, we reasoned that its function 
triggers directly or indirectly a genetic program that initiates the early 
steps of osteoblast commitment and differentiation. In order to identify the 
components of this genetic program, we compared gene expression profiles 
on a genome-wide scale of skeletal tissues from wild-type and of Runx2 (-/-) 
embryos. In chapter 6 of this thesis, it has been shown by comparing gene 
expression data obtained from limbs and calvaria that such an approach 
can lead to the recognition of putative novel Runx2 targets genes. Here, 
we further analyzed the function of Runx2 in developing bone, by focussing 
on genes that are strongly downregulated in the knockout mice. Using this 
approach we identified in this study a set of new bone markers, but in addition 
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genes that are known to play a role in the development of the epidermis. 
MATERIALS AND METHODS
Collection of tissue material
Animals with a disrupted Runx2 function as a result of an insertion 
of a LacZ-neo cassette into the third exon of the Runx2 gene have been 
described previously (36). Runx2 (-/-) mice die immediately after birth, and 
therefore wild-type and mutant embryos were obtained from mating Runx2 
(+/-) animals. In the morning, vaginal plugs were determined as evidence 
for mating. Females with a plug were separated from males and embryos 
collected from pregnant females at embryonic day 14.5 (0.5 is midday of the 
day of observation of a vaginal plug). Dissection of embryos was carried out in 
cold sterile phosphate-buffered saline (PBS, Gibco). After dissection, calvaria 
were snap frozen in a 24-well plate precooled on dry ice, and subsequently 
stored at -80ºC. Genomic DNA was isolated from brain or yolk sac for PCR 
genotyping in order to identify wild-type and Runx2 (-/-) calvaria. 
RNA isolation
A total of 31 wild-type calvaria and 39 calvaria from knock-out animals 
were separately pooled in 1 ml of TRIzol (Invitrogen) and homogenized using 
a Ultra-Turrax homogenizer (T25 basic, IKA-Werke). After incubation for 5 
min at room temperature, the mixture was transferred into an Eppendorf tube 
which was centrifuged at 12000 rpm for 10 min at 4ºC to remove debris. The 
supernatant was transferred into a fresh tube and extracted with chloroform, 
after which RNA was precipitated by addition of sodium acetate 0.8M / NaCl 
1.2M and isopropanol and after air drying dissolved in 50 μl of DEPC-treated 
H2O.
Microarray processing and data analysis
Before amplification and labelling, the quality of total RNA was 
evaluated by capillary electrophoresis by using an Agilent 2100 Bioanalyzer 
(Agilent Technologies,). Double-stranded cDNA was synthesized from 5 μg 
total RNA preparation using the SUPERSCRIPT™ II system (Invitrogen) in 
combination with a T7(dT)24 cDNA Primer (Ambion). The double-stranded 
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cDNA was used as a template for the preparation of biotin-labelled cRNA 
using the BioArray High Yield RNA Transcript Labelling Kit (Enzo Diagnostics). 
Subsequently, 10 µg of biotin-labelled cRNA were hybridized to the MOE430A 
Array (Affymetrix), washed, and stained with phycoerythrin-streptavidin 
conjugate (Molecular Probes), after which the signals were amplified by 
staining the array with biotin-labelled anti-streptavidin antibodies (Vector 
Laboratories) and subsequently phycoerythrin-streptavidin. The arrays were 
laser scanned with an Agilent GeneArray Laser Scanner 2500 according to 
the manufacturer’s instructions. Data were saved as raw image file and 
quantified using Microarray Suite 5.0 software (Affymetrix). Normalization 
and statistical analysis of the data was performed using Rosetta Resolver 
Version 3.2 (Rosetta Biosoftware). Normalization of the data was carried out 
using the error model developed for Affymetrix GeneChips.. From both the 
wild-type and the Runx2 (-/-) calvaria samples four replicate arrays were 
hybridized. 
In situ hybridization
For in situ hybridization, embryos were dissected from the uterus, 
and fixed overnight in 4% paraformaldehyde/PBS at 4ºC. Subsequently, 
specimens were dehydrated using ethanol and xylene, embedded in paraffin 
and sectioned (5 μm) onto coated slides. The slides were dewaxed, rehydrated, 
and subsequently pre-treated with Proteinase K and acetic anhydride after 
which they were hybridized overnight at 50ºC in a humidified chamber. In 
situ hybridization was performed using 35S-riboprobes (Amersham). Labelled 
antisense probes were generated by transcription with T7 or T3 polymerase. 
After hybridization, the slides were washed at 63ºC, followed by RNase 
treatment at 37ºC and a final wash at 63ºC. Autoradiography was performed 
using NTB-2 photo emulsion (Kodak). Slides were exposed at 4ºC and after 
development treated with Hoechst 33258 staining.
Cell culture and transfection assays
 Promoter regions covering approximately 2 kb of the proximal 
promoters of murine Msx1, Msx2, Dlx5 and Osx were obtained as PCR 
products from mouse genomic DNA and cloned into the pGL2basic 
promoterless luciferase expression vector (Clontech). Subsequently, deletion 
constructs were generated by digestions and religation reactions. COS cells 
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and C3H10T1/2 cells were cultured in DMEM/10% fetal bovine serum (FBS) 
(Invitrogen). Transfections in these cells were carried out using Lipofectamin 
Plus (Invitrogen) according to the manufacturer’s instructions. The day prior 
to transfection, 3x105 cells per well were seeded in 6 well plates in serum-free 
DMEM medium (Invitrogen). Per well, a total of 750 ng of plasmid were used. 
To normalize transfection efficiency, an equal amount of pSV/β-galactosidase 
plasmid was added to each DNA mix. One day after transfection, the medium 
was replaced by DMEM/10% FBS. Cell lysates were harvested 48 hours 
after transfection for use in luciferase and β-galactosidase assays. Cells 
were therefore washed twice with cold PBS, lysed by three cycles of freeze-
thawing and harvested by scraping them in 120 μl of Tris 0.25M pH 7.8, after 
which the lysate was centrifuged to pellet debris. To normalize transfection 
efficiency between experiments, ß-galactosidase activity was determined in a 
colorimetric enzyme assay using resorufin ß-galactopyranoside (Sigma) as a 
substrate. Luciferase activity was determined by using D-luciferin sodium salt 
(BD Pharmingen) in 100 mM Tris-HCl pH 7.8, 15 mM MgSO4, 5 mM ATP and 1 
mM dithiothreitol. Transfections were performed in triplicate.
 C2C12 cells were maintained in alpha-MEM (BioWhittaker) 
supplemented with 10% bovine calf serum (Hyclone) and seeded at a density 
of 2.6x104 cells per cm2 one day before transfection. Cells were transfected 
with pRunx2 or pCDNA3.1 plasmids using lipofectamin 2000 (Invitrogen) 
according to the manufacturer’s instructions. RNA was extracted 24 hours 
after transfection by means of TRIzol. After DNAse treatment of the RNA, 
cDNA was synthesized and subsequently used for SYBR Green® PCR analysis 
as described previously (41).
Immunofluorescence
 Primary antibodies used for immunofluorescence were rabbit anti-
loricrin and guinea pig anti-K14 (22). Secondary antibodies used were 
Alexa-conjugated fluorochromes 594 goat anti-guinea pig or 488 goat anti-
rabbit. Sections of paraffin-embedded samples were deparaffinized in xylene, 
rehydrated, and washed in PBS. After antigen retrieval, tissue sections were 
incubated with the primary antibody in PBS/BSA overnight at 4ºC. After three 
washes with PBS, the sections were incubated with secondary antibodies in 
BSA/PBS for 1 hour at room temperature. Subsequently, the sections were 
washed, air dried and mounted. 
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RESULTS
Microarray analysis of developing calvaria
To study the role of Runx2 in developing calvaria, a microarray 
analysis was carried out on calvaria derived from wild type (WT) and Runx2 
(-/-) (KO) embryos. Calvaria, including the overlaying skin, were isolated 
from 14.5 dpc embryos since it has been shown that at this stage Runx2 
acts as a transcriptional activator of Ibsp (5). Differential gene expression 
between WT and KO calvaria was determined by using Affymetrix MOE430A 
oligonucleotide arrays that represent 22,625 unique transcripts. To minimize 
variation in sampling, thirty one WT and thirty nine KO specimen were pooled. 
.In order to reduce measurement error, all hybridizations were performed 
with four replicate arrays.
By comparing WT expression values with KO values, a total number 
of 1277 transcripts was found to be significantly modulated (p<0.01), of 
which 531 transcripts showed lower expression values in KO tissue than in 
WT tissue (downregulated transcripts), while 746 transcripts that showed 
higher expression levels in the KO than in the WT calvaria (upregulated 
transcripts). Of these 1277 regulated genes, a subset of 42 genes (38 known 
genes and 4 ESTs) showed more than 1.6 fold expression modulation with 
very high significance (p<10-6). Of these genes, 26 were downregulated and 
16 upregulated in calvaria of KO mice (see Table 1).
 Among the 26 strongly downregulated genes in Table 1A, 12 are 
already known to have a function in bone or at least to be expressed in 
osteoblasts, namely Ibsp (bone sialoprotein), Spp1 (osteopontin), Akp2 
(alkaline phosphatase), Calca (calcitonin alpha), Mglap (matrix gla protein), 
Msx1, Msx2 and Dlx5, Matn4 (matrilin 4), Scgf (stem cell growth factor), 
Tnc (tenascin C) and Ptprv (protein tyrosine phosphatase receptor type V). 
At least two of these genes (Ibsp and Spp1) have previously been identified 
as direct transcriptional targets of Runx2 (14, 15, 37), a result that validates 
our current approach. In addition to the known bone markers, our analysis 
thus revealed genes downstream of Runx2 that have not previously been 
associated with ossification.
The downregulation of the homeobox genes Msx1 and Msx2 in the 
Runx2 (-/-) calvaria is surprising. Msx2 is believed to control transition of 
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undifferentiated mesenchyme stem cells into Runx2 expressing mesenchymal 
cells and to be important for maintenance of proliferating osteoblast 
progenitors (19, 29). Expression of Msx2 in the developing skull therefore 
precedes Runx2 expression (1, 19), and Runx2 levels have been shown 
to be downregulated in skull bone of Msx2 (-/-) mice (19, 38), as well as 
dental mesenchyme of Msx1 (-/-) mice (43). Therefore, these genes can 
be considered to act genetically upstream of Runx2. The decreased Msx1 
and Msx2 expression observed in Runx2 (-/-) calvaria suggests that Runx2 
is part of a feed-forward loop that sustains osteogenic differentiation in the 
developing calvaria.
Validation of differential expression of osteoblast transcription factors
To validate the observed downregulation of Msx2 in Runx2 (-/-) 
calvaria, expression of Msx2 was analyzed in the developing skull of WT 
and KO embryos by means of in situ hybridization (Fig.1). For comparison, 
expression of Runx2 and Osx (osterix) was analyzed in parallel, which on 
microarray were found to be downregulated by 1.53 and 1.4 fold respectively. 
Osterix has previously been shown to be a marker for osteoblast commitment 
and its expression in developing bone is downstream of Runx2 (35). 
Consistent with the microarray data, Runx2 mRNA levels were 
considerably higher in the skull of the WT embryo than in the Runx2 (-/-) 
embryo at 14.5 dpc, although no complete repression was observed in the 
latter animals (Fig. 1A). The Runx2 knockout resulted from insertion of a lacZ 
cassette in the coding region of the Runx2 gene, generating a transcribed but 
non-functional allele (36). The observed downregulation is in agreement with 
a positive autoregulatory effect of Runx2 as a result of the high affinity of 
Runx2 for its own promoter, as previously described (14). 
As an indication for impaired osteoblast differentiation, Osx expression 
was analyzed in wild-type and Runx2 (-/-) calvaria at stages 14.5 and 16.5 
dpc. Figure 1B shows that Osx was strongly expressed in the developing 
calvaria of the WT (Figs. 1Ba and 1Bc), while expression was completely 
absent in the calvaria of Runx2 (-/-) mice (Figs. 1Bb and 1Bd). 
The in situ hybridization data presented in Fig.1C show that Msx2 
levels were strongly reduced in Runx2 (-/-) calvaria, in agreement with the 
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microarray data. Although expression was strongly reduced in comparison 
to wild-type, weak Msx2 expression could still be detected in the knockout 
animals (Fig. 1Cb, 1Cd and 1Cf). Higher order magnifications of the calvaria 
at 14.5 dpc showed that the bone-forming mesenchymal cell layer in which 
Msx2 is expressed, is less organized in Runx2 (-/-) mice than in wild-type 
(Figs. 1Cd and 1Cd). Notably, the KO calvaria contained less Msx2 expressing 
cells than WT calvaria. This suggests that Msx2-induced expression of 
Runx2 underlies expansion of Msx2-expressing cells. In combination with 
the observed autoregulation of Runx2, the data on Msx2 expression support 
the model that Runx2 is part of a feed forward loop that controls osteoblast 
expansion in the developing calvaria. 
Figure 1.
Analysis of mRNA expression of osteoblast transcription factors in wild-type and 
Runx2 (-/-) calvaria by means of in situ hybridization. 
(A-C): Frontal sections through the head of embryos at stage 14.5 and 16.5 dpc 
showing expression of Runx2 (A), Osx (B) and Msx2 (C). Figures 1Cc and 1Cd are 
higher magnifications of 1Ca and 1Cb respectively. (For full colour figure, see page 
247).
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Runx2 has been shown to bind and activate its own promoter (14) 
which explains the observed downregulation in the calvaria. In order to test 
if Msx1, Msx2, Dlx5 and Osx are also direct Runx2 target genes, we carried 
out DNA transfection experiments using proximal promoter fragments of 
these genes cloned in front of a luciferase gene. These promoter sequences 
each contained a putative Runx2 binding site with core sequence similarity to 
ACCAC (Fig. 2A). 
The constructs were cotransfected with an expression vector for Runx2 or 
an empty control vector in COS or C3H10T1/2 cells. Using the optimized 
Osteocalcin promoter fragment p116/luc (13) as a positive control, we 
observed a two-fold induction of luciferase activity by Runx2, indicating that 
Runx2 is indeed able to activate target genes in COS cells after transfection 
(Fig. 2B). In contrast, no reproducible induction of luciferase activity was 
measured in this assay when using the various constructs for Msx1, Msx2, 
Dlx5 or Osx (Fig. 2B). Similar results were obtained in murine C3H10T1/2 
fibroblasts (not shown). These data show that under the conditions tested 
Runx2 expression is not sufficient to activate the promoter fragments of 
these genes. Subsequently we tested whether the endogenous expression 
levels of Bglap1, Msx1, Msx2, Dlx5 and Osx could be upregulated by transient 
transfection of C2C12 cells with a Runx2 expression vector. 
Figure 2C shows that based on quantitative real-time PCR (RT-PCR) analysis 
transfection of Runx2 resulted in a five-fold increase of Bglap1 mRNA levels, 
but no effects were observed on Msx1, Msx2 or Osx expression. Expression of 
Dlx5 could not be measured above background levels in C2C12. Together with 
the microarray and in situ data, the results suggest that Msx1, Msx2 and Osx 
are only indirect target genes of Runx2 in developing calvaria.
Differential expression of skin-related genes
A remarkable result of the microarray data is the observation that 
besides genes related to bone development, also genes involved in epidermal 
development are differentially regulated in Runx2 (-/-) mice. In comparison, 
out of the 42 of the genes listed in Table 1, 14 are related to skeletal 
development, but at least an additional 11 of them have been described 
in literature to be expressed or to function in skin-related cell types such 
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B C
Figure 2.
Analysis of Runx2-induced gene expression
A: Generation of Msx1, Msx2, Dlx5 and Osx promoter 
constructs. Promoter fragments were cloned into a 
promoterless pGL2-expression vector. Putative Runx2 
binding sites with core sequence similarity to ACACC 
were identified and indicated as R1-R5. Subsequently, 
deletion constructs were cloned by digestion and 
religation by using the restriction sites as indicated. 
B: Analysis of Runx2-induced promoter activity. Different 
promoter-luciferase constructs were cotransfected 
with Runx2 expression vector (pRunx2 grey bars) 
or pCDNA3.1 control vector (white bars) and β-
galactosidase expression vector in COS cells (p116/luc, 
Msx1, Msx2 and Dlx5) or C3H10T1/2 (Osx) as described 
in Materials and Methods. Cells were transfected with 
reporter construct (250 ng), pRunx2 (350 ng) and 
pSV/β-galactosidase (50 ng). Induced activity of the 
Ocn (osteocalcin) promoter (p116/luc) was used as a 
positive control. Luciferase and β-galactosidase activity 
were determined 48 hours after transfection. Luciferase 
activity was normalized for β-galactosidase activity. 
Transfections were performed in triplicate and values 
were averaged after normalization. 
C: Analysis of Runx2-induced gene expression in C2C12 
cells by means of RT-PCR. Gene expression levels 
were determined 24 hours after transfection in cells 
transfected with pRunx2 (grey bars), or in control cells 
that were either transfected with empty pCDN3.1 vector 
or left untreated (white bars). Gene expression levels 
were normalized for Gapdh expression. 
A
Msx1
Msx2
Dlx5
Osx
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as keratinocytes and dermal fibroblasts (see table 1, A and B). Typically, 
expression of Lor (loricrin), Krt2-1 (keratin complex 2, basic, gene  1) and 
Krt1-10 (keratin complex 1, acidic, gene 10) is restricted to terminally 
differentiating keratinocytes (7), while Calm4 (calmodulin 4) is a marker 
for late keratinocyte differentiation (18), and Crabp2 (cellular retinoic acid 
binding protein 2) is induced by retinoic acid in keratinocytes (11). The EST 
1110014F24Rik is the mouse ortholog of the human Dermokine gene, which 
is also expressed in keratinocytes (31). Elovl4 (elongation of very long chain 
fatty acids-like 4) is predominantly expressed in the retina, but expression 
has also been detected in other tissues including skin (30). Finally, Krt1-17 
(keratin complex 1, acidic, gene 17) was found to be strongly induced in the 
knockout tissue. Since in our experiments the skin layer on top of the calvaria 
was included for microarray analysis, the data obtained suggest that skin 
development adjacent to calvaria is significantly different between WT and 
Runx2 (-/-) mice.
To validate these data, protein expression of loricrin was examined 
by means of immunofluorescence in skin of the head of WT and Runx2 (-/-) 
embryos (Fig. 3A). At 18.5 dpc, a strong signal was detected in the epidermis 
of WT embryos, while only weak expression was detected in the Runx2 
deficient tissue. Loricrin is known to be present in the cornified cell envelope 
and keratins are the major proteins of keratinocytes. In conclusion, the list 
of genes affected by Runx2 ablation contains a significant number of skin-
related genes. This observation indicates that development of the skin on 
top of the calvaria is impaired in Runx2 deficient mice. In particular, the data 
suggest that keratinocyte differentiation is blocked or delayed in the Runx2 
(-/-) mice. 
Upregulation of keratocan in Runx2 deficient tissue
Kera (Keratocan) is the gene that shows the highest increase in gene 
expression in the Runx2 (-/-) samples. Keratocan is an extracellular keratan 
sulfate proteoglycan with cornea-specific expression in the adult eye and is 
known to play a role in corneal transparency (20, 28). To validate the result 
of upregulated Kera expression in Runx2 (-/-) tissue, Kera mRNA expression 
levels were analyzed in developing calvaria at 14.5 and 16.5 dpc (Figure 3). 
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Only very weak expression of Kera was detected in the WT tissue at 14.5 dpc 
(Fig. 3Ba) while a strong signal was seen in the Runx2 (-/-) embryo (Fig. 
3Bb). At 16.5 dpc, expression in the WT embryo was observed in the cell 
layer adjacent to the calvaria (Fig. 3Ca and Fig 3Cc). Similar to 14.5 dpc, 
Kera expression in the KO mice was much stronger than in the WT mice (Fig. 
3Cb). These data show that Runx2 suppresses Kera expression during normal 
skull development. The increased expression of Kera in Runx2 (-/-) tissue 
indicates that in these mice a subepidermal cell layer is present with abnormal 
gene expression. These results are in line with the observed disregulation 
of keratinocyte markers and underscore the aberrant skin development in 
Runx2 (-/-) mice.
Figure 3.
Analysis of protein expression of 
loricrin (A) and mRNA expression 
of Kera (B, C)) in wild-type and 
Runx2 (-/-) calvaria by means of 
immunofluorescence and in situ 
hybridization.
A: Immunofluorescent detection of 
loricrin (green) and the epithelial 
marker K14 (red) expression in 
the epidermis adjacent to calvaria 
at stage 18.5 dpc. 
B: Frontal sections through the 
head, showing Kera mRNA 
expression at stage 14.5 (B) 
and 16.5 (C). Figures 2Bc, 2Bd, 
2Cc, 2Cd represent higher order 
magnification pictures of 2Ba, 
2Bb, 2Ca and 2Cb respectively. 
(For colour figure, see page 248).
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DISCUSSION
 In the present study, we have analyzed Runx2-dependent gene 
expression in developing bone of the skull. A microarray experiment was 
performed in which gene expression levels were compared between calvaria 
of wild-type and Runx2 (-/-) embryos at day 14.5 of gestation. We focused 
on a subset of 42 transcripts that showed the highest difference in expression 
level. Strongest repression was observed in the calvaria of KO mice for Ibsp 
and Spp1, which are known direct target genes for Runx2 (15). In addition, 
we observed downregulation of Msx1, Msx2 and Dlx5 in KO embryos, all three 
genes that have previously been identified as upstream regulators of Runx2 
expression. Based on these observations we propose that Runx2 and Msx 
proteins control each other’s expression.
Mice deficient in Msx1 or Msx2 are known to show defects in skull 
ossification, in part caused by reduced proliferation and differentiation of 
the skeletogenic mesenchyme (19, 38, 39, 43). Expression levels of Runx2 
in developing bone are diminished in Msx1 (-/-) (43) and Msx2 (-/-) mice 
(19, 38), thus supporting the hypothesis that these factors act in a genetic 
pathway upstream of Runx2. Although such reduced Runx2 expression was 
not observed in Dlx5 (-/-) deficient mice (3), it has been shown that at least 
in vitro, overexpression of Dlx5 strongly induces Runx2 expression, while on 
the other hand forced expression of Runx2 is not sufficient to upregulate Dlx5 
(25). These results are in line with the recent observation that Dlx5 is able to 
bind and activate the promoter of the osseous Runx2 isoform (26). Thus, we 
find that modulators of Runx2 expression display higher expression levels in 
WT calvaria than in Runx2 (-/-) calvaria at 14.5 dpc. In agreement with our 
finding, downregulation of Dlx5 and Msx2 in Runx2 (-/-) calvaria has recently 
been noted by others (8).
The positive effect of Runx2 expression on regulators of Runx2 itself, 
together with the autoregulatory function of Runx2, suggests a feed forward 
loop that sustains osteogenic differentiation in committed cells. This feed 
forward loop might be exerted by direct or indirect effects of Runx2 on the 
promoters of Dlx5 and Msx2. We have isolated the Dlx5 and Msx2 5’ flanking 
sequences but did not observe increased promoter activity from these 
sequences in the presence of Runx2. Furthermore, the in situ data presented 
here indicate that the lower Msx2 expression in Runx2 (-/-) tissue is primarily 
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caused by a decrease in the number of cells expressing Runx2. This notion is 
corroborated by an observed difference in the number of mesenchymal cells 
forming the bone of the calvaria between wild-type and knockout embryos at 
later stages during development (23, 36). By analyzing the developing skull 
of Msx2 (-/-) mice, it has been shown that Msx2 induces Runx2 expression at 
12.5 dpc, but a proliferation defect due to the absence of Msx2 occurred only 
later at 14.5 dpc (19). Therefore, our data suggest an indirect mechanism 
in which induction of Runx2 expression by Msx2 establishes a signalling loop 
that drives expansion of Msx2 positive osteoprogenitor cells. Subsequently, 
these cells further differentiate under influence of Runx2 into Osx-expressing 
cells and subsequently into mature osteoblasts, as schematically outlined in 
Fig. 4. 
The data further revealed that Runx2 expression is correlated with 
skin development, since not only bone-related genes were modulated, but 
also skin-specific genes. The genes Lor, Krt1-10 and Krt2-1 were strongly 
downregulated in the knockout tissue. Expression of these genes is restricted 
to terminally differentiating keratinocytes (7, 33). Moreover, expression 
levels of Krt1-17 were strongly upregulated in the Runx2 (-/-) compared 
to WT specimen. Expression of Krt1-17 is related to the onset of epithelial 
differentiation and precedes expression of the terminal differentiation markers 
Figure 4.
Proposed model for Runx2 function during calvaria development. Mesenchymal cells 
are induced by Msx2 to express Runx2, which on its turn, sustains Msx2 expression, 
thereby resulting in expansion of the Msx2-expressing cells. Subsequently, these 
cells differentiate under influence of Runx2 into Osx-expressing preosteoblasts, 
and further under influence of both Osx and Runx2 into Ibsp expressing mature 
osteoblasts. Progression of skin development parallels calvaria development. 
The keratinocyte gene Krt1-17 is expressed during the early stages of epithelial 
differentiation. While development of calvaria progresses, expression of the late 
keratinocyte genes Krt1-10 and Lor is induced. This induction requires Runx2 
activity. For details see text.
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Lor, Krt1-10 and Krt2-1 (32). The results therefore imply that keratinocyte 
differentiation, and consequently skin development, is delayed or blocked at 
an early stage in the Runx2 (-/-) embryos. It is interesting to note the onset 
of Krt17 expression occurs between 10.5-12.5 dpc in cells that respond to 
mesenchymal cues (32). Krt2-1 and Krt1-10, which showed higher expression 
in wild-type than in knock-out mice, are induced in differentiating epidermis 
between 13.5-15.5 dpc (7, 32). Together, this means that the development of 
the epidermis coincides with the onset of osteoblast differentiation within the 
skull which occurs around day 13-14 (5). 
To examine whether the development of the skin barrier function is 
affected in Runx2 (-/-) embryos, we carried out a skin permeability assay, 
which is based on penetration of the epidermis by the histological stain 
toluidine blue (17). The skin barrier function develops around 17.5 dpc 
during embryonic development, and is known to be delayed in Lor (-/-) 
deficient mice (22). Despite the strong downregulation of loricrin in Runx2 
(-/-) embryos, we did not observe any difference in the skin barrier function 
between Runx2 (-/-) and WT embryos at embryonic stage 17.5 dpc (data not 
shown). This result suggests that Runx2 (-/-) mice may have a molecular skin 
phenotype at the gene expression level, but that the physiological function of 
skin appears normal, at least at the stage analyzed.
The mechanism by which Runx2 controls skin development remains 
speculative and needs further investigation. Either Runx2 plays a cell-
autonomous role in epithelial or dermal cells, or the disorganized skin 
development results from impaired skull development in a paracrine fashion. 
Expression of non-osseous Runx2 isoforms has been identified in skin 
fibroblasts, but not in epithelial cells (4, 6, 23). Since in the mouse model 
used, all Runx2 isoforms are inactivated (36), the data might reflect a direct 
role of Runx2 in skin formation. However, a clear direct function of Runx2 
in skin development has not been observed to date. Komori and co-workers 
did not show major differences in the skin of wild-type and Runx2 (-/-) 
embryos, although they observed that the number of skin fibroblasts was 
slightly reduced in the mutant mice (23). This is supported by data obtained 
from additional microarray experiments in which we compared whole limbs 
of wild-type and Runx2 (-/-) embryos ((42), Chapter 6 of this thesis). These 
experiments confirmed the downregulation of osteoblast genes such as Ibsp, 
Spp1, Akp2 and Dlx5, but not of the keratinocyte genes shown in Table 1A. 
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Together these results strongly point towards a local skin phenotype on the 
head of Runx2 (-/-) embryos.
We propose that the effect on skin development is caused by a 
Runx2-mediated interaction of the mesenchymal layer forming the skull and 
the adjacent skin layer. Reciprocal epithelial-mesenchymal interactions are 
required to establish appropriate development of specified compartments 
of organs and tissues. Formation of mesenchymal cell condensations that 
prefigure skeletal elements is induced by interaction with epithelium (reviewed 
by Hall (16)) and at least during embryonic chick development it has been 
shown that the epidermis is required for development of the frontal bone 
(40). Conversely, development of cells in the epidermis has been shown to 
require signalling cues of underlying mesenchyme (7). Our data indicate that 
this interaction is abrogated in the Runx2 (-/-) mutants. Such interactions 
have been reported previously to occur during tooth development. In 
addition to its role in bone development, Runx2 also controls odontoblast 
differentiation during tooth development. For a proper control of tooth 
morphogenesis, epithelial-mesenchymal interactions are required that are 
controlled by Runx2-mediated FGF signalling (2, 12). For skull development, 
such interactions have not been described yet.
The observation that subepidermal expression of Kera is strongly 
induced in the knockout embryos is in line with such interaction between 
the skull and the skin. During mouse embryogenesis, Kera promoter activity 
has been detected in several tissues among which are the limbs, tail, snout 
and the forehead (27). Furthermore, expression of the keratocan gene has 
been detected in bovine skin (10), while in chicken embryos its expression 
has been demonstrated in the subepidermal mesenchyme (9). Expression of 
Kera in wild-type mice appeared to be adjacent to the bone (Fig. 3Ba), but it 
has not been established which cell type expressed Kera in the knockout. The 
increase in Kera expression may either reflect a transdifferentiation process 
of Runx2 (-/-) mesenchymal cells, or may arise from a disturbed interaction 
between mesenchyme and surrounding dermal cells. 
In conclusion, the experiments described here, showed a defect in skin 
development adjacent to calvaria of Runx2 (-/-) embryos. This indicates that 
Runx2 regulates expression of genes that act as signalling cues for epidermis 
development. Moreover, based on differential expression of known osteoblast 
genes, it is proposed that Runx2 is part of a feed forward loop that sustains 
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cell expansion in the developing calvaria. These novel finding illustrate the 
advantage of combining microarray technology with mutant mouse models. 
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 The vertebrate skeleton is comprised by two tissues, namely cartilage 
and bone. During embryogenesis, both tissues are derived from condensations 
of mesenchymal stem cells that have the potential to turn into chondrocytes 
to form cartilage, or into osteoblasts to form bone. In adults, newly formed 
osteoblasts are derived from mesenchymal stem cells in the bone marrow from 
which also adipocytes are derived. How stem cells develop into osteoblasts, 
and the relationship between the osteoblast, chondrocyte and adipocyte 
progenitors remains subject of further investigation. For the development 
of effective anabolic therapies against diseases that are characterized by 
decreased bone mass, such as osteoporosis, it is important to understand 
the molecular mechanisms that trigger osteoblast differentiation in more 
detail. In this thesis, we studied the mouse osteoblast transcriptome with the 
aim to discover novel genes and genetic pathways that act as regulators of 
osteoblast differentiation, which may have therapeutic potential to improve 
bone mass. 
 Two different approaches were followed to monitor genome-wide 
gene expression in differentiating osteoblasts, using both in vitro and in 
vivo microarray-based expression analysis. For the in vitro analyses, time-
dependent changes in gene transcript levels were analyzed in cells that 
were induced to differentiate from multipotent progenitors into osteoblasts. 
These studies led to the identification of novel genetic markers for osteoblast 
differentiation and skeletal development. One of these genes encodes Wif1 
(Wnt inhibitory factor 1), a protein belonging to the class of Wnt antagonists. 
Our studies revealed that expression of Wnt antagonists is typically associated 
with late phase osteoblast differentiation. The present studies indicate that 
Wnt signalling is activated during the earliest stages of differentiation, while 
antagonism of Wnt signalling is required for osteoblast maturation.
 The in vivo analysis was carried out by comparing gene expression in 
skeletal elements of wild-type and mutant mouse embryos, of which the latter 
show a bone formation defect. As a result, we have discovered novel in vivo 
target genes of the key skeletal transcription factor Runx2. We further show 
that differentiating osteoblasts express genes whose products interact with 
cell types other than osteoblasts. Indeed, our studies show for the first time 
that the phenotype of mice with arrested osteoblast development may not be 
restricted to skeletal cell types alone. 
 In this part of the thesis, the application of microarray technology 
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to uncover genetic processes that underlie osteoblast differentiation and 
bone physiology are discussed. We first review the C2C12 cells as a model 
system for osteoblast differentiation and stem cell development, based on our 
results and recent literature. One of the most important findings in this thesis 
that contributes to describing molecular mechanisms controlling osteoblast 
differentiation is a dual role of Wnt signalling on osteoblast development. 
The role of Wnt signalling with focus on Wnt antagonists in osteoblast 
differentiation and bone development is discussed and presented in a model. 
Finally, putative drug targets are discussed that may be used in anabolic 
strategies. 
8.1 THE C2C12 DIFFERENTIATION MODEL
8.1.1 C2C12 as a model system for osteoblast differentiation
 In this thesis, the murine cell line C2C12 was used as a model system 
for in vitro osteoblast differentiation. The default differentiation pathway of 
C2C12 cells is fusion into multinucleated myoblasts, but bone morphogenetic 
proteins (BMP) induce these cells to differentiate into osteoblasts (47, 51). 
After 6 days of BMP2 treatment, high mRNA expression levels of the osteoblast 
marker genes Akp2 (alkaline phosphatase 2, liver) and Bglap1 (bone gamma-
carboxyglutamate protein 1, or osteocalcin) were observed (Chapter 2), as 
well as extracellular calcium deposition and matrix mineralization (Chapters 
3). The time course differentiation of C2C12 thus covers the entire process of 
osteoblast development. Furthermore, high concentrations of BMP2 (>300 ng/
ml) resulted in a homogenous population of Akp2 positive cells when analyzed 
by means of cytochemical staining (data not shown). Based on our results, 
it can be stated that C2C12 cells closely resemble “established” osteoblasts 
in terms of their gene expression profiles. Most of the known osteoblast 
markers were found to be strongly induced during microarray analysis, while 
20 percent of the genes induced during the late phase of differentiation were 
osteoblast specific (Chapter 2). 
Studies in mutant animal models reveal a growing number of genes 
that play a role in bone metabolism (62, 75). A large number of those genes 
were also found to be upregulated during osteoblast differentiation of C2C12 
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cells, including Akp2, Mmp14 (matrix metalloproteinase 14), Bglap1, Dcn 
(decorin), ApoE (apolipoprotein A), Bgn (biglycan), Vdr (vitamin D receptor), 
Col1a1 (procollagen, type I, alpha 1) and Col1a2 (procollagen, type I, alpha 
2). Mutation of these genes can cause diverse skeletal phenotypes including 
dwarfism, osteoporosis (reduced bone mass) and osteopetrosis (increased 
bone mass). Moreover, polymorphisms in the promoters or coding sequences 
of the COL1a1, COL1a2, VDR, BGLAP1 and APOE genes have been related 
to differences in bone mineral density and predisposition to osteoporosis in 
humans ((62, 65) and references therein). Evidently, the C2C12 data set 
encompasses genes that are directly associated with bone disorders, and thus 
provides a basis for the identification of therapeutic targets. 
  
8.1.2 C2C12 as stem cell model
8.1.2.1 C2C12 cells resemble multipotent stem cells 
 The identity of stem cells and the relationship between multipotent 
stem cells and committed progenitor cells is still poorly understood. The 
question can be raised where C2C12 cells are positioned in a model of 
mesenchymal stem cell differentiation. C2C12 cells have originally been 
isolated from muscle tissue. A number of different types of stem cells have 
been isolated from skeletal muscle (reviewed in (41)), of which the so-called 
satellite cells show self-renewal and muscle generation and are therefore 
usually referred to as muscle stem cells. In addition to their myogenic 
differentiation, satellite stem cells also show osteogenic and adipogenic 
differentiation capacity in tissue culture when treated with  BMP, or by a 
combination of isobutylmethylxanthine, dexamethasone, indomethacin and 
insulin (2). In terms of differentiation capacity, C2C12 cells behave similar to 
such satellite cells. 
C2C12 cells automatically fuse into multi-nucleated myotubes when 
reaching confluence under culture conditions. Furthermore, proliferating 
C2C12 cells express the skeletal muscle specific transcription factor Myod1 
(myogenic differentiation 1) (Chapter 4), which is not expressed by 
satellite cells (2). Although they can therefore be considered as committed 
myoprogenitor cells, C2C12 cells are not restricted to the myoblast lineage, 
since they exhibit multipotent lineage potential. In addition to their ability 
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to undergo osteoblast differentiation upon BMP treatment (see references 
47 and 51, and this thesis), C2C12 cells can also differentiate into lipid-
accumulating adipocytes by treatment with the above combination of stimuli 
(1) or by inhibition of Wnt signalling (69). It remains uncertain, however, 
whether C2C12 cells can also differentiate into chondrocytes. Expression 
of the chondrocyte markers Sox9 (SRY-box containing gene 9) and Col2a1 
(procollagen, type II, alpha 1) (33), but not of Col10a1 (procollagen, type 
X, alpha 1) is induced by BMP7 in C2C12 cells (35). Expression of the gene 
for Col2a1 was induced in our experiment, while genes for Col10a1 and Sox9 
were not represented on array. A number of chondrocyte markers are thus 
induced in C2C12, but unlike for instance C3H10T1/2 cells, C2C12 cells seem 
to have lost the ability to undergo BMP-induced chondrocyte differentiation, 
since BMP-treated C2C12 cells remain negative for staining of cartilage matrix 
by Alcian blue (53). These data do, however, not exclude the possibility 
that C2C12 cells can undergo chondrocyte differentiation by other stimuli. 
For instance, TGFβ (transforming growth factor beta) is known to induce 
chondrocyte differentiation of mesenchymal stem cells (64) and embryonic 
stem cells (50). In C2C12 cells, TGFB1 represses both myotube formation and 
BMP-induced osteoblast differentiation (18), but it has not been investigated 
whether C2C12 cells adopt the chondrocyte phenotype instead. C2C12 
cells are thus committed myoblast progenitor cells with at least tripotential 
differentiation capacity. 
The in vitro differentiation potential of C2C12 cells is very similar to 
that of satellite cells. It can be speculated that a population of mesenchymal 
stem cells exists in vivo with similar properties. Denervation, i.e. removal 
of nerves,  leads to expansion of adipose tissue within skeletal muscle (22, 
79), a process that also occurs during  muscle diseases including muscular 
dystrophy. Moreover, ectopic bone formation can be induced in skeletal muscle 
by BMPs (14), while ossification of muscles occurs in the human disease FOP 
(Fibrodysplasia Ossificans Progressiva) (71). The cells that are responsible 
for this heterotopic fat or bone tissue formation have not been identified, but 
C2C12 differentiation seems to be relevant to study the causes of such human 
disorders. 
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8.1.2.2 C2C12 cells versus mesenchymal stem cells 
Given that C2C12 cells can at least differentiate into osteoblasts 
and adipocytes, they thus closely resemble the differentiation capacity of 
bone-marrow derived mesenchymal stem cells (MSC). Both murine (4, 73) 
and human (64) MSC remain multipotent when placed in culture, and they 
can differentiate at least into osteoblasts, chondrocytes and adipocytes. 
Despite this similarity in differentiation capacity, it is uncertain whether 
undifferentiated C2C12 cells are indeed comparable to MSC in terms of 
their differentiation program. As mentioned above, it is not known whether 
C2C12 cells can differentiate into chondrocytes, while it has been shown for 
murine bone-derived MCS that these cells may not be able to undergo full 
differentiation into functional myocytes (7). 
Both C2C12 cells and MSC reach the phenotypic stage of mineralized 
osteoblasts, but a difference exists in the genetic pathways that are activated 
at the onset of differentiation. BMP2 is sufficient to induce full osteoblast 
differentiation of C2C12 cells, while MSC require the glucocorticoid hormone 
dexamethasone to initiate osteoblast differentiation. Human MSC (hMSC) 
express AKP2 in presence of dexamethasone, but not in presence of BMP 
alone (20). However, BMP is able to induce AKP2 expression in human 
MSC cells pre-treated with dexamethasone (19). Similarly, dexamethasone 
induces Akp2 expression in purified murine MSC (4, 73), while BMP strongly 
enhances Akp2 expression in bone marrow cells that already express Akp2 
at basal levels (6). These studies imply that a purified population of MSC 
needs dexamethasone for the induction of AKP2 expression and that BMP 
can enhance differentiation of MSC once differentiation has been triggered by 
other agents. In analogy, a population of calvaria-derived primary osteoblasts 
consists of subpopulations of Akp2-positive and Akp2-negative cells of which 
only the latter are dependent on dexamethasone to induce differentiation 
(74). 
 In contrast to AKP2, expression of the osteoblast transcription factor 
OSX (osterix) can be induced in hMSC by BMP2, -4, -6 and -7 (25). The 
presence of dexamethasone does also not appear to be necessary for BMP 
to induce expression of other osteoblast markers such as SPP1 (secreted 
phosphoprotein 1) or IBSP (integrin binding sialoprotein) (19). Hence, MSC 
are able to respond to BMP signalling, but lack the ability to fully undergo 
BMP-induced osteogenesis. Together, these results suggest that MSC initially 
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require dexamethasone to form an AKP2-positive pre-osteoblast that can 
subsequently be induced by BMP to differentiate further along the osteoblast 
lineage. In C2C12 cells, both Runx2 and Osx expression are strongly induced 
by BMP2 (chapter 3 of this thesis), while BMPs induce OSX, but not RUNX2 in 
hMSC (25). These results further support that C2C12 cells, in contrast to MSC, 
are fully able to undergo BMP-induced differentiation. Apparently, activation 
of different genetic pathways in C2C12 cells and MSC eventually results in 
a similar phenotype. A comparative analysis of genome-wide expression in 
such model systems may be a fruitful approach to identify the earliest key 
regulators and characterize distinct progenitor states in the hierarchy of 
mesenchymal stem cell differentiation. 
  Since C2C12 cells do not require dexamethasone to induce Akp2 
induction, it can be speculated that C2C12 cells are already more committed 
towards the osteoblast lineage than MSC. However, C2C12 cells resemble 
MSC in that they do not basally express Akp2 (Chapter 2, and CT-values > 30) 
and can therefore not be considered as pre-osteoblasts if these are defined 
as Akp2-expressing cells (56). On the other hand, C2C12 cells show basal 
expression of Runx2 (quantitative RT-PCR CT-values ~25), and high basal 
RUNX2 levels have also been found in human MSC (20) and E. Piek, personal 
communication). The observed high basal expression of Runx2 in both C2C12 
and hMSC is surprising, since the induction of Runx2 expression is considered 
to be characteristic for the formation of committed osteoprogenitor cells 
with restricted differentiation capacity relative to mesenchymal stem cells. 
Still, Runx2-expressing hMSC and C2C12 cells appear to be multipotential, 
and therefore it cannot be excluded that the observed basal expression of 
Runx2 is an artefact of tissue culture conditions. On the other hand, it can 
also not be excluded that two different cell populations exist in our cultures, 
only one of which expresses Runx2. If so, this could be an indication that the 
culture contains a mixture of Runx2 negative stem cells and Runx2 positive 
osteoprogenitor cells. In this respect, two questions need to be answered. 
First, do all stem cells eventually differentiate into Runx2 positive cells, or 
does a small fraction of stem cells remain present that does not differentiate? 
Secondly, which cellular properties cause such distinct states in one cell 
culture? 
An alternative explanation for basal Runx2 expression could be that 
the cells can behave both as stem cells and as progenitor cells, dependent on 
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the culture conditions applied, similar as has been described for hematopoietic 
stem cells in Chapter 1.2.2 of the Introduction. The basal Runx2 expression 
could therefore be an indication that mesenchymal stem cell differentiation is 
non-hierarchical and that commitment may be a reversible process. 
8.2 WHAT DID WE LEARN ABOUT STEM CELLS AND OSTEOBLAST 
DIFFERENTIATION?
The power of microarray technology is the large scale acquisition 
of data on the expression behaviour of genes that show, for instance, 
comparable time dependent expression patterns. In Chapters 2 and 4, such 
information was used to identify differentiation stage specific osteoblast 
markers and novel early regulators of osteoblast differentiation. It is a further 
challenge to analyze the massive amount of expression information, such that 
the underlying biological processes can be better understood. One way to do 
this, is analyzing the data in terms of functionally related genes. 
In chapter 2, we presented 342 genes of which expression was 
differentially modulated during BMP2-induced osteoblast differentiation of 
C2C12 cells. A functional analysis on the upregulated genes showed that 
functionally related genes are co-regulated, resulting in the overrepresentation 
of various functional gene categories at distinct stages of differentiation 
(Chapter 2). Although the analysis was restricted to a subset of the up-
regulated genes with the strongest expression modulations (> 2-fold on 
array), the result globally describes ongoing processes during osteoblast 
differentiation. Furthermore, the analysis was limited with respect to the 
number of functional categories included. 
During the last years, such gene annotation databases have 
frequently been updated and online tools have become available to analyze 
gene expression data in terms of gene function. Here we briefly describe 
novel results, that were not presented earlier and that have been obtained by 
functional gene analysis during C2C12 differentiation using the most recent 
database annotations. Our previous analysis on BMP2-treated C2C12 cells 
was extended to the total of 928 genes that were found to be modulated 
at least 1.5 fold on microarray. Subsequently, an analysis was carried out 
on the 470 upregulated and 458 downregulated genes using GOTM (Gene 
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Ontology Tree Machine (85)), to identify functional groups with enriched gene 
numbers. As expected, we observed that the term skeletal development was 
significantly enriched (p<0.05) in the upregulated genes. The downregulated 
genes were significantly enriched for genes of the GO terms muscle cell 
differentiation and muscle development, showing that C2C12 cells already 
express muscle cell genes at a basal level which are down-regulated by BMP2, 
thereby inhibiting myogenic differentiation. Most of the enriched GO-terms of 
the downregulated genes were related to cell cycle regulation, including cell 
cycle, cell division, G1 phase, M phase, DNA replication, which is indicative for 
decreased proliferation during progression of osteoblast differentiation (3). 
These results therefore underscore the identity of C2C12 cells. 
The analysis also resulted in enrichment of GO terms that are 
unexpected for the process of osteoblast differentiation. Significant 
enrichment of neuron development and neuron differentiation genes was 
found in the upregulated C2C12 genes. This is remarkable since it has been 
shown that upon osteogenic differentiation mesenchymal stem cells reduce 
expression of neural genes. In agreement with the study by Egusa (23), we 
observed in our microarray experiment that the neural stem cell marker Nes 
(nestin) is down-regulated in BMP2-treated C2C12 cells. These results thus 
show that differentiating osteoblasts reduce expression of neural stem cell 
genes, while simultaneously inducing expression of genes related to neural 
development.  However, given the homogeneity of the C2C12 model in terms 
of Akp2 positive cells (see section 8.1.1), this result implies that expression of 
neural development genes is an intrinsic feature of developing osteoblasts. 
One explanation of neural gene expression in osteoblasts is that 
these genes have previously not been annotated as being involved in 
osteoblast differentiation or skeletal development. Another explanation is that 
osteoblasts may participate in the regulation of neuron development in bone. 
Osteoblasts may express genes that are involved in the regulation of bone 
innervation during development. In addition to the enrichment of neuronal 
markers in osteoblasts, two other results obtained in our studies underscore 
this idea. The EST709999, which was identified in our study as a novel 
marker for osteoblast differentiation and bone development, has later been 
annotated as Tnn (tenascin N). The tenascin family of extracellular proteins 
plays a role in tissue innervation (13, 43) and indeed it has been shown that 
Tnn is functionally involved in axon outgrowth (59). Furthermore we observed 
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that EST709999/Tnn is specifically expressed in the periosteum of developing 
bone, which could be an indication that Tenascin N may participate in the 
attraction of axons to the bone. The hypothesis that osteoblasts express 
genes to modulate axon attractions is further supported by our result that 
expression of genes of the GO term axon guidance was changed in vivo in 
Runx2 (-/-) embryos (Chapter 7). This indicates that the process of axon 
guidance is disturbed by the ablation of osteoblasts in developing calvaria. Our 
data thus suggest that osteoblasts express genes that facilitate interactions 
between the developing bone and the nerve system. 
 Our studies on C2C12 cells have so far been focused on upregulated 
genes. However, interesting information about stem cell differentiation may 
be available from the downregulated genes as well. These downregulated 
genes were, for instance, enriched for GO terms related to chromosome 
assembly and chromosome maintenance. Moreover, a number of terms 
related to RNA splicing were found to be enriched in the downregulated 
genes. It may be of interest to address further studies to the genes within 
these classes, since they could account for epigenetic and post-transcriptional 
mechanisms that are responsible for the switch of myogenic to osteogenic 
differentiation. It must be noted that proteins may have broader functions 
than indicated by current GO annotations. Since cell cycle-related GO terms 
dominate the enriched categories, it is possible that the genes of these 
classes are also related to the decreased proliferation. Studies on individual 
genes will be required to investigate their particular function during osteoblast 
differentiation. GO analysis may thus be a valuable tool to choose genes of 
interest for subsequent functional studies.   
8.3 WHAT DID WE LEARN ABOUT BONE?
Organs are much more complex than cultured cell lines, and therefore 
the physiological relevance of in vitro cell differentiation may be debatable. 
In a study by Clancy et al. (14), our C2C12 data as presented in chapter 
2 were compared with a microarray analysis on in vivo endochondral bone 
formation which was ectopically induced by means of intramuscular BMP2 
injection. These authors also compared their data with a microarray analysis 
on osteoblast differentiation of human mesenchymal stem cells in vitro (21). 
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Despite the fact that different microarrays were used (Incyte cDNA arrays for 
C2C12 and Affymetrix oligonucleotide arrays in the Clancy study), 26 out of 
122 genes identified by Clancy et al. were also found in our C2C12 data, while 
only 7 genes showed overlap with the hMSC data set. Thus, the C2C12 data 
outnumbered the overlap with human MSC data almost four times, this in spite 
of the fact that 23,000 human genes were studied, while our experiments 
were performed on an array with less than 10,000 sequences. Reasonable 
explanations for this difference may be the use of other microarrays, species 
differences, or different inducers of differentiation (i.e. BMP2 in ectopic bone 
formation and differentiation of C2C12 cells, compared to dexamethasone 
for hMSC). These data clearly show that C2C12 osteoblast differentiation is a 
model system which provides relevant knowledge for in vivo bone formation. 
8.3.1 Wnt signalling and osteoblast differentiation
Wnt signalling has been shown to control various aspects of 
skeletogenesis, including bone cell differentiation (16, 38, 40) and bone 
homeostasis (28, 31, 49). Its effect on bone mass is mainly exerted on 
osteoblasts (reviewed by Glass and Karsenty (29)), implicating that Wnt is a 
regulatory pathway of osteoblast differentiation and/or osteoblast function. 
Indeed in C2C12 cells the GO terms Wnt receptor signalling pathway and 
Regulation of Wnt receptor signalling pathway showed significant enrichment 
within the subset of upregulated genes.
8.3.1.1 Wnt signalling has a dual role during osteoblast differentiation 
The studies presented in this thesis indicate that Wnt signalling exerts 
a dual role on osteoblast differentiation. We showed that activation of Wnt 
signalling occurs at the onset of osteoblast differentiation. In Chapter 4, data 
are presented that Tcf7 expression is induced by BMP2 during the earliest 
stages of osteoblast commitment. Similar to Tcf7, expression of Wnt4 and 
Wnt10b was induced during the first 24 hrs of C2C12 differentiation (Chapter 
3). In NIH3T3 fibroblasts, the BMP-responsive gene Smad7 was induced by 
BMP2 (Chapter 4), but Wnt4 and Wnt10b expression levels did not change 
(Chapter 3), indicating that Wnt4 and Wnt10b are not general BMP2 target 
genes. Together, these results are in line with data that signalling by the 
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Wnt pathway is activated during the early phases of BMP-induced osteoblast 
differentiation (67). Stable expression of Tcf7 in C2C12 cells resulted in 
decreased Bglap1 expression, while Wif1 expression was increased following 
BMP-induced differentiation (Chapter 4). Identical effects were observed 
when C2C12 cells were treated with lithium chloride (LiCl) to activate 
canonical Wnt signalling (Chapter 3), indicating that Tcf7 increases Wnt 
activity in differentiating C2C12 cells. The decreased Bglap1 expression can 
be explained by repressed transactivation activity of Runx2 by Tcf7 (81) or 
Lef1 (46) on the Bglap1 promoter. On the other hand Tcf7 has an activating 
effect on the Spp1 (osteopontin) promoter (24). Tcf7 thus has a promoter-
context dependent effect on regulating osteoblast gene expression.
We have further shown that of all Wnt signalling components 
studied, predominantly Wnt antagonists are induced during the late phase 
of differentiation (Chapter 3). The expression pattern of Dkk3 (Dickkopf 3) 
was similar to that of Akp2, while Sfrp2 (Secreted frizzled-related protein 2) 
was expressed later than Akp2, but earlier than Bglap1. This indicates that 
these Wnt antagonists are expressed in Akp2 positive preosteoblasts and may 
function during osteoblast maturation. Finally, Wif1 expression was strongly 
upregulated. Expression of Wif1 was furthermore detected in differentiated 
osteoblasts in vivo (detectable expression in calvaria only after 16.5dpc, 
data not shown). Together these data strongly imply that Wnt activity is 
specifically modulated during distinct stages of osteoblast differentiation and 
bone development.
Based on these results and results from other studies, we hypothesize 
that activation of Wnt signalling is required to induce osteoblast differentiation 
from mesenchymal stem cells, while committed osteoblasts must escape from 
Wnt signalling to undergo further differentiation. This hypothesis is supported 
by the observation that continuous Wnt activation by means of LiCl prevents 
the C2C12 cells from complete osteoblast differentiation (Chapter 3). The 
proposed negative effect of Wnt activity on osteoblast differentiation is in 
agreement with other studies showing that treatment of murine osteoblasts 
and primary bone marrow cells (78) as well as human mesenchymal stem cells 
(17) with either LiCl or Wnt3a has an inhibitory effect on differentiation. 
The inhibitory effect of LiCl on osteoblast differentiation as measured 
by calcium release in BMP2-treated C2C12 cells was not observed in BMP2-
treated MC3T3 preosteoblasts (data not shown). Similarly, Wnt3a only 
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inhibited osteoblast maturation when added to undifferentiated cells at an 
early stage of differentiation, but not when added to maturating cells (78). 
These results suggest that continuous Wnt activity exerts its effect during the 
osteoblast commitment phase, rather than during maturation of osteoblasts. 
This hypothesis is supported by in vivo data which show that Wnt activity is 
required to induce the osteoblast phenotype in uncommitted progenitor cells 
during development (16, 38, 40). Conditional inactivation of β-catenin in 
early mesenchymal condensations using Prx1-Cre mice (38) or Dermo1-Cre 
mice (16, 40) leads to arrested osteoblast development, while inactivation 
of β-catenin at a later stage in differentiating osteoblasts using Col1a1-Cre 
mice does not affect osteoblast number or function (28). These data imply 
that Wnt activation is only required during the osteoblast commitment phase. 
However, expression of stabilized β-catenin in embryos controlled by the Prx1 
promoter in mesenchymal condensations also negatively affects osteoblast 
differentiation, resulting in loss of bone formation (38). In contrast, Glass 
and co-workers showed that activation of β-catenin in Col1a1 expressing 
osteoblasts did not affect osteoblast differentiation (28). These data show, 
in line with the in vitro data, that Wnt activation is required in mesenchymal 
cells to induce the osteoblast phenotype, while continuous Wnt activation 
inhibits osteoblast differentiation, but only when stimulated from the earliest 
stages of differentiation. This implies that during the commitment phase, Wnt 
signalling must first be activated to establish the osteoblast lineage, while 
subsequently the committed osteoblasts must escape from Wnt signalling to 
achieve further differentiation into mature osteoblasts. A similar mechanism 
has also been described for epithelial differentiation of F9 stem cells, in which 
expression of Wnt antagonists is necessary to achieve further differentiation 
(70). 
8.3.1.2 Function of Wnt antagonists during bone development
The observation that Wnt antagonists are expressed during late phases 
of bone cell differentiation leads to the hypothesis that Wnt antagonism 
controls osteoblast maturation. The function of a number of Wnt antagonists 
in bone development has been studied in mutant mouse models. Results of 
these studies and our own observations are summarized in figure 1. Dkk2 (-
/-) mice are osteopenic due to a defect in osteoblast function, and osteoblasts 
taken from Dkk2-deficient mice poorly mineralize in culture, indicating that 
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Figure 1.
Wnt signalling exerts both positive and negative effects on osteoblast 
differentiation. 
The Wnt signalling components identified in our studies (Tcf7, Wnt4, Wnt10b, 
Dkk3, Sfrp2, Sfrp3 and Wif1) showed distinct expression kinetics during osteoblast 
differentiation. Expression of the activators of Wnt signalling (Wnt4, Wnt10b and 
Tcf7) is induced during the commitment of mesenchymal stem cells (MSC) towards 
Runx2 expressing osteoprogenitors. Expression of the Wnt antagonists Dkk3 and 
Sfrp2 was detected in Akp2 positive preosteoblasts, while Wif1 was found to be 
induced in Bglap1 expressing mature osteoblasts. 
Wnt10b has been shown to stimulate osteogenesis and inhibit the alternative 
differentiation pathway of MSC into adipocytes. Stable expression of Tcf7 enhances 
Akp2 levels, but inhibits Runx2-induced Bglap1 expression and Wif1 expression. 
Wnt antagonists have been shown to control various functional processes of 
osteoblast differentiation in vitro and in vivo. Both Dkk1 and Dkk2 are required to 
achieve matrix mineralization, while Dkk2 is also a positive regulator of osteoblast 
proliferation and differentiation. Sfrp3 inhibits proliferation and stimulates 
differentiation. Together, these data indicate that early activation of Wnt signalling 
is necessary to achieve osteoblast lineage commitment of MSC (indicated by the + 
sign). As differentiation proceeds, Wnt signalling becomes inhibitory on osteoblasts 
(-) and is controlled by Wnt antagonists to accomplish further differentiation and 
maturation of preosteoblasts.  
The function of Dkk3 and Sfrp2 in osteoblast differentiation is currently unknown. 
For Wif1, it has been shown that transgenic overexpression in mice results in low 
bone mass.  However, it has not been shown yet whether this decreased bone mass 
is, for instance, due to a negative effect of Wif1 on osteoblasts, or due to activation 
of osteoclast activity. See text for details. 
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Dkk2 is required for late phase gene expression in osteoblasts (55). In line 
with these results, van der Horst et al. (78) showed that Dkk2-mediated 
reduction of Wnt signalling is necessary for osteoblast differentiation. These 
authors showed by means of RNA interference that expression of both Dkk1 
and Dkk2 is required to achieve matrix mineralization, but that the function 
of Dkk2 differs from that of Dkk1 (78). Such knockdown of Dkk2, but not of 
Dkk1, decreased osteoblast proliferation, indicating that both proteins act 
during distinct stages of differentiation (78). Others have shown that transient 
overexpression of Dkk1 (67) or addition of recombinant Dkk1 (54) inhibits 
matrix mineralization of MC3T3, while transgenic overexpression of Dkk1 in 
preosteoblasts results in decreased bone formation and bone mass in mice 
(54). These data indicate that expression of Dkk1 is necessary to achieve 
matrix mineralization, but that the expression levels determine whether Dkk1 
acts in a stimulatory or inhibitory way.  
In addition to the members of the Dkk family, secreted frizzled-related 
proteins (Sfrp) have also been shown to influence osteoblast differentiation 
and bone formation. Genetic inactivation of Sfrp1 increases trabecular, 
but not cortical bone mass in mice (8). Expression of Runx2 and Bglap1 
is increased in bones of Sfrp1 (-/-) mice (27). Furthermore, ablation of 
Sfrp1 leads to decreased osteoblast apoptosis (8). Thus, Sfrp1 is a negative 
regulator of bone formation. In chapter 3, it was shown that SFRP3 (or 
FRZB1) expression was strongly induced during osteoblastic differentiation 
of human MSC. Recombinant Sfrp3 has been shown to inhibit osteoblast 
proliferation and enhance osteoblast differentiation and maturation in vitro 
(12). Together, these results show that Wnt antagonists control osteoblast 
proliferation, differentiation, maturation or apoptosis. Osteoblasts thus 
express Wnt antagonists that may act as positive (e.g. Dkk2) or negative 
(e.g. Sfrp1) regulators of bone mass. This means that Wnt signalling can 
exert both a stimulatory and an inhibiting effect on bone mass, which is in 
part controlled by the expression levels of Wnt antagonists. The dissimilar 
expression kinetics of the Wnt antagonists observed in our studies implies 
that antagonizing Wnt signalling must be cell stage specific to achieve proper 
osteoblast differentiation and bone mass regulation. 
Despite various reports on the effects of activation or inhibition of 
Wnt signalling in osteoblasts and bone, the role of Wnt during osteoblast 
differentiation, and therefore bone development, is not well understood. For 
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instance, the precise mechanism by which Wnt may control adult bone mass 
is not known. Loss of function mutations in the human LRP5 receptor result 
in decreased bone mass, while other mutations in LRP5 have been observed 
that cause syndromes characterized by high bone mass (44). Studies in mice 
have implicated that Lrp5-mediated canonical Wnt signalling is involved in 
bone mass regulation by controlling osteoblast number and activity (31, 
49). However, Glass et al. (28) showed that modulated β-catenin activity 
in osteoblasts has an effect on bone mass by indirect regulation of the 
osteoclasts, while no differences in osteoblast numbers were observed. This 
could mean that the effect of Lrp5 on bone is not driven by canonical Wnt 
signalling. It is, however, not clear to what extent such mouse models indeed 
reflect specific modulation of the canonical Wnt pathway, since many proteins 
are involved in Wnt signalling and Wnt components also interact with other 
signalling pathways.
To better understand the effects of Wnt signalling on bone, it is of 
crucial importance to know the interactions between the various regulators of 
the pathway. Most of the Wnts have been shown to be expressed in primary 
calvarial cells (37), but their specific functions still need to be elucidated. 
Establishing the binding specificity of Wnts and their (co)receptors and the 
Wnt antagonists will be important to understand the functions of the Wnt 
antagonists. We showed that Wif1 is expressed during the late phase of 
osteoblast differentiation both in vitro and in vivo, but its role during bone 
development is not clear. It is also not known to which Wnts endogenous Wif1 
binds in bone. Human WIF1 has been shown to bind to and inhibit the activity 
of Drosophila Wingless and XWnt8, while XWnt3A activity was only weakly 
inhibited (39). It may be speculated that Wif1 modulates Wnt4 activity, 
since Wif1 and Wnt4 are co-expressed in osteoblasts (49, 76). Osteoblast 
differentiation in vivo has been shown to be under positive control of Wnt4 
during chicken limb development (36), and Wif1 might provide a feedback 
control on Wnt4 activity. During eye development, Wif1 and Wnt4 are co-
expressed, and co-immunoprecipitate from retina tissues, which is indicative 
for a biochemical interaction between Wif1 and Wnt4 (42) and therefore it is 
reasonable to belief that they functionally interact during bone development 
as well. 
It further remains to be elucidated which Wnt pathways are affected 
by Wif1. Ryk, the receptor related to tyrosine kinases, is known to contain a 
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WIF-domain (61). In vertebrates, Ryk is widely expressed, and its expression 
is required for morphogenesis of craniofacial structures and limbs (34). Ryk 
has been shown to physically interact with Wnt1 or Wnt3a as has been shown 
by means of co-immunoprecipitation (57), while knockdown of Ryk protein by 
means of siRNA showed that Ryk is required for Wnt1-induced Tcf activation 
(57). These data strongly suggest that Ryk is a functional Wnt receptor that 
transduces its signals via the canonical Wnt pathway. In transfection assays, 
WIF1 inhibits the activity of a TCF-reporter construct, showing that WIF1 is 
able to suppress activity of the canonical Wnt pathway (72). It can thus be 
speculated that Wif1 can antagonize the receptor activity by competing with 
Ryk for Wnt binding. Nevertheless, Wif1 may function via other pathways as 
well. In Drosophila, the RYK orthologue derailed acts via Wnt5-stimulated 
noncanonical signalling (84). It has further been shown in Drosophila that 
the Wif1 orthologue Shifted does not antagonize Wnt activity, but has a 
role in sequestering lipid modified Hedgehog (30, 32). Interestingly, while 
Shifted and WIF1 share high similarity at the protein level, WIF1 could not 
restore the function of loss of Shifted (32). Examination of mouse models and 
biochemical data on the interaction of Wif1 with Wnts and their (co)receptors 
as well the downstream signalling pathway will be necessary to elucidate the 
function of Wif1. 
8.3.2 Role of Wnt/Wif1 in the hematopoietic stem cell niche 
The advantage of an in vitro model system is the homogeneity of 
differentiation. In contrast, cells in tissues are generally very heterogeneous. 
However, such cellular heterogeneity may be highly functional, since stem 
cells are embedded in niches where they receive signals from other cell types 
that are essential for their functioning. Stem cells can undergo self-renewal, 
but information based on cell-cell communication mechanisms by which stem 
cells are triggered to proliferate or differentiate may be lost in culture. On the 
other hand, in a process of mutual communication stem cells may express 
genes that have a paracrine function in the regulation of other cell types 
present in the tissue. 
Our in vivo studies provided clues on such mechanisms. The 
results described in chapter 6 indicate that ablation of osteoblasts on the 
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organismal level leads to abnormalities in development of mast cells, which 
are of hematopoietic origin. In chapter 7, we presented data that propose a 
developmental interaction between calvaria and skin. Indeed, in our in vivo 
studies the GO term cell-cell communication was enriched. Furthermore, in 
our C2C12 experiment (chapter 2), the strongest functional enrichments 
were observed for genes which encode secreted and extracellular proteins 
that were expressed during the late stages of differentiation. 
  Osteoblasts are part of the physical environment in which 
hematopoietic stem cells (HSC) reside, the so-called hematopoietic stem cell 
niche. Here, osteoblasts secrete cytokines such as CXCL12 to attract HSC 
to their niche (45, 52, 63). The trigger for osteoblasts to secrete CXCL12 is 
provided by neurons (48). This further indicates that osteoblasts exhibit cell-
to-cell communications with neurons, as outlined above. Furthermore, the 
Runx2 target gene Spp1 has been show to be required for engraftment of HSC 
in the marrow, and to inhibit HSC proliferation in vivo (60). Together, these 
data provide evidence that osteoblasts are important regulators of HSC. 
In addition to their role in osteoblast development, expression of 
Wnt components by osteoblasts may be required for the maintenance 
of hematopoietic stem cells (HSC). Wnt signalling is believed to control 
hematopoietic stem cell self-renewal in vivo (reviewed in reference 66). The 
observation that disruption of β-catenin in bone marrow progenitor cells 
resulted in normal hematopoietic self-renewal and differentiation (15) is 
an indication that Wnt indirectly regulates hematopoietic stem cells via its 
influence on the stem cell niche. The primary site for hematopoietic stem cells, 
referred to as the hematopoietic stem cell niche, is located in the trabecular 
bone area and the endosteum (86), which is strikingly similar to the regions 
where we observed Wif1 expression in our in situ hybridization experiments. 
For a thorough analysis of the function of Wif1 and other components, it will 
be interesting to investigate their effect on skeletal cells, as well as on the 
numbers and function of hematopoietic cells. 
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8.4 DRUG TARGETS
Efficient drugs for treatment of osteoporosis can either act by inhibiting 
bone degradation (anti-catabolic drugs) or by increasing bone deposition 
(anabolic drugs) (68). Currently most drugs used are anti-catabolic, but 
there is an increasing interest in the development of anabolic drugs which will 
directly facilitate an increase in bone mass.  
An efficient drug target for osteoporosis must have a number of 
characteristics. The protein or the pathway in which the protein functions 
must be involved in regulating bone mass. To minimize side effects, 
the protein must preferentially function with a high specificity in bone. 
Furthermore, the protein should be easily accessible for drugs, which is the 
case for instance for secreted proteins or membrane receptors. One of such 
proteins with therapeutic interest is SOST (sclerostin), which is specifically 
located in osteocytes and has been shown to decrease bone formation without 
influencing bone resorption (77). Inactivating mutations in the SOST gene 
have been identified in patients with sclerosteosis, a disease characterized 
by increased bone formation (5, 26). Transgenic mice that overexpress SOST 
in osteoblasts have reduced bone mass and more fragile bones compared 
to wild-type mice (82). It can be anticipated that targeting such a negative 
regulator of bone formation could lead to an increase of bone mass. Indeed, 
neutralizing antibodies against Sost increase bone mineral density in a rat 
model of post-menopausal osteoporosis (80). This result of an anabolic drug 
confirms the therapeutic potential of targeting a bone specific gene product 
to increase bone mass. 
Putative candidates identified in our study are the markers for bone 
development EST AA794190 and Wif1. Currently, the EST AA794190 has not 
been annotated, but a BLAST search shows that it is a splice variant of the 
gene encoding the G-protein coupled receptor Gpcr115. The function of this 
receptor, or its ligand, is not known to date. Since such receptors are an 
established family of drug targets, this osteoblast marker is of considerable 
interest for further study. However, this would first require a more detailed 
expression analysis of this gene in developing and adult bone. We showed 
that this gene is expressed in tooth, but not above background in skeletal 
elements (Chapter 2) at 16.5 dpc. The expression profile in vitro was almost 
identical to that of osteocalcin, which is only weakly expressed before birth. 
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The expression of EST AA794190 might thus be at stages later than 16.5 dpc. 
Further research is therefore required to examine whether EST AA794190 
is expressed in bone and, if so, it has a function in the regulation of bone 
mass. 
The most interesting candidate for drug therapy identified in this 
study is the Wnt antagonist Wif1, since this molecule meets the requirements 
of a drug target for osteoporosis. Wif1 is a secreted molecule and therefore 
relatively easy to target with therapeutic agents that modulate Wif1 activity. 
We showed that Wif1 is expressed during development in osteoblasts in 
trabecular bone (Chapters 2 and 3). Expression in trabecular bone may be of 
therapeutic interest since women lose more of trabecular bone than of cortical 
bone as they age (50% and 35% respectively). As a result, loss of bone mass 
occurs earlier in trabecular bone than in cortical bone, and whether the most 
important clinical features of osteoporosis occur is determined by changes in 
trabecular bone (58). Furthermore, Wif1 is not only expressed in osteoblasts 
during development, but also in osteoblasts of adult mice and humans (11). 
Most interestingly, transgenic mice expressing Wif1 from a rat collagen type 
1 promoter fragment exhibit reduced bone mass (11), showing that Wif1 
indeed has a role in the regulation of bone homeostasis. If high Wif1 levels 
result in decreased bone mass, this result raises the hypothesis that, similar 
as for Sost, reducing Wif1 levels could achieve the opposite effect, thereby 
preventing or healing osteoporosis. 
To date, Wif1 deficient mice have not been described. If such mice 
are vital, a straightforward approach to examine the effect of reduced Wif1 
levels on restoring bone mass would be to induce osteoporosis in Wif1 (-/-) 
animals. Osteoporosis can be induced by ovariectomy of mice, resulting in 
estrogen depletion and concomitant bone loss. A more elaborate approach 
to validate this hypothesis, would be the combination of animal models for 
osteoporosis and mutant animals with reduced Wif1 levels, for instance Wif1 
(+/-) or conditional Wif1 (-/-) mice. A few mouse models with osteoporosis-
like phenotypes are available, including mice that are deficient in the non-
collagenous matrix protein biglycan (83), the inhibitor of osteoclast formation 
osteoprotegerin (10), or stem cell-related antigen (9). The origin of the 
osteoporotic phenotype in these mice is different and to date it is not known 
whether Wif1 exerts an autocrine effect on osteoblasts or a paracrine effect 
on osteoclasts. Crossing Wif1 mutant with such osteoporotic mice could be 
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supportive in understanding the molecular basis of Wif1 on bone metabolism 
in vivo.
Currently, PTH (parathyroid hormone) is the only approved anabolic 
agent, and it is used for postmenopausal as well as male osteoporosis. 
Since anabolic agents restore bone mass, they can be expected to decrease 
the risk of fractures more efficiently than antiresorptive drugs. Anabolic 
drugs therefore have a great potential in the treatment of osteoporosis. 
Microarray technology and bioinformatic analyses have opened new ways to 
the understanding of bone biology and develop such anabolic therapies to 
increase bone mass by the stimulation of bone formation.
REFERENCES
1. Akimoto, T., Ushida, T., Miyaki, S., Akaogi, H., Tsuchiya, K., Yan, Z., Williams, R. S., and 
Tateishi, T. Mechanical stretch inhibits myoblast-to-adipocyte differentiation through 
Wnt signalling. Biochem Biophys Res Commun 329:381-5; 2005.
2. Asakura, A., Komaki, M., and Rudnicki, M. Muscle satellite cells are multipotential stem 
cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation 
68:245-53; 2001.
3. Aubin, J. E. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 
2:81-94; 2001.
4. Baddoo, M., Hill, K., Wilkinson, R., Gaupp, D., Hughes, C., Kopen, G. C., and Phinney, 
D. G. Characterization of mesenchymal stem cells isolated from murine bone marrow 
by negative selection. J Cell Biochem 89:1235-49; 2003.
5. Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., 
Wuyts, W., Van Den Ende, J., Willems, P., Paes-Alves, A. F., Hill, S., Bueno, M., Ramos, 
F. J., Tacconi, P., Dikkers, F. G., Stratakis, C., Lindpaintner, K., Vickery, B., Foernzler, D., 
and Van Hul, W. Increased bone density in sclerosteosis is due to the deficiency of a 
novel secreted protein (SOST). Hum Mol Genet 10:537-43; 2001.
6. Balk, M. L., Bray, J., Day, C., Epperly, M., Greenberger, J., Evans, C. H., and Niyibizi, 
C. Effect of rhBMP-2 on the osteogenic potential of bone marrow stromal cells from an 
osteogenesis imperfecta mouse (oim). Bone 21:7-15; 1997.
7. Belema Bedada, F., Technau, A., Ebelt, H., Schulze, M., and Braun, T. Activation of 
myogenic differentiation pathways in adult bone marrow-derived stem cells. Mol Cell 
Biol 25:9509-19; 2005.
8. Bodine, P. V., Zhao, W., Kharode, Y. P., Bex, F. J., Lambert, A. J., Goad, M. B., Gaur, T., 
Stein, G. S., Lian, J. B., and Komm, B. S. The Wnt antagonist secreted frizzled-related 
protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol 
Endocrinol 18:1222-37; 2004.
9. Bonyadi, M., Waldman, S. D., Liu, D., Aubin, J. E., Grynpas, M. D., and Stanford, W. L. 
Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis 
in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A 100:5840-5; 2003.
10. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, 
S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., and Simonet, W. S. osteoprotegerin-
deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 
234
Chapter 8
235
General Discussion
12:1260-8; 1998.
11. Cao, J., Morony, S., Warmington, K., Pretorius, J., McDorman, K., and Paszty, C. 
Transgenic Overexpression of WIF-1, a Secreted Wnt Antagonist Expressed in Bone, 
Causes Decreased Bone Mineral Density and Increased Susceptibility to Bone Fracture 
in Mice: a Role for WIF-1 in Bone Biology. Abstracts of the 26th Annual Meeting of the 
American Society for Bone and Mineral Research; 2004.
12. Chung, Y. S., Baylink, D. J., Srivastava, A. K., Amaar, Y., Tapia, B., Kasukawa, Y., and 
Mohan, S. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone 
Miner Res 19:1395-402; 2004.
13. Cifuentes-Diaz, C., Faille, L., Goudou, D., Schachner, M., Rieger, F., and Angaut-Petit, D. 
Abnormal reinnervation of skeletal muscle in a tenascin-C-deficient mouse. J Neurosci 
Res 67:93-9; 2002.
14. Clancy, B. M., Johnson, J. D., Lambert, A. J., Rezvankhah, S., Wong, A., Resmini, 
C., Feldman, J. L., Leppanen, S., and Pittman, D. D. A gene expression profile for 
endochondral bone formation: oligonucleotide microarrays establish novel connections 
between known genes and BMP-2-induced bone formation in mouse quadriceps. Bone 
33:46-63; 2003.
15. Cobas, M., Wilson, A., Ernst, B., Mancini, S. J., MacDonald, H. R., Kemler, R., and 
Radtke, F. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 
199:221-9; 2004.
16. Day, T. F., Guo, X., Garrett-Beal, L., and Yang, Y. Wnt/beta-catenin signalling in 
mesenchymal progenitors controls osteoblast and chondrocyte differentiation during 
vertebrate skeletogenesis. Dev Cell 8:739-50; 2005.
17. de Boer, J., Siddappa, R., Gaspar, C., van Apeldoorn, A., Fodde, R., and van Blitterswijk, 
C. Wnt signalling inhibits osteogenic differentiation of human mesenchymal stem cells. 
Bone 34:818-26; 2004.
18. de Jong, D. S., Steegenga, W. T., Hendriks, J. M., van Zoelen, E. J., Olijve, W., 
and Dechering, K. J. Regulation of Notch signalling genes during BMP2-induced 
differentiation of osteoblast precursor cells. Biochem Biophys Res Commun 320:100-
7; 2004.
19. Diefenderfer, D. L., Osyczka, A. M., Garino, J. P., and Leboy, P. S. Regulation of BMP-
induced transcription in cultured human bone marrow stromal cells. J Bone Joint Surg 
Am 85-A Suppl 3:19-28; 2003.
20. Diefenderfer, D. L., Osyczka, A. M., Reilly, G. C., and Leboy, P. S. BMP responsiveness 
in human mesenchymal stem cells. Connect Tissue Res 44 Suppl 1:305-11; 2003.
21. Doi, M., Nagano, A., and Nakamura, Y. Genome-wide screening by cDNA microarray 
of genes associated with matrix mineralization by human mesenchymal stem cells in 
vitro. Biochem Biophys Res Commun 290:381-90.; 2002.
22. Dulor, J. P., Cambon, B., Vigneron, P., Reyne, Y., Nougues, J., Casteilla, L., and Bacou, 
F. Expression of specific white adipose tissue genes in denervation-induced skeletal 
muscle fatty degeneration. FEBS Lett 439:89-92; 1998.
23. Egusa, H., Schweizer, F. E., Wang, C. C., Matsuka, Y., and Nishimura, I. Neuronal 
differentiation of bone marrow-derived stromal stem cells involves suppression of 
discordant phenotypes through gene silencing. J Biol Chem 280:23691-7; 2005.
24. El-Tanani, M., Platt-Higgins, A., Rudland, P. S., and Campbell, F. C. Ets gene PEA3 
cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. 
J Biol Chem 279:20794-806; 2004.
25. Friedman, M. S., Long, M. W., and Hankenson, K. D. Osteogenic differentiation of 
human mesenchymal stem cells is regulated by bone morphogenetic protein-6. J Cell 
Biochem; 2005.
26. Gardner, J. C., van Bezooijen, R. L., Mervis, B., Hamdy, N. A., Lowik, C. W., Hamersma, 
H., Beighton, P., and Papapoulos, S. E. Bone mineral density in sclerosteosis; affected 
individuals and gene carriers. J Clin Endocrinol Metab 90:6392-5; 2005.
27. Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V., Komm, B. S., 
234
Chapter 8
235
General Discussion
Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. Canonical WNT 
signalling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol 
Chem 280:33132-40; 2005.
28. Glass, D. A., 2nd, Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, 
M. M., Long, F., McMahon, A. P., Lang, R. A., and Karsenty, G. Canonical Wnt signalling 
in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-64; 
2005.
29. Glass, D. A., 2nd, and Karsenty, G. Molecular bases of the regulation of bone 
remodelling by the canonical Wnt signalling pathway. Curr Top Dev Biol 73:43-84; 
2006.
30. Glise, B., Miller, C. A., Crozatier, M., Halbisen, M. A., Wise, S., Olson, D. J., Vincent, A., 
and Blair, S. S. Shifted, the Drosophila ortholog of Wnt inhibitory factor-1, controls the 
distribution and movement of Hedgehog. Dev Cell 8:255-66; 2005.
31. Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, 
H., Cundy, T., Glorieux, F. H., Lev, D., Zacharin, M., Oexle, K., Marcelino, J., Suwairi, 
W., Heeger, S., Sabatakos, G., Apte, S., Adkins, W. N., Allgrove, J., Arslan-Kirchner, 
M., Batch, J. A., Beighton, P., Black, G. C., Boles, R. G., Boon, L. M., Borrone, C., 
Brunner, H. G., Carle, G. F., Dallapiccola, B., De Paepe, A., Floege, B., Halfhide, M. L., 
Hall, B., Hennekam, R. C., Hirose, T., Jans, A., Juppner, H., Kim, C. A., Keppler-Noreuil, 
K., Kohlschuetter, A., LaCombe, D., Lambert, M., Lemyre, E., Letteboer, T., Peltonen, 
L., Ramesar, R. S., Romanengo, M., Somer, H., Steichen-Gersdorf, E., Steinmann, B., 
Sullivan, B., Superti-Furga, A., Swoboda, W., van den Boogaard, M. J., Van Hul, W., 
Vikkula, M., Votruba, M., Zabel, B., Garcia, T., Baron, R., Olsen, B. R., and Warman, M. 
L. LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. 
Cell 107:513-23.; 2001.
32. Gorfinkiel, N., Sierra, J., Callejo, A., Ibanez, C., and Guerrero, I. The Drosophila 
ortholog of the human Wnt inhibitor factor Shifted controls the diffusion of lipid-
modified Hedgehog. Dev Cell 8:241-53; 2005.
33. Gu, K., Zhang, L., Jin, T., and Rutherford, R. B. Identification of potential modifiers 
of Runx2/Cbfa1 activity in C2C12 cells in response to bone morphogenetic protein-7. 
Cells Tissues Organs 176:28-40; 2004.
34. Halford, M. M., Armes, J., Buchert, M., Meskenaite, V., Grail, D., Hibbs, M. L., Wilks, 
A. F., Farlie, P. G., Newgreen, D. F., Hovens, C. M., and Stacker, S. A. Ryk-deficient 
mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nat 
Genet 25:414-8; 2000.
35. Harada, S., Sampath, T. K., Aubin, J. E., and Rodan, G. A. Osteogenic protein-1 up-
regulation of the collagen X promoter activity is mediated by a MEF-2-like sequence 
and requires an adjacent AP-1 sequence. Mol Endocrinol 11:1832-45; 1997.
36. Hartmann, C., and Tabin, C. J. Dual roles of Wnt signalling during chondrogenesis in 
the chicken limb. Development 127:3141-59.; 2000.
37. Hens, J. R., Wilson, K. M., Dann, P., Chen, X., Horowitz, M. C., and Wysolmerski, J. J. 
TOPGAL mice show that the canonical Wnt signalling pathway is active during bone 
development and growth and is activated by mechanical loading in vitro. J Bone Miner 
Res 20:1103-13; 2005.
38. Hill, T. P., Spater, D., Taketo, M. M., Birchmeier, W., and Hartmann, C. Canonical Wnt/
beta-catenin signalling prevents osteoblasts from differentiating into chondrocytes. 
Dev Cell 8:727-38; 2005.
39. Hsieh, J. C., Kodjabachian, L., Rebbert, M. L., Rattner, A., Smallwood, P. M., Samos, C. 
H., Nusse, R., Dawid, I. B., and Nathans, J. A new secreted protein that binds to Wnt 
proteins and inhibits their activities. Nature 398:431-6.; 1999.
40. Hu, H., Hilton, M. J., Tu, X., Yu, K., Ornitz, D. M., and Long, F. Sequential roles of 
Hedgehog and Wnt signalling in osteoblast development. Development 132:49-60; 
2005.
41. Huard, J., Cao, B., and Qu-Petersen, Z. Muscle-derived stem cells: potential for muscle 
236
Chapter 8
237
General Discussion
regeneration. Birth Defects Res C Embryo Today 69:230-7; 2003.
42. Hunter, D. D., Zhang, M., Ferguson, J. W., Koch, M., and Brunken, W. J. The extracellular 
matrix component WIF-1 is expressed during, and can modulate, retinal development. 
Mol Cell Neurosci 27:477-88; 2004.
43. Joester, A., and Faissner, A. The structure and function of tenascins in the nervous 
system. Matrix Biol 20:13-22; 2001.
44. Johnson, M. L., Harnish, K., Nusse, R., and Van Hul, W. LRP5 and Wnt signalling: a 
union made for bone. J Bone Miner Res 19:1749-57; 2004.
45. Jung, Y., Wang, J., Schneider, A., Sun, Y. X., Koh-Paige, A. J., Osman, N. I., McCauley, 
L. K., and Taichman, R. S. Regulation of SDF-1 (CXCL12) production by osteoblasts; a 
possible mechanism for stem cell homing. Bone 38:497-508; 2006.
46. Kahler, R. A., and Westendorf, J. J. Lymphoid enhancer factor-1 and beta-catenin 
inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol 
Chem 278:11937-44; 2003.
47. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, 
V., Wozney, J. M., Fujisawa-Sehara, A., and Suda, T. Bone morphogenetic protein-2 
converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J 
Cell Biol 127:1755-66.; 1994.
48. Katayama, Y., Battista, M., Kao, W. M., Hidalgo, A., Peired, A. J., Thomas, S. A., and 
Frenette, P. S. Signals from the sympathetic nervous system regulate hematopoietic 
stem cell egress from bone marrow. Cell 124:407-21; 2006.
49. Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H., Glass, D. A., 2nd, 
Hartmann, C., Li, L., Hwang, T. H., Brayton, C. F., Lang, R. A., Karsenty, G., and Chan, 
L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent 
embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 
157:303-14.; 2002.
50. Kawaguchi, J., Mee, P. J., and Smith, A. G. Osteogenic and chondrogenic differentiation 
of embryonic stem cells in response to specific growth factors. Bone 36:758-69; 
2005.
51. Lee, M. H., Javed, A., Kim, H. J., Shin, H. I., Gutierrez, S., Choi, J. Y., Rosen, V., Stein, 
J. L., van Wijnen, A. J., Stein, G. S., Lian, J. B., and Ryoo, H. M. Transient upregulation 
of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor 
beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype 
but is not sufficient for osteoblast differentiation. J Cell Biochem 73:114-25.; 1999.
52. Levesque, J. P., Hendy, J., Takamatsu, Y., Simmons, P. J., and Bendall, L. J. Disruption 
of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell 
mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187-96; 2003.
53. Li, G., Peng, H., Corsi, K., Usas, A., Olshanski, A., and Huard, J. Differential effect of 
BMP4 on NIH/3T3 and C2C12 cells: implications for endochondral bone formation. J 
Bone Miner Res 20:1611-23; 2005.
54. Li, J., Sarosi, I., Cattley, R. C., Pretorius, J., Asuncion, F., Grisanti, M., Morony, S., 
Adamu, S., Geng, Z., Qiu, W., Kostenuik, P., Lacey, D. L., Simonet, W. S., Bolon, B., 
Qian, X., Shalhoub, V., Ominsky, M. S., Zhu Ke, H., Li, X., and Richards, W. G. Dkk1-
mediated inhibition of Wnt signalling in bone results in osteopenia. Bone 39:754-66; 
2006.
55. Li, X., Liu, P., Liu, W., Maye, P., Zhang, J., Zhang, Y., Hurley, M., Guo, C., Boskey, A., 
Sun, L., Harris, S. E., Rowe, D. W., Ke, H. Z., and Wu, D. Dkk2 has a role in terminal 
osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-52; 
2005.
56. Lian, J. B., Gary S. Stein, G. S., and Aubin, J. E. Bone Formation: Maturation and 
Functional Activities of Osteoblast Lineage Cells. In: M. J. Favus (ed.), Primer on the 
Metabolic Bone Diseases and Disorders of Mineral Metabolism, pp. 13-28. Washington, 
DC: American Society for Bone and Mineral Research; 2003.
57. Lu, W., Yamamoto, V., Ortega, B., and Baltimore, D. Mammalian Ryk is a Wnt coreceptor 
236
Chapter 8
237
General Discussion
required for stimulation of neurite outgrowth. Cell 119:97-108; 2004.
58. Mundy, G. R. Pathogenesis of osteoporosis and challenges for drug delivery. Adv Drug 
Deliv Rev 42:165-73; 2000.
59. Neidhardt, J., Fehr, S., Kutsche, M., Lohler, J., and Schachner, M. Tenascin-N: 
characterization of a novel member of the tenascin family that mediates neurite 
repulsion from hippocampal explants. Mol Cell Neurosci 23:193-209; 2003.
60. Nilsson, S. K., Johnston, H. M., Whitty, G. A., Williams, B., Webb, R. J., Denhardt, 
D. T., Bertoncello, I., Bendall, L. J., Simmons, P. J., and Haylock, D. N. Osteopontin, 
a key component of the hematopoietic stem cell niche and regulator of primitive 
hematopoietic progenitor cells. Blood 106:1232-9; 2005.
61. Patthy, L. The WIF module. Trends Biochem Sci 25:12-3; 2000.
62. Peacock, M., Turner, C. H., Econs, M. J., and Foroud, T. Genetics of osteoporosis. Endocr 
Rev 23:303-26; 2002.
63. Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, 
T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., Sandbank, J., Zipori, D., and 
Lapidot, T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 
and up-regulating CXCR4. Nat Immunol 3:687-94; 2002.
64. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., 
Moorman, M. A., Simonetti, D. W., Craig, S., and Marshak, D. R. Multilineage potential 
of adult human mesenchymal stem cells. Science 284:143-7; 1999.
65. Ralston, S. H. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 
87:2460-6; 2002.
66. Rattis, F. M., Voermans, C., and Reya, T. Wnt signalling in the stem cell niche. Curr Opin 
Hematol 11:88-94; 2004.
67. Rawadi, G., Vayssiere, B., Dunn, F., Baron, R., and Roman-Roman, S. BMP-2 controls 
alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine 
loop. J Bone Miner Res 18:1842-53.; 2003.
68. Riggs, B. L., and Parfitt, A. M. Drugs used to treat osteoporosis: the critical need for 
a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 
20:177-84; 2005.
69. Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., and 
MacDougald, O. A. Inhibition of adipogenesis by Wnt signalling. Science 289:950-3.; 
2000.
70. Shibamoto, S., Winer, J., Williams, M., and Polakis, P. A blockade in Wnt signalling is 
activated following the differentiation of F9 teratocarcinoma cells. Exp Cell Res 292:
11-20; 2004.
71. Shore, E. M., Glaser, D. L., and Gannon, F. H. Osteogenic induction in hereditary 
disorders of heterotopic ossification. Clin Orthop Relat Res:303-16; 2000.
72. Taniguchi, H., Yamamoto, H., Hirata, T., Miyamoto, N., Oki, M., Nosho, K., Adachi, Y., 
Endo, T., Imai, K., and Shinomura, Y. Frequent epigenetic inactivation of Wnt inhibitory 
factor-1 in human gastrointestinal cancers. Oncogene 24:7946-52; 2005.
73. Tropel, P., Noel, D., Platet, N., Legrand, P., Benabid, A. L., and Berger, F. Isolation and 
characterization of mesenchymal stem cells from adult mouse bone marrow. Exp Cell 
Res 295:395-406; 2004.
74. Turksen, K., and Aubin, J. E. Positive and negative immunoselection for enrichment of 
two classes of osteoprogenitor cells. J Cell Biol 114:373-84; 1991.
75. Turner, R. T., Maran, A., Lotinun, S., Hefferan, T., Evans, G. L., Zhang, M., and Sibonga, 
J. D. Animal models for osteoporosis. Rev Endocr Metab Disord 2:117-27; 2001.
76. Vaes, B. L., Dechering, K. J., Feijen, A., Hendriks, J. M., Lefevre, C., Mummery, C. L., 
Olijve, W., van Zoelen, E. J., and Steegenga, W. T. Comprehensive microarray analysis 
of bone morphogenetic protein 2-induced osteoblast differentiation resulting in the 
identification of novel markers for bone development. J Bone Miner Res 17:2106-18.; 
2002.
77. van Bezooijen, R. L., ten Dijke, P., Papapoulos, S. E., and Lowik, C. W. SOST/sclerostin, 
238
Chapter 8
an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor 
Rev 16:319-27; 2005.
78. van der Horst, G., van der Werf, S. M., Farih-Sips, H., van Bezooijen, R. L., Lowik, C. 
W., and Karperien, M. Downregulation of Wnt signalling by increased expression of 
Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 
cells. J Bone Miner Res 20:1867-77; 2005.
79. Wagatsuma, A. Upregulation of gene encoding adipogenic transcriptional factors C/
EBPalpha and PPARgamma2 in denervated muscle. Exp Physiol 91:747-53; 2006.
80. Warmington, K., Morony, S., Sarosi, I., Gong, J., Stephens, P., Winkler, D. G., 
Sutherland, M. K., Latham, J. A., Kirby, H., Moore, A., Robinson, M., Kostenuik, P. 
J., Simonet, S., Lacey, D. L., and Paszty, C. Sclerostin Antagonism in Adult Rodents, 
via Monoclonal Antibody Mediated Blockade, Increases Bone Mineral Density and 
Implicates Sclerostin as a Key Regulator of Bone Mass During Adulthood. Abstracts 
of the 26th Annual Meeting of the American Society for Bone and Mineral Research; 
2004.
81. Westendorf, J. J., Kahler, R. A., and Schroeder, T. M. Wnt signalling in osteoblasts and 
bone diseases. Gene 341:19-39; 2004.
82. Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. 
E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling-Hampton, K., Appleby, M., 
Brunkow, M. E., and Latham, J. A. Osteocyte control of bone formation via sclerostin, 
a novel BMP antagonist. Embo J 22:6267-76; 2003.
83. Xu, T., Bianco, P., Fisher, L. W., Longenecker, G., Smith, E., Goldstein, S., Bonadio, 
J., Boskey, A., Heegaard, A. M., Sommer, B., Satomura, K., Dominguez, P., Zhao, C., 
Kulkarni, A. B., Robey, P. G., and Young, M. F. Targeted disruption of the biglycan gene 
leads to an osteoporosis-like phenotype in mice. Nat Genet 20:78-82; 1998.
84. Yoshikawa, S., McKinnon, R. D., Kokel, M., and Thomas, J. B. Wnt-mediated axon 
guidance via the Drosophila Derailed receptor. Nature 422:583-8; 2003.
85. Zhang, B., Schmoyer, D., Kirov, S., and Snoddy, J. GOTree Machine (GOTM): a 
web-based platform for interpreting sets of interesting genes using Gene Ontology 
hierarchies. BMC Bioinformatics 5:16; 2004.
86. Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W. G., Ross, J., Haug, J., Johnson, 
T., Feng, J. Q., Harris, S., Wiedemann, L. M., Mishina, Y., and Li, L. Identification of 
the haematopoietic stem cell niche and control of the niche size. Nature 425:836-41; 
2003.
       C
H
A
P
T
E
R
 9
Full Colour Figures
 
240
Chapter 9
241
Full colour figures
Figure 2 (Chapter 2) (opposite page). 
Cluster analysis of gene expression during BMP2-induced osteoblast differentiation. 
(A) Output of hierarchical clustering of 342 genes with the standard correlation of 10log 
transformed microarray data, as a heatmap with the corresponding dendrogram. The 
log transformed inductions levels are indicated with different colour intensities in blue 
and red representing down- and up-regulation respectively. In the heatmap, each gene 
is represented as a single column and measured time points are represented as rows. 
According to the dendrogram, 6 clusters were identified that are indicated with the 
coloured bars below the heatmap. For each cluster, the averaged expression pattern 
in the time course (normalized on a scale to 1) was calculated from log transformed 
microarray data of all genes within a cluster and shown as graphs. A number of 8 genes 
was not included in the clusters since their expression profiles were unique according 
to the dendrogram. (B) Representation of the genes within the clusters U3 and U4. The 
clusters are shown with the name and the GenbankTM accession numbers for each gene. 
Averaged microarray (MA) values of the duplicate experiments at each time point are 
indicated with different colour intensity on a red scale. 
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Figure 5 (Chapter 2).
Expression of genes identified by microarray in the developing mouse skeleton at E16.5 
by in situ hybridization.
A-J: transverse sections through the head at the level of the jaws for a control osteoblast 
marker Cbfa1 (A,F) and for Wif-1 (B,G) and the three ESTs AA222756 (C,H), AA709999 
(D,I) and AA794190 (E,J). K-O: transverse sections through the body at the level of the 
midriff, showing expression in the ribs for Cbfa1 (K), Wif-1 (L), AA222756 (M), AA709999 
(N) and AA794190 (O). P-T: transverse sections through the body showing expression in 
the vertebrae for Cbfa1 (P), Wif-1 (Q), AA222756 (R), AA709999 (S) and AA794190 (T). 
Inserts are higher magnifications of structures in the main figures.
Abbreviations: bs, basisphenoid bone; fb, frontal bone; md, mandible; mx, maxilla; 
M, Meckel’s cartilage; nb, nasal bone; nc, nasal cavity; r, ribs; tg, tongue; to, tooth; v, 
vertebra; vi, vibrissa.
Cbfa1 Wif1 AA222756 AA709999 AA794190
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Figure 4 (Chapter 3). 
Expression of Wif1 in developing mouse vertebrae. 
(A-F) Expression in proximal tail vertebrae of Cbfa1 (A, C, E) and Wif1 (B, D, F). 
(C,D) Higher magnifications of dark field images of vertebrae shown in A and B. 
(E,F) Haematoxylin counterstaining. Pictures show bright field images of vertebrae 
shown in C and D. Abbreviations: id, intervertebral disc; bc, bone collar; pc, 
proliferating chondrocytes; hc, hypertrophic chondrocytes; tb, trabecular bone. 
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Figure 1 (Chapter 4).
Expression profiles of the significantly (p<0.01) regulated BMP2-responsive genes. 
Genes regulated within 24 hrs after BMP2 treatment are shown, grouped according 
to Model-based clustering of 10log transformed microarray data (normalized on a 
scale to 1). Induction levels are indicated with different colour intensities in red and 
blue, representing up-and down-regulation respectively. 
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Figure 1 (Chapter 4), continued.
Protein function profile graphs show the number of genes within each cluster with a 
particular function. Genes with unknown function or other functions were labelled as 
“Other”. EST: Expressed Sequence Tag, TF: transcription factor, EMe: Extracellular 
messenger, IS: Intracellular signalling protein, Rec: Receptor, EMa: Extracellular 
matrix protein, CPl: Cytoplasmatic protein and CSk: Cytoskeletal protein. 
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Figure 3 (Chapter 4).
In vivo expression of Hey1 and Tcf7 in the developing mouse skeleton. 
(A-C) Transverse sections of E14.5 mouse embryos at the level of the jaws for the 
control osteoblast marker Cbfa1 (A), Tcf7 (B) and Hey1 (C), (D-F) Sagital sections 
of E16.5 mouse embryos at the level of the nasal cavities for Cbfa1 (D), Tcf7 (E) and 
Hey1 (F), (G-I) Mouse proximal tail vertebrae for Cbfa1(G), Tcf7 (H) and Hey1 (I). 
Abbreviations used: bm, bone marrow; C1v, cartilage primordium of C1 vertebra; 
cl, clavicle; h, cartilage primordium of humurus; hc, hypertrophic chondroblasts; id, 
intervertebral disc; Jo, Jacobson’s organ; M, Meckel’s cartilage; md, mandible; mx, 
maxilla; nc, nasal cavity; nca, nasal capsule; P, periosteal bone; pc, proliferating 
chondroblasts; sc, scapula; T, trabecular bone; tg, tongue; to, tooth; vb, vertebral 
body.
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Figure 1 (Chapter 7).
Analysis of mRNA expression of osteoblast transcription factors in wild-type and 
Runx2 (-/-) calvaria by means of in situ hybridization. 
(A-C): Frontal sections through the head of embryos at stage 14.5 and 16.5 dpc 
showing expression of Runx2 (A), Osx (B) and Msx2 (C). Figures 1Cc and 1Cd are 
higher magnifications of 1Ca and 1Cb respectively. 
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Figure 3 (Chapter 7).
Analysis of protein expression of loricrin (A) and mRNA expression of Kera (B, C)) 
in wild-type and Runx2 (-/-) calvaria by means of immunofluorescence and in situ 
hybridization.
A: Immunofluorescent detection of loricrin (green) and the epithelial marker K14 
(red) expression in the epidermis adjacent to calvaria at stage 18.5 dpc. 
B: Frontal sections through the head, showing Kera mRNA expression at stage 14.5 
(B) and 16.5 (C). Figures 2Bc, 2Bd, 2Cc, 2Cd represent higher order magnification 
pictures of 2Ba, 2Bb, 2Ca and 2Cb respectively. 
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SUMMARY
The skeleton is formed by two distinct tissues, namely bone and 
cartilage. Bone is virtually a static organ, but at the cellular level it is very 
dynamic. Bone is continuously being broken down and rebuilt. This process 
of so-called bone remodelling is tightly regulated by two different cell types. 
The osteoclasts are the cells responsible for the degradation of old bone, 
while osteoblasts on the other hand synthesize new bone. Bone strength is 
determined by the balance between osteoclast and osteoblast activity. During 
ageing, this balance is gradually shifted in favor of bone resorption. However, 
a dramatic disturbance in favor of bone resorption occurs during osteoporosis, 
a disease characterized by a strong increase in bone fracture risk. Therapies 
against osteoporosis are currently based on inhibition of osteoclast activity in 
order to reduce the amount of bone resorption. An alternative strategy would 
be to stimulate new bone formation by enhancing the activity of osteoblasts. 
In order to develop therapeutic agents with the aim to specifically target 
osteoblast activity, a detailed knowledge on the formation of osteoblasts and 
maintenance of osteoblast function is required. 
Osteoblasts originate from mesenchymal stem cells. A characteristic 
feature of stem cells is their ability to differentiate into different cell types. 
In addition to osteoblasts, mesenchymal stem cells can also differentiate into 
for instance cartilage cells, fat cells or muscle cells. The genetic programs 
that are activated in stem cells to determine their differentiation towards the 
osteoblast lineage and genes that control the activity of mature osteoblasts 
are still poorly understood. Many genes have already been recognized that 
are functionally involved in the regulation of osteoblast differentiation and 
bone development, but in most cases their expression is not restricted to 
osteoblasts. A detailed overview of changes in gene expression patterns 
during differentiation of mesenchymal stem cells into osteoblasts will be key to 
understand how the osteoblast phenotype is established. A method to acquire 
such broad information about gene expression patterns is the so-called 
transcriptome analysis. The transcriptome describes the whole population 
of gene transcripts in a cell, and provides a basis for the identification of cell 
type specific gene expression. The transcriptome can be analysed by means 
of microarrays, a technique that allows for genome-wide gene expression 
analysis. 
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In this thesis, we have employed microarray-based gene expression 
profiling to study the transcriptome of differentiating osteoblast during in 
vitro cell culture (Chapters 2-5) as well as during skeletogenesis (Chapters 6 
and 7). 
For the in vitro analyses gene expression profiles were measured during 
bone morphogenetic protein (BMP) induced differentiation of the multipotent 
mouse C2C12 progenitor cell line. In order to identify novel marker genes 
for bone development, we focused on genes of which expression was up-
regulated in mature osteoblasts (Chapter 2). Out of a total of 342 modulated 
transcripts, a number of 52 transcripts showed similar expression kinetics as 
the known osteoblast markers alkaline phosphatase (Akp2) and osteocalcin 
(Bglap1). Out of these genes, we subsequently identified 9 novel markers for 
in vitro osteoblast differentiation, of which 3 transcripts were shown to be 
expressed in skeletal elements during embryonic development. 
 One of these new markers for bone development appeared the gene 
encoding Wnt Inhibitory Factor 1 (Wif1), an antagonist of the Wnt signal 
transduction pathway. While performing our studies, an important  function of 
Wnt signalling in the regulation of bone mass had been shown by others. We 
therefore examined in detail the expression profiles of other Wnt signalling 
components during osteoblast differentiation. We showed that of all Wnt 
components present on microarray, the strongest expression regulation was 
observed for antagonists of Wnt activity, including Dkk3, Sfrp2, and Wif1 
(Chapter 3). Remarkably, induction of these antagonists occurred during late 
stages of bone cell differentiation, indicating that these genes are expressed 
in cells that are already committed towards the osteoblast phenotype. 
However, during the early phase of differentiation, in which the stem cells 
become committed, expression of activators of Wnt signalling appeared 
to be induced. Our studies revealed that Wnt10b, Wnt4 and Tcf7 were co-
regulated with the gene encoding the transcription factor Runx2, which is 
the earliest determinant of the osteoblast phenotype (Chapters 3 and 4). 
The latter result is in agreement with published data in which it has been 
shown in mice that activation of the Wnt signalling cascade is necessary to 
induce the osteoblast phenotype in mesenchymal cell condensations during 
skeletogenesis. These data imply that activation of Wnt induces osteoblast 
differentiation. However, we have shown that continuous activation of Wnt 
signalling during differentiation reduces expression of osteoblast genes, 
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resulting in inhibition of osteoblast function. Our data thus suggest that 
expression of Wnt antagonists in osteoblasts is required to diminish Wnt 
activity which is essential to control osteoblast maturation. Together, the data 
have led to a model in which activation of Wnt signalling is initially required 
to induce osteoblast differentiation in mesenchymal stem cells, after which 
Wnt antagonists are expressed to provide a negative feedback loop to control 
maturation of the osteoblasts. 
 The strong expression of Wnt antagonists as observed in our study is 
indicative for an important function of this class of molecules in osteoblasts 
and bone. Therefore, Wif1 may be a candidate molecule for further studies 
on therapeutic targets. Mice specifically over-expressing Wif1 in osteoblasts 
exhibit a reduced bone mass in comparison with control mice. It can be 
hypothesized that reduced levels of Wif1 activity may result in the opposite 
effect, namely increased bone mass. If true, specific inactivation of Wif1 in 
bone could be a strategy to treat osteoporosis. 
 Our in vitro microarray studies have resulted in the identification 
of a large number of osteoblast-related genes, but care should be taken to 
correlate in vitro gene expression with an in vivo function. The use of cell 
lines is limited since they do not take into account the physiological context 
in which they reside in vivo, where they may interact with other cell types 
resulting in a mutual influence of their behavior. Therefore, we aimed to study 
bone specific gene expression in vivo during skeletogenesis. For this purpose, 
Runx2 knockout mice were used. The transcription factor Runx2 determines 
osteoblast commitment and controls expression of osteoblast specific genes. 
Mice lacking functional Runx2 show arrested osteoblast differentiation and fail 
to form bone. To identify genes of which expression is controlled by Runx2 
in vivo, we analyzed gene expression profiles in calvaria, forelimbs and 
hindlimbs of both Runx2 knockout and wildtype embryos. We were able to 
identify 25 transcripts of which expression levels in all three skeletal tissues 
were lowered in Runx2 deficient mice compared to wild type littermates 
(Chapter 6). The occurrence of the Runx2 binding site appeared enriched in 
the promoter sequences of these transcripts, indicating that these genes are 
indeed in vivo Runx2 target genes. 
 The power of microarray analysis is the ability to study large groups of 
genes in a single experiment. One of the possible ways to look at microarray 
data is to examine those genes that encode proteins with similar functions or 
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involvement in a particular developmental process. We have examined such 
similarities in our data in order to see which biological processes are controlled 
by Runx2. An unexpected finding was that many genes were modulated in 
Runx2 deficient embryos of which it has been shown that they have a function 
in non-skeletal cell types (Chapter 7). This observation indicates that absence 
of osteoblasts results in aberrant development of other cell types and reflects 
the interaction of different cell types in tissues. Our study showed, for 
instance, that genes of which expression is restricted to developing skin were 
strongly down-regulated in the skin adjacent to calvaria of Runx2 deficient 
mice. Based on these results, we have speculated that during embryonic 
development, a Runx2-controlled interaction exists between mesenchymal 
tissue that forms the skull and the adjacent skin. In conclusion, these studies 
showed that microarray analysis on mutant mice tissues may be a powerful 
tool to examine gene functions during development. 
 To summarize, the studies in this thesis have shown that the 
combination of microarray technology and bioinformatic analyses have 
provided new possibilities to the understanding of bone biology. Our studies 
have resulted in the identification of many genes of which expression in 
osteoblasts had not previously been detected. Consequently, our studies 
have contributed to a more detailed knowledge on osteoblast differentiation 
and provide focus points to develop strategies that will prevent and treat bone 
disorders. 
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Het skelet wordt gevormd door twee verschillende weefsels, namelijk 
kraakbeen en bot. Als orgaan lijkt bot zeer statisch, maar op cellulair niveau 
is het een zeer dynamisch weefsel. Voortdurend wordt oud bot afgebroken 
en nieuw bot aangemaakt. Deze zogenoemde bot-remodulering wordt 
gecontroleerd door twee verschillende celtypen, namelijk de osteoblasten en 
de osteoclasten. De osteoblasten zijn de cellen die nieuw bot aanmaken, terwijl 
de osteoclasten het botweefsel afbreken. De stevigheid van bot wordt bepaald 
door de balans tussen de activiteit van osteoblasten enerzijds en osteoclasten 
anderzijds. Bij iedereen die ouder wordt, vindt er relatief meer botafbraak 
dan botopbouw plaats. Soms kan de balans tussen osteoblast- en osteoclast-
activiteit echter zo ernstig verstoord raken dat osteoporose ontstaat. Deze 
ziekte wordt gekenmerkt door een sterke afname van de botsterkte waardoor 
patiënten een verhoogd risico op breuken hebben. Huidige therapieën tegen 
osteoporose zijn er op gericht om de activiteit van osteoclasten te remmen 
om zodoende de botafbraak te beperken. Een alternatieve strategie zou zijn 
om de botaanmaak door osteoblasten te stimuleren. Om aangrijpingspunten 
voor zulke therapieën te identificeren, is een nauwkeurig inzicht in de vorming 
van osteoblasten noodzakelijk. 
Osteoblasten differentiëren vanuit zogenoemde mesenchymale 
stamcellen. Stamcellen hebben als eigenschap dat zij kunnen differentiëren 
tot meerdere typen cellen met een specifieke functie. Zo kunnen 
mesenchymale stamcellen naast osteoblasten ook uitgroeien tot onder 
andere kraakbeencellen, vetcellen en spiercellen. Het is onduidelijk welke 
genetische programma’s de ontwikkeling van een mesenchymale stamcel 
richting osteoblast sturen en welke genen de functie van rijpe osteoblasten 
controleren. Hoewel van veel genen een functie tijdens osteoblast-
differentiatie en botontwikkeling is aangetoond, blijkt de expressie van deze 
genen niet tot osteoblasten beperkt te zijn. Een gedetailleerd overzicht van 
de veranderingen in genexpressie tijdens de differentiatie van een stamcel is 
noodzakelijk om te begrijpen hoe de specificiteit van een bepaald celtype tot 
stand komt. Een manier om een compleet overzicht van genexpressie in een 
cel te verkrijgen is zogenoemde transcriptoom-analyse. Het transcriptoom is 
gedefinieerd als de verzameling van alle genen die op een bepaald moment 
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in een cel tot expressie komen. Het transcriptoom wordt geanalyseerd met 
behulp van de microarray techniek waarmee het mogelijk is om genexpressie 
op genoom-wijde schaal te bestuderen. 
 Dit proefschrift behandelt analyses van het muizen osteoblast 
transcriptoom. Om te onderzoeken van welke genen expressie specifiek 
is voor osteoblasten hebben wij het osteoblast transcriptoom zowel in 
vitro (celkweek, zie hoofdstukken 2-5) als in vivo (muizen embryo’s, zie 
hoofdstukken 6 en 7) onderzocht. De eiwitten waarvoor zulke genen coderen, 
vervullen mogelijk een regulatoire rol tijdens osteoblast-differentiatie en 
botvorming, en kunnen bijdragen aan de ontwikkeling van medicijnen tegen 
osteoporose. 
Voor de in vitro transcriptoom-analyses werden genexpressie 
profielen gemeten in multipotente muis C2C12 progenitor cellen, die onder 
invloed van de osteogene stimulator bone morphogenetic protein (BMP) 
naar osteoblast differentiëren. Om nieuwe markers voor botontwikkeling te 
identificeren werd gekeken naar genen die karakteristiek tot expressie komen 
in rijpe osteoblasten (Hoofdstuk 2). Van 342 transcripten die gemoduleerd 
werden tijdens de differentiatie bleken er 52 een vergelijkbaar expressie-
profiel te hebben met de al bekende osteoblast marker-genen alkalische 
fosfatase ( Akp2) en osteocalcine ( Bglap1). Vervolgens werden 9 transcripten 
geïdentificeerd die specifiek door BMP werden geïnduceerd in osteoblasten. 
Expressie van 3 van deze transcripten werd in bot aangetoond tijdens de 
embryonale ontwikkeling.
Een van deze nieuwe botmarkers was het gen dat codeert voor Wnt 
inihitory factor 1 (Wif1), een antagonist van de Wnt signaaltransductie-route. 
Omdat gedurende ons onderzoek in andere studies een relatie tussen Wnt 
signalering en botmassa werd aangetoond, hebben wij specifiek gekeken naar 
de genexpressie-profielen van andere Wnt componenten tijdens osteoblast-
differentiatie. Daarbij hebben wij aangetoond dat van alle Wnt componenten 
die aanwezig waren op de microarray, de sterkste expressie-regulering optrad 
voor antagonisten van Wnt, waaronder Dkk3, Sfrp2, en Wif1 (Hoofdstuk 3). 
Opmerkelijk was dat deze Wnt antagonisten werden geïnduceerd tijdens 
de late fase van osteoblast-differentiatie. Dit betekent dat deze genen tot 
expressie komen als vastligt dat de cellen osteoblasten zijn. Tijdens de vroege 
fase, waarin bepaald wordt dat een stamcel een osteoblast wordt, bleken 
juist activatoren van Wnt signalering geïnduceerd te worden. Uit onze studies 
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bleek dat expressie van de Wnt activatoren Wnt10b, Wnt4 en Tcf7 tijdens 
dezelfde fase plaats vindt als expressie van Runx2, de vroegste determinant 
van het osteoblast fenotype (Hoofdstukken 3 en 4). Deze laatste resultaten 
komen overeen met gepubliceerde studies waarin in muizen is aangetoond 
dat activering van de Wnt route essentieel is om het osteoblast fenotype 
vast te leggen. Echter, wij hebben laten zien dat wanneer Wnt signalering 
continu geactiveerd is tijdens differentiatie, de expressie van osteoblast-
genen geremd wordt, wat uiteindelijk resulteert in inhibitie van osteoblast-
functie. Onze resultaten suggereren dat expressie van Wnt antagonisten in 
osteoblasten noodzakelijk is om Wnt activiteit te remmen en daarmee de 
voortgang van differentiatie te controleren. Bijeengenomen hebben deze 
resultaten geleid tot een model waarin eerst activering van Wnt signalering 
nodig is om een stamcel aan te sturen tot osteoblast. Vervolgens wordt Wnt 
signalering geremd door expressie van Wnt antagonisten waardoor verdere 
differentiatie tot een mature osteoblast kan plaatsvinden. 
Onze studies suggereren dat expressie van Wnt antagonisten, en dus 
remming van Wnt activiteit, een belangrijke voorwaarde is voor osteoblast 
differentiatie. Dit maakt Wif1 tot een mogelijk therapeutisch target. Het is 
aangetoond dat muizen waarin Wif1 in bot tot overexpressie wordt gebracht, 
een verlaagde botmassa hebben ten opzichte van normale muizen. Omgekeerd 
zou een verlaging van Wif1 tot gevolg kunnen hebben dat de botsterkte 
verhoogd wordt. Indien dit het geval is, biedt specifieke inactivering van Wif1 
activiteit in bot wellicht een mogelijkheid om osteoporose te remmen. 
Hoewel onze microarray studies in cellijnen hebben geleid tot de 
identificatie van osteoblast specifieke genen, is het moeilijk om genexpressie 
in vitro te correleren met genfunctie in bot. Cellijnen zijn een beperkt 
modelsysteem omdat zij niet representatief zijn voor de fysiologische context 
waarin osteoblasten functioneren. Cellen in weefsels kunnen namelijk 
interacties met elkaar aangaan en elkaars gedrag beïnvloeden. Om op 
genoom-wijde schaal botspecifieke genen tijdens embryonale ontwikkeling 
te identificeren, hebben wij micorarray analyses uitgevoerd op botweefsel 
van muizen embryo’s. Hiervoor werd gebruik gemaakt van muizen waarin het 
Runx2 gen is geïnactiveerd. De transcriptiefactor Runx2 controleert osteoblast-
differentiatie door expressie van osteoblast specifieke genen te reguleren. In 
muizen waarin Runx2 niet functioneel is, is osteoblast-differentiatie volledig 
geblokkeerd, waardoor er geen botvorming plaatsvindt. Om in vivo genen 
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te identificeren die door Runx2 worden aangestuurd, werd genexpressie in 
schedeldakjes, voorpootjes en achterpootjes van normale muizen vergeleken 
met dezelfde weefsels van Runx2 deficiënte muizen. Een aantal van 25 
transcripten bleek in zowel de schedeldakjes, als in de voor- en achterpootjes 
lager tot expressie te komen in de Runx2 knockout muizen dan in wild-type 
muizen (Hoofdstuk 6). De DNA bindingssequentie voor de transcriptiefactor 
Runx2 bleek verrijkt aanwezig te zijn in de promoter sequenties van 
deze genen. Dit is een sterke aanwijzing dat de geïdentificeerde genen 
daadwerkelijk in vivo Runx2 target-genen en regulatoren van skeletvorming 
zijn. 
De kracht van de microarray techniek is dat grote groepen genen 
tegelijkertijd geanalyseerd kunnen worden. Een van de mogelijkheden hierbij 
is om genen te onderzoeken die een vergelijkbare functies hebben of die 
bij bepaalde biologische processen betrokken zijn. Wij hebben dit laatste 
geanalyseerd om te onderzoeken welke biologische processen door Runx2 
gereguleerd worden. Een onverwacht resultaat was dat in de Runx2 knockout 
embryo’s genen gemoduleerd bleken te zijn waarvan bekend is dat zij 
betrokken zijn bij de ontwikkeling van weefsels die niet bot-gerelateerd zijn. 
Dit duidt erop dat Runx2 deficiënte muizen niet alleen een fenotype hebben 
in skelet-cellen, maar ook in andere typen cellen. Een mogelijke verklaring 
hiervoor is dat de afwezigheid van osteoblasten tot resultaat heeft dat andere 
celtypen zich niet ontwikkelen, hetgeen impliceert dat er een interactie 
bestaat tussen osteoblasten en andere cel typen. Zo bleek uit onze studie dat 
in Runx2 knockout embryo’s expressie-niveaus van genen die zeer specifiek 
tot expressie komen tijdens huidontwikkeling, verlaagd waren in de huid 
aangrenzend aan het schedeldak (Hoofdstuk 7). Op basis van deze resultaten 
hebben wij de hypothese opgesteld dat tijdens embryonale ontwikkeling 
Runx2-gecontroleerde interacties plaatsvinden tussen mesenchymaal weefsel 
dat de schedel vormt, en de aangrenzende huidlaag. Concluderend betekenen 
deze resultaten dat microarray analyse op mutante muizen een krachtige 
methode is om genfunctie tijdens ontwikkeling te bestuderen. 
Samenvattend hebben de studies in dit proefschrift laten zien dat 
microarray technologie in combinatie met bioinformatische analyses nieuwe 
perspectieven bieden om de biologie van het bot te leren begrijpen. Onze 
studies hebben dan ook bijgedragen aan nieuwe inzichten in het proces van 
osteoblast-differentiatie en botontwikkeling, en bieden de mogelijkheid om 
therapieën te ontwikkelen om bij ziekteprocessen botvorming te stimuleren. 
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